<!DOCTYPE html>
<html style="overflow: hidden;">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">


<meta name="wpd_version" content="0.2">
<meta name="wpd_baseurl" content="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/article/pii/S0166354298000254?np=y">
<meta name="wpd_url" content="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/article/pii/S0166354298000254?np=y">
<meta name="wpd_date" content="2013-04-23T16:27Z">

<script src="204774041.js"></script>
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<script> var ts1 = new Date().getTime(); </script>
<!-- static const char articletmpl_sccsId[] = "%W%  %G% %U%  Retrieved: %H% %T%"; -->
<meta name="robots" content="NOARCHIVE">
<meta name="robots" content="noodp">
<meta name="robots" content="noydir">
<link rel="canonical" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/article/pii/S0166354298000254">


<link rel="shortcut icon" href="faviconSD.ico" type="image/x-icon">
<title>

ScienceDirect.com - 

    
        
    
    Antiviral Research
 - The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection</title>






<script>

if( typeof(ts1) == "undefined" ){ ts1= new Date().getTime(); }
Array.prototype.rt = function(label,ts){this.push( "{lbl:"+label+",ts:"+(ts||ts==0?ts:new Date().getTime())+"}" );}
var prs = [];
prs.rt( "head", ts1 );
function loadPDF(){}
</script>


<!--[if lte IE 7]>
<script src="http://cdn.els-cdn.com/sd/js/json2_131R4.js.min"></script>
<![endif]-->

<link rel="stylesheet" type="text/css" href="S0166354298000254.css" media="all">
</head>
<body style="overflow: hidden;">


<div id="dic_bubble" class="selection_bubble fontSize13 noSelect" style="z-index: 9999; border: 1px solid rgb(74, 174, 222);"></div><script>prs.rt('body_start');</script>
<script>

var refLinkURL = "http://www.sciencedirect.com/science/relLink/ajaxReq?_eid=1-s2.0-S0166354298000254";
var updatedCitedBy = "http://www.sciencedirect.com/science/referenceResolution/ajaxRefResol?_updateCitedBy=";
var refResolvePath = "http://www.sciencedirect.com/science/referenceResolution/ajaxRefResol?_eid=1-s2.0-S0166354298000254&_refCnt=146&_docType=converted-article";

// these variables handle the reference resolution. Please ignore the naming.
// the first variable myMap will hold an associative array of links by bibID
// the second variable myXabsCounts holds the scopus counts.
var myMap = []; // html of links for references.
var myXabsCounts = []; // scopus counts
</script>
<div style="width: 1262px; left: 0px;" class="js" id="header-area">
  <div id="header" class="outerWrapper">
<div style="background-color: rgb(255, 255, 255); position: relative;" class="outerWrapper">
<div id="masthead">

<!-- INSERTS THE TEMPLATE VARIABLES POPULATED FROM DB for SCIVERSE and PRODUCT labels -->

<div class="logoSciVerseBlk"> <a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/" <span="" class="logoSciVerseImg">&nbsp;</a> </div> <div class="logoScienceDirectBlk"><a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/" title="ScienceDirect -The world's leading full-text scientific database"><span class="logoScienceDirectImg">&nbsp;</span></a></div>

</div>
<div id="suites" class="clearfix" aria-label="SciVerse" role="navigation">
<ul class="suites"><li><a href="http://www.hub.sciverse.com/action/home" title="Hub - SciVerse's integrated search">Hub</a></li><li><a title="ScienceDirect - the world's leading full-text scientific database" class="selected">ScienceDirect</a></li><li><a href="http://www.scopus.com.libgate.library.nuigalway.ie/" title="Scopus - the largest abstract and citation database of research literature and quality web sources">Scopus</a></li><li><a href="http://www.applications.sciverse.com/action/userhome" title=" Applications - SciVerse Applications" class="last">Applications</a></li></ul>
</div>
</div>		

     <!-- if not logged in -->
	   

			

    <div id="login" class="clearfix">
    	<ul>
		<li>
    
      <a href="https://www-sciencedirect-com.libgate.library.nuigalway.ie/science?_ob=RegistrationURL&amp;_method=display&amp;_type=ip&amp;_returnURL=http%3A%2F%2Fwww.sciencedirect.com%2Fsciencenp%3Dy&amp;_acct=C000007922&amp;_version=1&amp;_userid=103680&amp;md5=a003226ccf19a695734972d3bd54db42" target="_top" title="Register a ScienceDirect username and password for using alerts and other personal features">Register</a>
    
  </li>
  <!--top right widget-->
  <li class="login " id="loginPlus"><a href="javascript:LoginBox.flipLogin('loginBox',null);" title="Login to ScienceDirect" class="novisit plus nojs" id="loginPlusScript">Login</a><noscript><a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=HomePageURL&_method=userHomePage&_fl=y&_acct=C000007922&_version=1&_urlVersion=0&_userid=103680&md5=0773bdb54cea8075a9f1176d3dba54dc" title="Open the Login Box" class="plus" id="loginPlusNoScript" >Login</a></noscript>
  </li>
           
           <li class="last"><a href="http://www.scival.com/" title="Go to SciVal Suite">Go to SciVal Suite</a></li> 
        </ul>
    </div>
    
	<div id="loginBox" style="width: 600px; display: none;">
		
        <div style="width: 285px; float: right; border-left: 1px solid rgb(155, 155, 155); padding-left: 10px; min-height: 180px;">
        
        <div class="sampletext">
        <div style="font-weight: bold; padding-bottom: 5px;">Login via your institution</div>
		
		
		<div><a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=FederationURL&amp;_method=display&amp;_type=f&amp;prevURL=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0166354298000254%3Fnp%3Dy&amp;_acct=C000007922&amp;_version=1&amp;_userid=103680&amp;md5=f3508a614debf1e80eb4d8a0d8308a63" title="Go to Athens/ Institution login">Athens / Institution login</a></div>
		
        </div>
	
				
		
                  
                
            
            
        </div>
		
        <div class="padding" style="width: 285px;">
            <form name="sdLogin" method="POST" action="https://www-sciencedirect-com.libgate.library.nuigalway.ie/science/login" id="login-box-form" style="margin: 0px;">
            <b><span style="text-align: right; font-weight: bold;">Login using your SciVerse credentials</span></b>
			<input name="login" value="login" type="hidden">
            <div style="margin-top: 20px;">
            <label for="username"><span style="text-align: right;">Username:</span>
            <input id="username" name="userid" title="Please enter your username here" type="text"></label>
            </div>
            
            <div style="margin-top: 7px;">
            <label for="password"><span style="text-align: right;">Password:</span>
            <input id="password" name="password" maxlength="20" title="Please enter your password here" onkeypress="if(13==event.keyCode)this.form.submit();if (13==event.keyCode)return false;" type="password"></label>
            </div>
                   
                       
			
			<div class="remember">
			<input checked="" name="rememberid" id="rememberMe" value="Y" class="allCheck top2fix" title="Checking this option will log you in automatically next time you visit ScienceDirect" type="checkbox">
			<label for="rememberMe" title="Checking this option will log you in automatically next time you visit ScienceDirect">Remember me</label>
			</div>
            
			<input name="_ob" value="MiamiLogonURL" type="hidden">
			<input name="targetURL" value="http://www.sciencedirect.com/science/article/pii/S0166354298000254?np=y" type="hidden">
			<input name="returnURL" value="http://www.sciencedirect.com/science/article/pii/S0166354298000254?np=y" type="hidden">
            <div class="submit">
			
			<div style="float: left; padding-left: 0px;"><input class="button" name="arrow" alt="Login to ScienceDirect" title="Login to ScienceDirect" value="Login" type="Submit"></div>
        
			
			<div class="notRegistered"><span class="astPad">| </span><span><a href="https://www-sciencedirect-com.libgate.library.nuigalway.ie/science?_ob=RegistrationURL&amp;_method=display&amp;_type=ip&amp;_returnURL=http%3A%2F%2Fwww.sciencedirect.com%2Fsciencenp%3Dy&amp;_acct=C000007922&amp;_version=1&amp;_userid=103680&amp;md5=a003226ccf19a695734972d3bd54db42" title="" target="_top">Not Registered?</a></span></div>
			
			
			<div style="clear: left;"></div>
            </div>
			
            <div class="forgotpass">
			<a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=ReminderURL&amp;_method=display&amp;_acct=C000007922&amp;_version=1&amp;_userid=103680&amp;md5=d42879e2c3ee578ec4edb1badc8cf513" target="passwd" onclick="var remindWin;remindWin=window.open('','passwd','scrollbars=yes,resizable=yes,directories=no,toolbar=n,menubar=no,status=no,width=650,height=300');" title="Click here for help in recovering your ScienceDirect access">Forgotten username or password?</a>
            </div>
            </form>
        </div>
	</div>

	<!-- logged in -->
	     



<div id="navigationTop" class="clearfix" aria-label="ScienceDirect" role="navigation">
    <ul class="nav main">
        <li class="last">
            <a class=" canonHomeLink" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/" method="userHomePage" btn="Y" zone="TopNavBar" origin="home" target="_top" name="Home" title="Home">Home</a>
        </li>
        <li>
            <!--<h1>-->
            <a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/browse" type="all" auth="y" zone="TopNavBar" origin="article" target="_top" name="Publications" title="Publications">Publications</a>
            <!--</h1>-->
        </li>
        
        <li>
            <a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=MiamiSearchURL&amp;_method=requestForm&amp;_btn=Y&amp;_zone=TopNavBar&amp;_origin=article&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=1&amp;_userid=103680&amp;md5=6f00b17e70582bccfd79c0043e2d7e9d" target="_top" name="Search" title="Search">Search</a>
        </li>
        
        
        <li>
            <a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=UserSubscriptionURL&amp;_method=begin&amp;_btn=Y&amp;_zone=TopNavBar&amp;_origin=article&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=1&amp;_userid=103680&amp;md5=8246689b76c81456079cab859fc0613c" target="_top" name="account" title="My settings">My settings</a>
        </li>
        
        
        
        <li>
            <a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=MiamiSDIURL&amp;_method=listAlerts&amp;_btn=Y&amp;_zone=TopNavBar&amp;_origin=article&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=0&amp;_userid=103680&amp;md5=7614e1367f59f6ad24497b7cb1295fc7" target="_top" name="alert" title="Alerts">My alerts</a>
        </li>
        
        
    </ul>
    <ul class="nav misc">
        <li><span id="ChatHeader"></span></li>          
        <li class="last" style="margin-right: 247px;"><a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=HelpURL&amp;_file=browse_open_doc.htm&amp;_btn=Y&amp;_zone=TopNavBar&amp;_origin=article&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=0&amp;_userid=103680&amp;md5=3078a5cf677d428f5de42e4c8b948657" target="sdhelp" title="Help (Opens new window)" onclick="var helpWin; helpWin=window.open('http://www.sciencedirect.com/science?_ob=HelpURL&amp;_file=browse_open_doc.htm&amp;_btn=Y&amp;_zone=TopNavBar&amp;_origin=article&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=0&amp;_userid=103680&amp;md5=3078a5cf677d428f5de42e4c8b948657','sdhelp','scrollbars=yes,resizable=yes,directories=no,toolbar=no,menubar=no,status=no,width=760,height=570'); helpWin.focus(); return false">Help</a></li>      
    </ul> 
    
                
        <div id="bannerTop">                
            <div>Brought to you by:<br>
            
                <a href="http://www.library.nuigalway.ie.libgate.library.nuigalway.ie/" onclick="openNS('http://www.library.nuigalway.ie'); return false;">James Hardiman Library</a>
            
            </div>
        </div>
        
               
</div>

</div>


</div>













<div style="top: 102px; width: 1262px; left: 0px; bottom: 0px;" class="js" id="page-area">
  <div style="width: 1262px;" class="js" id="articleToolbar">
    <div id="articleNav">
  <ul aria-label="Article options" role="navigation">
    <li>
      <!-- return to gateway -->
       
      
    </li>





<li>
      <div class="icon_exportarticlesci_dir" title="Export citation">
        <div class="icon"></div>
        <a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=DownloadURL&amp;_method=confirm&amp;_eidkey=1-s2.0-S0166354298000254&amp;count=1&amp;_docType=FLA&amp;zone=toolbar&amp;_acct=C000007922&amp;_version=1&amp;_userid=103680&amp;md5=8c232b04e2a306b916a671ba55956f95">Export citation</a>
      </div>
</li>
  




<li>
  <div class="icon_pdf">
    <div class="icon"></div>
    <a id="pdfLink" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=MiamiImageURL&amp;_cid=271065&amp;_user=103680&amp;_pii=S0166354298000254&amp;_check=y&amp;_origin=article&amp;_zone=toolbar&amp;_coverDate=1998-Jun-01&amp;view=c&amp;originContentFamily=serial&amp;wchp=dGLzVlS-zSkWA&amp;md5=5491bfc4bb99e0f5db9bfdd2f7de75f3&amp;pid=1-s2.0-S0166354298000254-main.pdf" target="newPdfWin" pdfurl="http://www.sciencedirect.com/science?_ob=MiamiImageURL&amp;_cid=271065&amp;_user=103680&amp;_pii=S0166354298000254&amp;_check=y&amp;_origin=article&amp;_zone=toolbar&amp;_coverDate=1998-Jun-01&amp;view=c&amp;originContentFamily=serial&amp;wchp=dGLzVlS-zSkWA&amp;md5=5491bfc4bb99e0f5db9bfdd2f7de75f3&amp;pid=1-s2.0-S0166354298000254-main.pdf" class="big pdf ext_sdlink" style="cursor: pointer;" title="Download PDF">PDF  (3478 K)</a>
  </div>
</li>
 
 



<li class="optionsPos">
      <div id="moreOptionsButton" title="Show article options">
        <a href="#">More options...</a>
        <div class="down_sci_dir"></div>
      </div>

<!-- More Options Starts-->
<div id="moreOptionsMenu" class="articleOptions articleOptionssci_dir">
<ul class="menuContent">


    
    <li>
    <ul class="ereader">
        <li class="title">

            eReader format &nbsp;<a title="Help" onclick="var help; help=window.open('http://www.sciencedirect.com/science/help');">What's this?</a>
        </li>
        <li>
            <a id="epubLink" class="erLink" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/article/pii/S0166354298000254?np=y" title="ePub">
                <span class="icon epub">&nbsp;</span><span class="ereadertext">ePub</span>
            </a>
        </li>
        <li>
            <a id="mobiLink" class="erLink" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/article/pii/S0166354298000254?np=y" title="Mobipocket">
                <span class="icon mobi">&nbsp;</span><span class="ereadertext">Mobipocket</span>
            </a>
        </li>
    </ul>
    </li>
    





<li>
    <div class="emailsci_dir">
        <div></div>
        <a title="Email this article" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=EmailFriendURL&amp;_method=gatherInfo&amp;refSource=html&amp;count=1&amp;_eidkey=1-s2.0-S0166354298000254&amp;_acct=C000007922&amp;_version=1&amp;_userid=103680&amp;md5=da54f982ccffa453a05876c2d2fa4d18">Email article</a>
    </div>
</li>

  




   
       <li>
          <div id="alertOn" style="display: none;" class="alertsci_dir">
            <div></div>
            <span>

            Signed up for journal alerts&nbsp;[<a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=PublicationURL&amp;newIssueAlert=2&amp;_cid=271065&amp;_pubType=J&amp;_auth=y&amp;originContentFamily=serial&amp;_pii=S0166354298000254&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=0&amp;_userid=103680&amp;md5=1ed3344f6df343aeb88ca46ca4754a3c">remove</a>]</span>
          </div>
          <div id="alertOff" style="display: inline;" class="alertsci_dir">
            <div></div>
            <a title="Set new Volumes / Issues alert" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=PublicationURL&amp;newIssueAlert=2&amp;_cid=271065&amp;_pubType=J&amp;_auth=y&amp;originContentFamily=serial&amp;_pii=S0166354298000254&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=0&amp;_userid=103680&amp;md5=1ed3344f6df343aeb88ca46ca4754a3c">

            Alert me about new articles in this journal
            </a>
          </div>
          <div id="rsltInd" style="display: none;">
            <div class="imgIcon"><h3><img src="errorIcon.gif" alt="Failure" title="Failure"></h3></div>
            <div class="confirmMsgText">Your selection(s) could not be saved due to an internal error. Please try again.</div>
          </div>          
      </li>
    


<li>
    <div class="thumbnailsci_dir">
        <div></div>
        <a href="javascript:void(0);" id="optImgToggle" title="">Show thumbnail images</a>
    </div>
</li>

</ul>
<div id="articleOptionsAd" role="banner" class="ad"></div>
</div>
<!-- More options Ends -->
</li>
<li id="erToolbar"></li>




</ul>
</div>

<div class="sdSearch" aria-label="Quick search" role="search">
    <fieldset>
        <div class="left">
            <input style="color: rgb(155, 155, 155);" id="quickSearch" name="quickSearch" value="Search ScienceDirect" size="30" maxlength="450" title="Perform a quick search on ScienceDirect" type="text"><button class="submit" title="Submit quick search">Search</button>
        </div>
        <div id="quickSearchButton" class="right" title="Show more quick search options">
            <div class="down_sci_dir"></div>
        </div>
    </fieldset>
</div>
<div class="clear"></div>
<div style="width: 1235px;" class="quickSearch" id="sdQuickSearch" aria-label="Extended search" role="search">
<div class="extSearch" role="search" aria-label="Quick Search">


<form name="qkSrch" method="get" target="_top" action="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science" style="margin: 0px;">
<input name="_ob" value="QuickSearchURL" type="hidden">
<input name="_method" value="submitForm" type="hidden">
<input name="_acct" value="C000007922" type="hidden">
<input name="_origin" value="article" type="hidden">
<input name="_zone" value="qSearch" type="hidden">
<input name="md5" value="150d94845014a5f578fff24e6f5ff0a9" type="hidden">

<table style="margin: 0px;" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr valign="middle">

<!-- JS enabled. Code for Articles -->

<td align="center" nowrap="nowrap">
<label for="Articles" style="cursor: pointer; padding-right: 0px; margin-left: 2px;" class="nojs">Articles</label>
<input class="qsRadio nojs" name="searchtype" id="Articles" value="a" checked="checked" style="" type="radio">
<noscript>

<!-- JS disabled. Code for Articles -->
<span style="margin-left:13px;">Articles</span>
</noscript>
</td>


<!-- Code related for toggling labels -->


<td align="right"><label for="qs_all" id="fieldLabel">&nbsp;&nbsp;&nbsp;&nbsp;All fields</label></td>
<td align="left"><input class="textbox qsinput xpstyle qsImgBlurFocus" name="qs_all" id="qs_all" value="" size="30" maxlength="450" title="For example: heart attack AND behavior?" type="text"></td>




<td align="right"><label for="qs_author">&nbsp;&nbsp;&nbsp;&nbsp;Author</label></td>
<td colspan="5" align="left"><input class="textbox qsinput xpstyle" name="qs_author" id="qs_author" value="" size="33" maxlength="450" title="e.g. J S Smith or John Smith or Smith JS" style="_width:100%" type="text"></td>
<td nowrap="nowrap">

</td><td></td><td></td>
<td align="right" nowrap="nowrap" valign="middle" width="90%">
<a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=MiamiSearchURL&amp;_method=requestForm&amp;_btn=Y&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=1&amp;_userid=103680&amp;md5=36be44d02ea7cffa13df23aca528620a" style="vertical-align: bottom; font-size: 0.92em;">Advanced search</a>
</td>
</tr>
<tr>

<!-- JS enabled. Code for images -->

<td align="center" nowrap="nowrap">
<label for="Images" style="cursor: pointer; padding-right: 0px;" class="nojs">Images</label>
<input class="qsRadio nojs" name="searchtype" id="Images" value="i" type="radio">
<noscript>

<!-- JS disabled. Code for Images -->
<span style="margin-left:13px;"><a href="/science?np=y&imgSel=Y" >Images</a></span>
</noscript>
</td>


<td align="right"><label for="qs_title">&nbsp;&nbsp;&nbsp;&nbsp;Journal/Book&nbsp;title</label></td>
<td align="left"><input autocomplete="off" class="textbox qsinput xpstyle ui-autocomplete-input" id="qs_title" name="qs_title" value="" size="30" maxlength="450" title="For example: journal of molecular biology" type="text"><span class="ui-helper-hidden-accessible" aria-live="polite" role="status"></span></td>


<td class="toggleQukSrch2" align="right"><label for="qs_vol" id="volField">&nbsp;&nbsp;&nbsp;&nbsp;Volume</label></td>
<td class="toggleQukSrch" align="left"><input class="textbox qsinput xpstyle" name="qs_vol" id="qs_vol" value="" size="3" maxlength="10" style="width: 30px;" type="text"></td>
<td class="toggleQukSrch2" align="right"><label for="qs_issue" id="issueField">&nbsp;&nbsp;Issue</label></td>
<td class="toggleQukSrch" align="left"><input class="textbox qsinput xpstyle" name="qs_issue" id="qs_issue" value="" size="3" maxlength="10" style="width: 30px;" type="text"></td>
<td class="toggleQukSrch2" align="right"><label for="qs_pages" id="pageField">&nbsp;&nbsp;Page</label></td>
<td class="toggleQukSrch" align="right"><input class="textbox qsinput xpstyle" name="qs_pages" id="qs_pages" value="" size="3" maxlength="10" title="For example: 14-27" style="width: 30px;" type="text"></td>


<td align="right" nowrap="nowrap">
<input class="button" id="submit_search" alt="Submit Quick Search" title="Submit Quick Search" value="Search" name="sdSearch" type="Submit">
</td> 
<td colspan="8" align="right" nowrap="nowrap" valign="bottom">
<a class="icon_qmarkHelpsci_dir" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=HelpURL&amp;_origin=srch_form&amp;_zone=TopNavBar&amp;_file=qs_tips.htm&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=0&amp;_userid=103680&amp;md5=ae1e488939a34c669c24f09774e72b25" target="sdhelp" onmouseover="window.status='Help is Available';return true" onmouseout="window.status='';return true" onclick="var helpWin;helpWin=window.open('http://www.sciencedirect.com/science?_ob=HelpURL&amp;_file=qs_tips.htm&amp;_acct=C000007922&amp;_version=1&amp;_urlVersion=0&amp;_userid=103680&amp;md5=426a1ddabd0771203259aa91ecaa495c','sdhelp','scrollbars=yes,resizable=yes,directories=no,toolbar=no,menubar=no,status=no,width=760,height=570');helpWin.focus();return false" style="font-size: 0.92em; padding-right: 0px;">Search tips</a>
</td>
</tr>
</tbody></table>
</form>
</div>



 
</div>

<div style="color: rgb(255, 0, 0); font-weight: bold; border: 0px solid red;">
  
  
  
  
</div>





  </div>
  <div style="clear: both;"></div>
  <div style="margin-top: 26px; left: 3px;" class="js" id="leftCloseBar">
      <div class="closed" title="Open to view article outline"></div>
  </div>
  <div style="top: 26px; left: 3px; width: 258px;" id="leftPane" class="column js" aria-label="table of contents" role="navigation">
  <div class="js" id="leftPaneInner"><div id="olGraphCbBox"><label><input id="outlineGraphicsCheckBox" checked="true" type="checkBox">Show thumbnails in outline</label></div>
    <div data-st="0" style="top: 32px; overflow: hidden; background: none repeat ; 0% rgb(236, 242, 246);" id="outline" class="outline js">
      <script type="text/javascript">

      document.write("<div class='outlineMsg'>Article outline is loading...</div>");
      </script>
      <noscript>

      <div class="infoMsg">
      <div style="float: left; width: 20px; "><img border="0" src="http://cdn.els-cdn.com/sd/alertIcon.gif" valign="top" alt="Alert message"></div>
      <div style="padding-left:25px;">JavaScript is disabled on your browser. 
<div style="padding-top:10px;">
      Please enable JavaScript to use all the features on this page.</div></div>
      </div>
      </noscript>
      <ul style="display: block; background: none repeat ; 0% rgb(236, 242, 246);" id="itemOutline"><li style="margin-right: 15px;"><div id="ol_section_abstract" class="io item h2sec"><a class="tocLink" href="#section_abstract" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">Abstract<br></a></div></li><li style="margin-right: 15px;"><div id="ol_kwd_1" class="io item h2sec"><a class="tocLink" href="#kwd_1" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">Keywords<br></a></div></li><li style="margin-right: 15px;"><div id="ol_section_lbl1" class="io item h2sec"><a class="tocLink" href="#section_lbl1" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">1. Introduction<br></a></div></li><li style="margin-right: 15px;"><div id="ol_section_lbl2" class="io item h2sec"><a class="tocLink" href="#section_lbl2" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)<br></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG1" class="io item h2sec fig"><a class="tocLink" href="#FIG1" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr1.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr1.sml" data-thumbheight="93"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG2" class="io item h2sec fig"><a class="tocLink" href="#FIG2" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr2.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr2.sml" data-thumbheight="94"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG3" class="io item h2sec fig"><a class="tocLink" href="#FIG3" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr3.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr3.sml" data-thumbheight="93"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG4" class="io item h2sec fig"><a class="tocLink" href="#FIG4" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr4.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr4.sml" data-thumbheight="94"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG5" class="io item h2sec fig"><a class="tocLink" href="#FIG5" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr5.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr5.sml" data-thumbheight="93"></a></div></li><li style="margin-right: 15px;"><div id="ol_TBL1" class="io item h2sec tbl"><div class="olIcon olIconTbl"></div><a class="tocLink olIcon olIconTbl" href="#TBL1" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial'); ">Table 1</a></div></li><li style="margin-right: 15px;"><div id="ol_section_lbl3" class="io item h2sec"><a class="tocLink" href="#section_lbl3" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">3. Interaction of NNRTIs with their pocket site at the HIV-1 RT<br></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG6" class="io item h2sec fig"><a class="tocLink" href="#FIG6" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr6v7.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr6v7.sml" data-thumbheight="92"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG7" class="io item h2sec fig"><a class="tocLink" href="#FIG7" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr6v7.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr6v7.sml" data-thumbheight="92"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG8" class="io item h2sec fig"><a class="tocLink" href="#FIG8" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr8v9.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr8v9.sml" data-thumbheight="93"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG9" class="io item h2sec fig"><a class="tocLink" href="#FIG9" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr8v9.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr8v9.sml" data-thumbheight="93"></a></div></li><li style="margin-right: 15px;"><div id="ol_section_lbl4" class="io item h2sec"><a class="tocLink" href="#section_lbl4" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">4. HIV-1 resistance to NNRTIs<br></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG10" class="io item h2sec fig"><a class="tocLink" href="#FIG10" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img data-loaded="true" src="1-s2.0-S0166354298000254-gr10.sml" class="smlImgLazyJSB greyImg displayImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr10.sml" data-thumbheight="76"></a></div></li><li style="margin-right: 15px;"><div id="ol_TBL2" class="io item h2sec tbl"><div class="olIcon olIconTbl"></div><a class="tocLink olIcon olIconTbl" href="#TBL2" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial'); ">Table 2</a></div></li><li style="margin-right: 15px;"><div id="ol_section_lbl5" class="io item h2sec"><a class="tocLink" href="#section_lbl5" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">5. Optimization of NNRTI treatment regimens<br></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG11" class="io item h2sec fig"><a class="tocLink" href="#FIG11" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr11.sml" data-thumbheight="94"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG12" class="io item h2sec fig"><a class="tocLink" href="#FIG12" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr12v13.sml" data-thumbheight="94"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG13" class="io item h2sec fig"><a class="tocLink" href="#FIG13" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr12v13.sml" data-thumbheight="94"></a></div></li><li style="margin-right: 15px;"><div id="ol_section_lbl6" class="io item h2sec"><a class="tocLink" href="#section_lbl6" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">6. In vivo efficacy of NNRTIs<br></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG14" class="io item h2sec fig"><a class="tocLink" href="#FIG14" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr14.sml" data-thumbheight="94"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG15" class="io item h2sec fig"><a class="tocLink" href="#FIG15" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr15.sml" data-thumbheight="92"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG16" class="io item h2sec fig"><a class="tocLink" href="#FIG16" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr16.sml" data-thumbheight="93"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG17" class="io item h2sec fig"><a class="tocLink" href="#FIG17" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr17.sml" data-thumbheight="94"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG18" class="io item h2sec fig"><a class="tocLink" href="#FIG18" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr18.sml" data-thumbheight="92"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG19" class="io item h2sec fig"><a class="tocLink" href="#FIG19" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr19.sml" data-thumbheight="94"></a></div></li><li style="margin-right: 15px;"><div id="ol_FIG20" class="io item h2sec fig"><a class="tocLink" href="#FIG20" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');"><img src="grey_pxl.gif" class="smlImgLazyJSB greyImg" data-smlsrc="http://ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr20.sml" data-thumbheight="93"></a></div></li><li style="margin-right: 15px;"><div id="ol_section_lbl7" class="io item h2sec"><a class="tocLink" href="#section_lbl7" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">7. Conclusion<br></a></div></li><li style="margin-right: 15px;"><div id="ol_TBL3" class="io item h2sec tbl"><div class="olIcon olIconTbl"></div><a class="tocLink olIcon olIconTbl" href="#TBL3" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial'); ">Table 3</a></div></li><li style="margin-right: 15px;"><div id="ol_ack001" class="io item h2sec"><a class="tocLink" href="#ack001" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">Acknowledgements<br></a></div></li><li style="margin-right: 15px;"><div id="ol_bibl001" class="io item h2sec"><a class="tocLink" href="#bibl001" onclick="SD_UTIL.sendUserKeyEvent('displayTOCSection', 'article', 'leftPane', 'serial');">References<br></a></div></li></ul><div style="width: 241px; background: none repeat ; 0% rgb(236, 242, 246);" id="articleLeftAd"><iframe class="usmonndchupfwwcnugwg" style="background: none repeat ; 0% rgb(236, 242, 246);" border="0" cellspacing="0" src="S0166354298000254_1.html" frameborder="0" scrolling="no"></iframe><iframe class="usmonndchupfwwcnugwg" border="0" cellspacing="0" src="S0166354298000254_2.html" frameborder="0" scrolling="no"></iframe></div></div>
      <div style="display: none;" id="leftOpenBar">
        <div class="open" title="Open to view article outline"></div>
      </div>
  </div>
  </div>
  <div tabindex="-1" data-st="0" data-dir="u" style="top: 26px; left: 261px;" id="centerPane" class="column js">
    <div id="centerInner" class="centerInner svBigBox js" aria-label="Article" role="main">
      
<script>prs.rt('data_start');</script>
      <div class="authClaim"></div><div class="head"><div class="publisherLogo"><img data-loaded="true" style="display: inline;" alt="" id="pubLogo" class="imgLazyJSB" src="elsevier.gif" data-defaultlogo="/elsevier.gif"><noscript><img alt="" src="http://origin-cdn.els-cdn.com/sd/elsevier.gif"></noscript></div><div class="publicationHead"><div class="title"><a title="Go to Antiviral Research on SciVerse ScienceDirect" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/journal/01663542" querystr="?zone=centerPane" class="cLink"><span>Antiviral Research</span></a></div><p class="volIssue"><a title="Go to table of contents for this volume/issue" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/journal/01663542/38/3">Volume 38, Issue 3</a>, 1 June 1998, Pages 153–179</p></div><div class="publicationCover"><a querystr="?zone=publicationLogo" class="cLink" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/journal/01663542/38/3"><img data-loaded="true" style="display: inline;" alt="Cover image" src="S01663542.gif" class="toprightlogo imgLazyJSB" data-publogo="S01663542.gif"><noscript><img alt="Cover image" src="http://origin-ars.els-cdn.com/content/image/S01663542.gif" class="toprightlogo"></noscript></a></div></div><div id="" class="publicationType"><span id="">Mini-review</span></div><div class="module_topic_paths"></div><h1 class="svTitle" id="">The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection<span id="bFN1"><a href="#FN1" id="ancbFN1" class="intra_ref"><sup>1</sup></a></span></h1><ul class="authorGroup noCollab" id=""><li><a href="#" class="authorName" id="authname_N7f51ed20N2a5ee610" data-t="a" data-fn="Erik" data-ln="De Clercq" data-pos="1">Erik De Clercq</a></li></ul><div class="endLine"></div><ul class="affiliation"><li> <span id="">Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium</span></li></ul><!--VALIDHTML--><!--comment--><dl class="articleDates"><dd>Received 2 April 1998</dd><dd>Accepted 20 April 1998</dd><dd>Available online 6 August 1998</dd></dl><!--VALIDHTML--><ul class="articleDoi"><li><a id="ddDoi" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/S0166-3542(98)00025-4" target="doilink" onclick="var doiWin; doiWin=window.open('http://dx.doi.org/10.1016/S0166-3542(98)00025-4','doilink','scrollbars=yes,resizable=yes,directories=yes,toolbar=yes,menubar=yes,status=yes'); doiWin.focus()">http://dx.doi.org/10.1016/S0166-3542(98)00025-4</a>, <a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/help/doi.htm" target="sdhelp" onmouseover="window.status='Help is Available';return true" onclick="var helpWin; helpWin=window.open('http://www.sciencedirect.com/science/help/doi.htm','sdhelp','scrollbars=yes,resizable=yes,directories=no,toolbar=no,menubar=no,status=no,width=760,height=570'); helpWin.focus()">How to Cite or Link Using DOI</a></li></ul><!--VALIDHTML--><ul class="articleInfo"><li class="permissions" id="permissions"><div class="boxLink"><a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=RedirectURL&amp;_method=outwardLink&amp;_partnerName=936&amp;_eid=1-s2.0-S0166354298000254&amp;_pii=S0166354298000254&amp;_origin=article&amp;_zone=art_page&amp;_targetURL=https%3A%2F%2Fs100.copyright.com%2FAppDispatchServlet%3FpublisherName%3DELS%26contentID%3DS0166354298000254%26orderBeanReset%3Dtrue&amp;_acct=C000007922&amp;_version=1&amp;_userid=103680&amp;md5=7f795f55e4dec892159e436c7e305c94" rel="nofollow" class="olSpawnWindow" target="outwardLink">Permissions &amp; Reprints</a></div></li></ul><!--VALIDHTML--><div id="ppvPlaceHolder" class="hidden"></div><!--VALIDHTML--><div id="refersToAndreferredToBy"><dl id="referredToBy" class="documentThread"><!--Referred To By--></dl></div><!--VALIDHTML--><hr id="author1"><div class="abstract svAbstract "><h2 class="secHeading" id="section_abstract">Abstract</h2><p id="">Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have, in addition to the nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), gained a definitive place in the treatment of HIV-1 infections. Starting from the HEPT and TIBO derivatives, more than 30 structurally different classes of compounds have been identified as NNRTIs, that is compounds that are specifically inhibitory to HIV-1 replication and targeted at the HIV-1 reverse transcriptase (RT). Two NNRTIs (nevirapine and delavirdine) have been formally licensed for clinical use and several others are in preclinical or clinical development [thiocarboxanilide UC-781, HEPT derivative MKC-442, quinoxaline HBY 097 and DMP 266 (efavirenz)]. The NNRTIs interact with a specific `pocket' site of HIV-1 RT that is closely associated with, but distinct from, the NRTI binding site. NNRTIs are notorious for rapidly eliciting resistance due to mutations of the amino acids surrounding the NNRTI-binding site. However, the emergence of resistant HIV strains can be circumvented if the NNRTIs, alone or in combination, are used from the start at sufficiently high concentrations. In vitro, this procedure has proved to `knock-out' virus replication and to prevent resistance from arising. In vivo, various triple-drug combinations of NNRTIs (nevirapine, delavirdine or efavirenz) with NRTIs (AZT, 3TC, ddI or d4T) and/or PIs (indinavir or nelfinavir) have been shown to afford a durable anti-HIV activity, as reflected by both a decrease in plasma HIV-1 RNA levels and increased CD4 T-lymphocyte counts.</p></div><!--VALIDHTML--><script>prs.rt("abs_end");</script><div id="SD_BA1P" class="sgfNoTitleBar sgfNoGadgetBorder svDoNotLink"></div><!--VALIDHTML--><h2 id="kwd_1">Keywords</h2><ul class="keyword" id=""><li id=""><span id="">Delavirdine</span>; </li><li id=""><span id="">HIV</span>; </li><li id=""><span id="">Nevirapine</span>; </li><li id=""><span id="">NNRTIs (non-nucleoside reverse transcriptase inhibitors)</span>; </li><li id=""><span id="">Reverse transcriptase</span>; </li><li id=""><span id="">Triple-drug combinations</span></li></ul><!--VALIDHTML--><hr><h2 class="svArticle" id="section_lbl1">1. Introduction</h2><p class="svArticle section" id="">The therapy of HIV (human immunodeficiency virus) infections has, since the advent of azidothymidine, been dominated by the 2′,3′-dideoxynucleoside (ddN) derivatives, five of which are now licensed for clinical use: azidothymidine (AZT, zidovudine, Retrovir®), dideoxyinosine (ddI, didanosine, Videx®), dideoxycytidine (ddC, zalcitabine, Hivid®), didehydrodideoxythymidine (d4T, stavudine, Zerit®) and 3′-thiadideoxycytidine (3TC, lamivudine, Epivir®). Four HIV protease inhibitors [i.e. saquinavir (Invirase®), ritonavir (Norvir®), indinavir (Crixivan®) and nelfinavir (Viracept®)] have joined the current anti-HIV drug armamentarium (<a href="#BIB47" id="bBIB47" class="intra_ref">De Clercq, 1995</a>&nbsp;and&nbsp;<a href="#BIB50" id="bBIB50" class="intra_ref">De Clercq, 1997</a>) and NNRTIs (non-nucleoside reverse transcriptase inhibitors) (<a href="#BIB48" id="bBIB48" class="intra_ref">De Clercq, 1996a</a>&nbsp;and&nbsp;<a href="#BIB49" id="bBIB49" class="intra_ref">De Clercq, 1996b</a>) have recently gained an increasingly important role in the therapy of HIV infections. Several NNRTIs have proceeded onto clinical development (i.e. tivirapine, loviride, MKC-442, HBY 097, DMP 266) or are already licensed for clinical use [nevirapine (Viramune®), delavirdine (Rescriptor®)].</p><!--VALIDHTML--><p class="svArticle section" id="">The era of the NNRTIs started about a decennium ago with the discovery of 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) (<a href="#BIB5" id="bBIB5" class="intra_ref">Baba et al., 1989</a>&nbsp;and&nbsp;<a href="#BIB100" id="bBIB100" class="intra_ref">Miyasaka et al., 1989</a>) and tetrahydroimidazo[4,5,1-jkj][1,4]benzodiazepin-2(1<em>H</em>)-one and -thione (TIBO) ( <a href="#BIB107" id="bBIB107" class="intra_ref">Pauwels et al., 1990</a>&nbsp;and&nbsp;<a href="#BIB45" id="bBIB45" class="intra_ref">Debyser et al., 1991</a>) as specific HIV-1 inhibitors, targeted at the HIV-1 reverse transcriptase ( <a href="#BIB107" id="bBIB107" class="intra_ref">Pauwels et al., 1990</a>, <a href="#BIB6" id="bBIB6" class="intra_ref">Baba et al., 1991a</a>, <a href="#BIB7" id="bBIB7" class="intra_ref">Baba et al., 1991b</a>&nbsp;and&nbsp;<a href="#BIB45" id="bBIB45" class="intra_ref">Debyser et al., 1991</a>). These compounds excelled by their unique specificity for HIV-1: they were highly active against HIV-1, but inactive against HIV-2 or any other retrovirus, and, furthermore, their antiviral action could be attributed to a specific interaction with the viral reverse transcriptase (RT).</p><!--VALIDHTML--><p class="svArticle section" id="">Following the HEPT and TIBO derivatives, nevirapine (BI-RG-587) (<a href="#BIB98" id="bBIB98" class="intra_ref">Merluzzi et al., 1990</a>&nbsp;and&nbsp;<a href="#BIB86" id="bBIB86" class="intra_ref">Koup et al., 1991</a>), pyridinone derivatives L-696,229 and L-697,661 (<a href="#BIB66" id="bBIB66" class="intra_ref">Goldman et al., 1991</a>&nbsp;and&nbsp;<a href="#BIB67" id="bBIB67" class="intra_ref">Goldman et al., 1992</a>), and bis(heteroaryl)piperazine (BHAP) derivatives U-88204 and U-90152 (<a href="#BIB118" id="bBIB118" class="intra_ref">Romero et al., 1991</a>&nbsp;and&nbsp;<a href="#BIB119" id="bBIB119" class="intra_ref">Romero et al., 1993</a>) were identified as specific HIV-1 inhibitors. In contrast with HEPT and TIBO, which were first found to inhibit HIV-1 replication in cell culture before their target (HIV-1 RT) was unraveled, nevirapine, pyridinone and BHAP were discovered through an HIV-1 RT screening program before their antiviral activity in cell culture was established.</p><!--VALIDHTML--><p class="svArticle section" id="">Following HEPT, TIBO, nevirapine, pyridinone and BHAP, yet other compounds, i.e. TSAO-T and TSAO-m<sup>3</sup>T (<a href="#BIB10" id="bBIB10" class="intra_ref">Balzarini et al., 1992a</a>, <a href="#BIB11" id="bBIB11" class="intra_ref">Balzarini et al., 1992b</a>&nbsp;and&nbsp;<a href="#BIB12" id="bBIB12" class="intra_ref">Balzarini et al., 1992c</a>), loviride [<em>α</em>-APA (R89439)] (<span id="bBIB108"><a href="#BIB108" id="ancbBIB108" class="intra_ref">Pauwels et al., 1993</a></span>), PETT (LY 300046) (<span id="bBIB1"><a href="#BIB1" id="ancbBIB1" class="intra_ref">Ahgren et al., 1995</a></span>), new derivatives from HEPT [i.e. I-EBU (MKC-442)] (<span id="bBIB8"><a href="#BIB8" id="ancbBIB8" class="intra_ref">Baba et al., 1994</a></span>) and TIBO [i.e. 8-chloro-TIBO, tivirapine (R86183)] (<span id="bBIB109"><a href="#BIB109" id="ancbBIB109" class="intra_ref">Pauwels et al., 1994</a></span>), and various other compounds were described as specific HIV-1 RT inhibitors, and all these compounds have been collectively referred as NNRTIs ( <a href="#BIB48" id="bBIB48" class="intra_ref">De Clercq, 1996a</a>&nbsp;and&nbsp;<a href="#BIB49" id="bBIB49" class="intra_ref">De Clercq, 1996b</a>) to distinguish them from the ddNs, now also referred to as NRTIs (nucleoside reverse transcriptase inhibitors) ( <a href="#BIB47" id="bBIB47" class="intra_ref">De Clercq, 1995</a>&nbsp;and&nbsp;<a href="#BIB50" id="bBIB50" class="intra_ref">De Clercq, 1997</a>).</p><!--VALIDHTML--><h2 class="svArticle" id="section_lbl2">2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</h2><p class="svArticle section" id="">To qualify as an NNRTI, the compound should interact specifically with (a non-substrate binding site of) the RT of HIV-1, and inhibit the replication of HIV-1, but not HIV-2 (or any other retrovirus) at a concentration that is significantly lower than the concentration required to affect normal cell viability (<span id="bBIB48"><a href="#BIB48" id="ancbBIB48" class="intra_ref">De Clercq, 1996a</a></span>). The potency and selectivity of the NNRTIs as specific inhibitors of HIV-1 should be evident from the EC<sub>50</sub> (50% effective concentration, required to inhibit HIV-1 replication in cell culture) and the ratio of their CC<sub>50</sub> (50% cytotoxic concentration) to the EC<sub>50</sub>. The latter is termed selectivity index (SI). The interaction of the NNRTIs with HIV-1 RT should be evident from their <em>K</em><sub>i</sub> or IC<sub>50</sub> (50% inhibitory concentration) for the enzyme.</p><!--VALIDHTML--><p class="svArticle section" id="">Based on these premises, at least 30 different classes of NNRTIs could be considered (<span id="bFIG1"><a href="#FIG1" id="ancbFIG1" class="intra_ref">Fig. 1</a></span><span id="bFIG2"><a href="#FIG2" id="ancbFIG2" class="intra_ref">Fig. 2</a></span><span id="bFIG3"><a href="#FIG3" id="ancbFIG3" class="intra_ref">Fig. 3</a></span><span id="bFIG4"><a href="#FIG4" id="ancbFIG4" class="intra_ref">Fig. 4</a></span><span id="bFIG5"><a href="#FIG5" id="ancbFIG5" class="intra_ref">Fig. 5</a></span>): TIBO derivatives [i.e. 8-chloro-TIBO (R86183, tivirapine)] (<span id="bBIB109"><a href="#BIB109" id="ancbBIB109" class="intra_ref">Pauwels et al., 1994</a></span>), HEPT derivatives [i.e. I-EBU (MKC-442)] (<span id="bBIB8"><a href="#BIB8" id="ancbBIB8" class="intra_ref">Baba et al., 1994</a></span>), dipyridodiazepinones [i.e. nevirapine (BI-RG-587)] (<a href="#BIB98" id="bBIB98" class="intra_ref">Merluzzi et al., 1990</a>&nbsp;and&nbsp;<a href="#BIB86" id="bBIB86" class="intra_ref">Koup et al., 1991</a>), pyridinones (i.e. L-697,661) (<span id="bBIB66"><a href="#BIB66" id="ancbBIB66" class="intra_ref">Goldman et al., 1991</a></span>), BHAP derivatives [i.e. delavirdine (U-90152)] (<span id="bBIB59"><a href="#BIB59" id="ancbBIB59" class="intra_ref">Dueweke et al., 1993a</a></span>), TSAO derivatives (i.e. TSAO-m<sup>3</sup>T) (<a href="#BIB10" id="bBIB10" class="intra_ref">Balzarini et al., 1992a</a>&nbsp;and&nbsp;<a href="#BIB11" id="bBIB11" class="intra_ref">Balzarini et al., 1992b</a>), <em>α</em>-APA derivatives [i.e. loviride (R89439)] (<span id="bBIB108"><a href="#BIB108" id="ancbBIB108" class="intra_ref">Pauwels et al., 1993</a></span>), PETT derivatives [i.e. trovirdine (LY 300046)] ( <a href="#BIB1" id="bBIB1" class="intra_ref">Ahgren et al., 1995</a>&nbsp;and&nbsp;<a href="#BIB146" id="bBIB146" class="intra_ref">Zhang et al., 1995</a>), thiocarboxanilide derivatives (i.e. UC-781) ( <a href="#BIB15" id="bBIB15" class="intra_ref">Balzarini et al., 1995a</a>&nbsp;and&nbsp;<a href="#BIB33" id="bBIB33" class="intra_ref">Buckheit et al., 1997</a>), quinoxaline derivatives (i.e. HBY 097) ( <a href="#BIB81" id="bBIB81" class="intra_ref">Kleim et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB83" id="bBIB83" class="intra_ref">Kleim et al., 1995</a>), thiazolobenzimidazole (TBZ, NSC 625487) ( <a href="#BIB29" id="bBIB29" class="intra_ref">Buckheit et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB39" id="bBIB39" class="intra_ref">Chimirri et al., 1997</a>), thiazoloisoindolinone (BM+51.0836) ( <a href="#BIB91" id="bBIB91" class="intra_ref">Maass et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB99" id="bBIB99" class="intra_ref">Mertens et al., 1993</a>), indole carboxamide L-737,126 (<span id="bBIB139"><a href="#BIB139" id="ancbBIB139" class="intra_ref">Williams et al., 1993</a></span>), benzothiadiazine NSC 287474 (<span id="bBIB30"><a href="#BIB30" id="ancbBIB30" class="intra_ref">Buckheit et al., 1994a</a></span>), quinazolinone (<strong class="boldFont">13a</strong>) (<span id="bBIB135"><a href="#BIB135" id="ancbBIB135" class="intra_ref">Tucker et al., 1994</a></span>), benzoxazinone DMP 266 (efavirenz) (<span id="bBIB143"><a href="#BIB143" id="ancbBIB143" class="intra_ref">Young et al., 1995</a></span>), calanolide A ( <a href="#BIB78" id="bBIB78" class="intra_ref">Kashman et al., 1992</a>&nbsp;and&nbsp;<a href="#BIB145" id="bBIB145" class="intra_ref">Zembower et al., 1997</a>), pyrrolobenzodiazepinone (<strong class="boldFont">4</strong>) (<span id="bBIB52"><a href="#BIB52" id="ancbBIB52" class="intra_ref">De Lucca and Otto, 1992</a></span>), imidazodipyridodiazepine UK-129,485 (<span id="bBIB134"><a href="#BIB134" id="ancbBIB134" class="intra_ref">Terrett et al., 1992</a></span>), imidazopyridazine (<strong class="boldFont">33</strong>) (<span id="bBIB89"><a href="#BIB89" id="ancbBIB89" class="intra_ref">Livermore et al., 1993</a></span>), thiadiazolyl dialkylcarbamate (TDA RD-4-2024) ( <a href="#BIB73" id="bBIB73" class="intra_ref">Ijichi et al., 1995</a>&nbsp;and&nbsp;<a href="#BIB74" id="bBIB74" class="intra_ref">Ijichi et al., 1996</a>), arylpyridodiazepine and -thiodiazepine derivatives (i.e. MEN 10979) (<span id="bBIB25"><a href="#BIB25" id="ancbBIB25" class="intra_ref">Bellarosa et al., 1996</a></span>), DABO derivatives (i.e. DABO, <strong class="boldFont">12e</strong>) ( <a href="#BIB4" id="bBIB4" class="intra_ref">Artico et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB93" id="bBIB93" class="intra_ref">Massa et al., 1995</a>), HEPT-pyridinone hybrids (i.e. <strong class="boldFont">8a</strong>) (<span id="bBIB57"><a href="#BIB57" id="ancbBIB57" class="intra_ref">Dollé et al., 1995</a></span>), benzyloxymethylpyridinone (<strong class="boldFont">18a</strong>) (<span id="bBIB77"><a href="#BIB77" id="ancbBIB77" class="intra_ref">Jourdan et al., 1997</a></span>), alkoxy(arylthio)uracil (<strong class="boldFont">18</strong>) (<span id="bBIB80"><a href="#BIB80" id="ancbBIB80" class="intra_ref">Kim et al., 1997</a></span>), indolyldipyridodiazepinone (<strong class="boldFont">7a</strong>) (<span id="bBIB79"><a href="#BIB79" id="ancbBIB79" class="intra_ref">Kelly et al., 1997</a></span>), pyrrolobenzoxazepinone (<strong class="boldFont">16e</strong>) (<span id="bBIB36"><a href="#BIB36" id="ancbBIB36" class="intra_ref">Campiani et al., 1996</a></span>), highly substituted pyrroles (<span id="bBIB3"><a href="#BIB3" id="ancbBIB3" class="intra_ref">Antonucci et al., 1995</a></span>), the benzylthiopyrimidine U-31355 (<span id="bBIB2"><a href="#BIB2" id="ancbBIB2" class="intra_ref">Althaus et al., 1996</a></span>) and pyridazinobenzoxazepinones (<span id="bBIB24"><a href="#BIB24" id="ancbBIB24" class="intra_ref">Barth et al., 1996</a></span>). More recently, pyrrolobenzothiadiazepines (<span id="bBIB56"><a href="#BIB56" id="ancbBIB56" class="intra_ref">Di Santo et al., 1998</a></span>), indolobenzothiazepines (<span id="bBIB127"><a href="#BIB127" id="ancbBIB127" class="intra_ref">Silvestri et al., 1998</a></span>), and trioxothienothiadiazine (TTD) derivatives (<span id="bBIB141"><a href="#BIB141" id="ancbBIB141" class="intra_ref">Witvrouw et al., 1998</a></span>) have also been described as specific HIV-1 RT inhibitors.</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG1"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG1" data-t="f"><dt class="autoScroll" data-style="height:516px;width:322px;"><a class="figureLink" href="#gr1" title="Full-size image (11 K)"><img data-loaded="true" style="display: inline; height: 516px; width: 322px;" class="imgLazyJSB figure large" alt="Full-size image (11 K)" src="1-s2.0-S0166354298000254-gr1.gif" data-thumbeid="1-s2.0-S0166354298000254-gr1.sml" data-fulleid="1-s2.0-S0166354298000254-gr1.gif" data-thumbheight="93" data-thumbwidth="58" data-fullheight="516" data-fullwidth="322" border="0" height="516" width="322"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr1.sml" data-fulleid="1-s2.0-S0166354298000254-gr1.gif"><img class="figure large" border="0" alt="Full-size image (11 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr1.gif" data-thumbEID="1-s2.0-S0166354298000254-gr1.sml" data-fullEID="1-s2.0-S0166354298000254-gr1.gif"></noscript></a></dt><dd id="labelCaptionFIG1"><p class="caption">Fig. 1.&nbsp;<span id="">Structural formulae of the non-nucleoside reverse transcriptase inhibitors (NNRTIs).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG1" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr1.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr1.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG2"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG2" data-t="f"><dt class="autoScroll" data-style="height:499px;width:336px;"><a class="figureLink" href="#gr2" title="Full-size image (10 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (10 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr2.sml" data-fulleid="1-s2.0-S0166354298000254-gr2.gif" data-thumbheight="94" data-thumbwidth="63" data-fullheight="499" data-fullwidth="336" border="0" height="499" width="336"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr2.sml" data-fulleid="1-s2.0-S0166354298000254-gr2.gif"><img class="figure large" border="0" alt="Full-size image (10 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr2.gif" data-thumbEID="1-s2.0-S0166354298000254-gr2.sml" data-fullEID="1-s2.0-S0166354298000254-gr2.gif"></noscript></a></dt><dd id="labelCaptionFIG2"><p class="caption">Fig. 2.&nbsp;<span id="">Structural formulae of the non-nucleoside reverse transcriptase inhibitors (NNRTIs).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG2" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr2.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr2.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG3"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG3" data-t="f"><dt class="autoScroll" data-style="height:470px;width:318px;"><a class="figureLink" href="#gr3" title="Full-size image (10 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (10 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr3.sml" data-fulleid="1-s2.0-S0166354298000254-gr3.gif" data-thumbheight="93" data-thumbwidth="63" data-fullheight="470" data-fullwidth="318" border="0" height="470" width="318"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr3.sml" data-fulleid="1-s2.0-S0166354298000254-gr3.gif"><img class="figure large" border="0" alt="Full-size image (10 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr3.gif" data-thumbEID="1-s2.0-S0166354298000254-gr3.sml" data-fullEID="1-s2.0-S0166354298000254-gr3.gif"></noscript></a></dt><dd id="labelCaptionFIG3"><p class="caption">Fig. 3.&nbsp;<span id="">Structural formulae of the non-nucleoside reverse transcriptase inhibitors (NNRTIs).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG3" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr3.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr3.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG4"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG4" data-t="f"><dt class="autoScroll" data-style="height:550px;width:323px;"><a class="figureLink" href="#gr4" title="Full-size image (10 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (10 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr4.sml" data-fulleid="1-s2.0-S0166354298000254-gr4.gif" data-thumbheight="94" data-thumbwidth="55" data-fullheight="550" data-fullwidth="323" border="0" height="550" width="323"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr4.sml" data-fulleid="1-s2.0-S0166354298000254-gr4.gif"><img class="figure large" border="0" alt="Full-size image (10 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr4.gif" data-thumbEID="1-s2.0-S0166354298000254-gr4.sml" data-fullEID="1-s2.0-S0166354298000254-gr4.gif"></noscript></a></dt><dd id="labelCaptionFIG4"><p class="caption">Fig. 4.&nbsp;<span id="">Structural formulae of the non-nucleoside reverse transcriptase inhibitors (NNRTIs).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG4" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr4.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr4.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG5"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG5" data-t="f"><dt class="autoScroll" data-style="height:510px;width:336px;"><a class="figureLink" href="#gr5" title="Full-size image (10 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (10 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr5.sml" data-fulleid="1-s2.0-S0166354298000254-gr5.gif" data-thumbheight="93" data-thumbwidth="61" data-fullheight="510" data-fullwidth="336" border="0" height="510" width="336"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr5.sml" data-fulleid="1-s2.0-S0166354298000254-gr5.gif"><img class="figure large" border="0" alt="Full-size image (10 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr5.gif" data-thumbEID="1-s2.0-S0166354298000254-gr5.sml" data-fullEID="1-s2.0-S0166354298000254-gr5.gif"></noscript></a></dt><dd id="labelCaptionFIG5"><p class="caption">Fig. 5.&nbsp;<span id="">Structural formulae of the non-nucleoside reverse transcriptase inhibitors (NNRTIs).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG5" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr5.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr5.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">As shown in <span id="bTBL1"><a href="#TBL1" id="ancbTBL1" class="intra_ref">Table 1</a></span>, the most potent and most selective congeners among the NNRTIs (i.e. tivirapine, loviride, thiocarboxanilide UC-781, quinoxaline HBY 097 and efavirenz) were found to inhibit HIV-1-induced cytopathicity at nanomolar concentrations, with selectivity indexes of 30 000–200 000. All the compounds listed in <span id="bTBL1"><a href="#TBL1" id="ancbTBL1" class="intra_ref">Table 1</a></span> were also found to inhibit HIV-1 RT activity, albeit at widely varying IC<sub>50</sub> values, which may at least partially be related to the varying assay conditions (i.e. nature of the primer/template) used to monitor RT activity.</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="table_TBL1"><div class="textboxdefault"><dl id="TBL1" data-t="t" class="table " data-label="Table 1"><dd class="lblCap"><p class="caption"><span class="label">Table 1.
        </span>Inhibitory effects of NNRTIs on HIV-1 RT activity and HIV-1 cytopathicity</p></dd><dd class="table"><table><colgroup><col><col><col><col><col><col></colgroup><thead><tr><th rowspan="2" colspan="1">Compound</th><th rowspan="1" colspan="1">HIV-1 RT activity</th><th rowspan="1" colspan="3">HIV-1 cytopathicity<hr></th><th rowspan="2" colspan="1">References</th></tr><tr><th rowspan="1" colspan="1">IC<sub>50</sub> (<em>μ</em>M)<sup>a</sup></th><th rowspan="1" colspan="1">EC<sub>50</sub> (<em>μ</em>M)<sup>b</sup></th><th rowspan="1" colspan="1">CC<sub>50</sub> (<em>μ</em>M)<sup>c</sup></th><th rowspan="1" colspan="1">SI<sup>d</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Tivirapine [8-chloro-TIBO (R86183)]</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.0046</td><td rowspan="1" colspan="1">138</td><td rowspan="1" colspan="1">30000</td><td rowspan="1" colspan="1"><span id="bBIB109"><a href="#BIB109" id="ancbBIB109" class="intra_ref">Pauwels et al., 1994</a></span></td></tr><tr><td rowspan="1" colspan="1">HEPT [I-EBU (MKC-442)]</td><td rowspan="1" colspan="1">0.012</td><td rowspan="1" colspan="1">0.014</td><td rowspan="1" colspan="1">&gt;100</td><td rowspan="1" colspan="1">&gt;7000</td><td rowspan="1" colspan="1"><span id="bBIB8"><a href="#BIB8" id="ancbBIB8" class="intra_ref">Baba et al., 1994</a></span></td></tr><tr><td rowspan="1" colspan="1">Nevirapine (BI-RG-587), Viramune®</td><td rowspan="1" colspan="1">0.084</td><td rowspan="1" colspan="1">0.048</td><td rowspan="1" colspan="1">&gt;50</td><td rowspan="1" colspan="1">&gt;1000</td><td rowspan="1" colspan="1"><a href="#BIB98" id="bBIB98" class="intra_ref">Merluzzi et al., 1990</a>, <a href="#BIB86" id="bBIB86" class="intra_ref">Koup et al., 1991</a>&nbsp;and&nbsp;<a href="#BIB49" id="bBIB49" class="intra_ref">De Clercq, 1996b</a></td></tr><tr><td rowspan="1" colspan="1">Pyridinone L-697,661</td><td rowspan="1" colspan="1">0.019</td><td rowspan="1" colspan="1">0.012</td><td rowspan="1" colspan="1">&gt;60</td><td rowspan="1" colspan="1">&gt;4800</td><td rowspan="1" colspan="1"><span id="bBIB66"><a href="#BIB66" id="ancbBIB66" class="intra_ref">Goldman et al., 1991</a></span></td></tr><tr><td rowspan="1" colspan="1">Delavirdine (BHAP U-90152), Rescriptor®</td><td rowspan="1" colspan="1">0.26</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&gt;100</td><td rowspan="1" colspan="1">&gt;10000</td><td rowspan="1" colspan="1"><span id="bBIB59"><a href="#BIB59" id="ancbBIB59" class="intra_ref">Dueweke et al., 1993a</a></span></td></tr><tr><td rowspan="1" colspan="1">TSAO-m<sup>3</sup>T</td><td rowspan="1" colspan="1">4.7</td><td rowspan="1" colspan="1">0.034</td><td rowspan="1" colspan="1">139</td><td rowspan="1" colspan="1">4088</td><td rowspan="1" colspan="1"><a href="#BIB10" id="bBIB10" class="intra_ref">Balzarini et al., 1992a</a>&nbsp;and&nbsp;<a href="#BIB11" id="bBIB11" class="intra_ref">Balzarini et al., 1992b</a></td></tr><tr><td rowspan="1" colspan="1">Loviride (<em>α</em>-APA R89439)</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">0.013</td><td rowspan="1" colspan="1">710</td><td rowspan="1" colspan="1">54615</td><td rowspan="1" colspan="1"><span id="bBIB108"><a href="#BIB108" id="ancbBIB108" class="intra_ref">Pauwels et al., 1993</a></span></td></tr><tr><td rowspan="1" colspan="1">Trovirdine (PETT LY 300046)</td><td rowspan="1" colspan="1">0.007</td><td rowspan="1" colspan="1">0.016</td><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">5438</td><td rowspan="1" colspan="1"><a href="#BIB1" id="bBIB1" class="intra_ref">Ahgren et al., 1995</a>&nbsp;and&nbsp;<a href="#BIB146" id="bBIB146" class="intra_ref">Zhang et al., 1995</a></td></tr><tr><td rowspan="1" colspan="1">Thiocarboxanilide UC-781</td><td rowspan="1" colspan="1">0.02&nbsp;<sup>e</sup></td><td rowspan="1" colspan="1">0.002&nbsp;<sup>e</sup></td><td rowspan="1" colspan="1">&gt;100&nbsp;<sup>e</sup></td><td rowspan="1" colspan="1">&gt;50000</td><td rowspan="1" colspan="1"><a href="#BIB15" id="bBIB15" class="intra_ref">Balzarini et al., 1995a</a>&nbsp;and&nbsp;<a href="#BIB33" id="bBIB33" class="intra_ref">Buckheit et al., 1997</a></td></tr><tr><td rowspan="1" colspan="1">Quinoxaline HBY 097</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">200</td><td rowspan="1" colspan="1">200000</td><td rowspan="1" colspan="1"><span id="bBIB83"><a href="#BIB83" id="ancbBIB83" class="intra_ref">Kleim et al., 1995</a></span></td></tr><tr><td rowspan="1" colspan="1">Thiazolobenzimidazole NSC 625487 (TBZ)</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">0.21</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">292</td><td rowspan="1" colspan="1"><a href="#BIB29" id="bBIB29" class="intra_ref">Buckheit et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB39" id="bBIB39" class="intra_ref">Chimirri et al., 1997</a></td></tr><tr><td rowspan="1" colspan="1">Thiazoloisoindolinone BM+51.0836</td><td rowspan="1" colspan="1">0.016</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&gt;50</td><td rowspan="1" colspan="1">&gt;5000</td><td rowspan="1" colspan="1"><a href="#BIB93" id="bBIB93" class="intra_ref">Massa et al., 1995</a>&nbsp;and&nbsp;<a href="#BIB99" id="bBIB99" class="intra_ref">Mertens et al., 1993</a></td></tr><tr><td rowspan="1" colspan="1">Indole carboxamide L-737,126</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">&lt;0.003</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><span id="bBIB139"><a href="#BIB139" id="ancbBIB139" class="intra_ref">Williams et al., 1993</a></span></td></tr><tr><td rowspan="1" colspan="1">Benzothiadiazine NSC 287474</td><td rowspan="1" colspan="1">1.2</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&gt;130</td><td rowspan="1" colspan="1">&gt;32</td><td rowspan="1" colspan="1"><span id="bBIB30"><a href="#BIB30" id="ancbBIB30" class="intra_ref">Buckheit et al., 1994a</a></span></td></tr><tr><td rowspan="1" colspan="1">Quinazolinone (<strong class="boldFont">13a</strong>)</td><td rowspan="1" colspan="1">0.012</td><td rowspan="1" colspan="1">&lt;0.025</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><span id="bBIB135"><a href="#BIB135" id="ancbBIB135" class="intra_ref">Tucker et al., 1994</a></span></td></tr><tr><td rowspan="1" colspan="1">Efavirenz (Benzoxazinone DMP 266)</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">80000</td><td rowspan="1" colspan="1"><span id="bBIB143"><a href="#BIB143" id="ancbBIB143" class="intra_ref">Young et al., 1995</a></span></td></tr><tr><td rowspan="1" colspan="1">Calanolide A</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">200</td><td rowspan="1" colspan="1"><a href="#BIB78" id="bBIB78" class="intra_ref">Kashman et al., 1992</a>&nbsp;and&nbsp;<a href="#BIB145" id="bBIB145" class="intra_ref">Zembower et al., 1997</a></td></tr><tr><td rowspan="1" colspan="1">Pyrrolobenzodiazepinone (<strong class="boldFont">4</strong>)</td><td rowspan="1" colspan="1">0.04&nbsp;<sup>e</sup></td><td rowspan="1" colspan="1">&lt;0.3&nbsp;<sup>e</sup></td><td rowspan="1" colspan="1">10&nbsp;<sup>e</sup></td><td rowspan="1" colspan="1">&gt;33</td><td rowspan="1" colspan="1"><span id="bBIB52"><a href="#BIB52" id="ancbBIB52" class="intra_ref">De Lucca and Otto, 1992</a></span></td></tr><tr><td rowspan="1" colspan="1">Imidazodipyridodiazepine UK-129,485</td><td rowspan="1" colspan="1">0.156</td><td rowspan="1" colspan="1">&lt;0.002</td><td rowspan="1" colspan="1">&gt;10</td><td rowspan="1" colspan="1">&gt;5000</td><td rowspan="1" colspan="1"><span id="bBIB134"><a href="#BIB134" id="ancbBIB134" class="intra_ref">Terrett et al., 1992</a></span></td></tr><tr><td rowspan="1" colspan="1">Imidazopyridazine (<strong class="boldFont">33</strong>)</td><td rowspan="1" colspan="1">0.0006</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">2600</td><td rowspan="1" colspan="1"><span id="bBIB89"><a href="#BIB89" id="ancbBIB89" class="intra_ref">Livermore et al., 1993</a></span></td></tr><tr><td rowspan="1" colspan="1">TDA RD 4-2024</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">0.012</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">2280</td><td rowspan="1" colspan="1"><a href="#BIB73" id="bBIB73" class="intra_ref">Ijichi et al., 1995</a>&nbsp;and&nbsp;<a href="#BIB74" id="bBIB74" class="intra_ref">Ijichi et al., 1996</a></td></tr><tr><td rowspan="1" colspan="1">MEN 10979</td><td rowspan="1" colspan="1">0.18</td><td rowspan="1" colspan="1">0.0025</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">15000</td><td rowspan="1" colspan="1"><span id="bBIB25"><a href="#BIB25" id="ancbBIB25" class="intra_ref">Bellarosa et al., 1996</a></span></td></tr><tr><td rowspan="1" colspan="1">DABO (<strong class="boldFont">12e</strong>)</td><td rowspan="1" colspan="1">1.8</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">&gt;335</td><td rowspan="1" colspan="1">&gt;418</td><td rowspan="1" colspan="1"><span id="bBIB93"><a href="#BIB93" id="ancbBIB93" class="intra_ref">Massa et al., 1995</a></span></td></tr><tr><td rowspan="1" colspan="1">HEPT-pyridinone hybrid (<strong class="boldFont">8a</strong>)</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&gt;10</td><td rowspan="1" colspan="1">&gt;1000</td><td rowspan="1" colspan="1"><span id="bBIB57"><a href="#BIB57" id="ancbBIB57" class="intra_ref">Dollé et al., 1995</a></span></td></tr><tr><td rowspan="1" colspan="1">Benzyloxymethylpyridinone (<strong class="boldFont">18a</strong>)</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><span id="bBIB77"><a href="#BIB77" id="ancbBIB77" class="intra_ref">Jourdan et al., 1997</a></span></td></tr><tr><td rowspan="1" colspan="1">Alkoxy(arylthio)uracil (<strong class="boldFont">18</strong>)</td><td rowspan="1" colspan="1">12.3</td><td rowspan="1" colspan="1">0.064</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">516</td><td rowspan="1" colspan="1"><span id="bBIB80"><a href="#BIB80" id="ancbBIB80" class="intra_ref">Kim et al., 1997</a></span></td></tr><tr><td rowspan="1" colspan="1">Indolyldipyridodiazepinone (<strong class="boldFont">7a</strong>)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">0.028</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><span id="bBIB79"><a href="#BIB79" id="ancbBIB79" class="intra_ref">Kelly et al., 1997</a></span></td></tr><tr><td rowspan="1" colspan="1">Pyrrolobenzoxazepinone (<strong class="boldFont">16e</strong>)</td><td rowspan="1" colspan="1">0.25</td><td rowspan="1" colspan="1">0.47</td><td rowspan="1" colspan="1">4.9</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"><span id="bBIB36"><a href="#BIB36" id="ancbBIB36" class="intra_ref">Campiani et al., 1996</a></span></td></tr><tr><td rowspan="1" colspan="1">Highly substituted pyrrole (<strong class="boldFont">3</strong>)</td><td rowspan="1" colspan="1">0.64</td><td rowspan="1" colspan="1">2.3</td><td rowspan="1" colspan="1">175</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1"><span id="bBIB3"><a href="#BIB3" id="ancbBIB3" class="intra_ref">Antonucci et al., 1995</a></span></td></tr><tr><td rowspan="1" colspan="1">Benzylthiopyrimidine U-31355</td><td rowspan="1" colspan="1">50–80</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">&gt;16</td><td rowspan="1" colspan="1">&gt;50</td><td rowspan="1" colspan="1"><span id="bBIB2"><a href="#BIB2" id="ancbBIB2" class="intra_ref">Althaus et al., 1996</a></span></td></tr></tbody></table></dd><dd><p class="legend">The data, as listed, were obtained under different assay conditions (i.e. with different templates, for determination of HIV-1 RT activity; and with different virus strains and cell types, for determination of HIV-1-induced cytopathicity). This makes a direct comparison of the individual compounds rather difficult.<sup>a</sup>&nbsp;50% Inhibitory concentration, or concentration required to inhibit HIV-1 RT activity by 50%.<sup>b</sup>&nbsp;50% Effective concentration, or concentration required to inhibit HIV-1-induced cytopathicity by 50%.<sup>c</sup>&nbsp;50% Cytotoxic concentration, or concentration required to reduce viability of the host cells by 50%.<sup>d</sup>&nbsp;Selectivity index, or ratio of CC<sub>50</sub> to EC<sub>50</sub>.<sup>e</sup>&nbsp;Values for thiocarboxanilide UC-781 and pyrrolobenzodiazepinone (<strong class="boldFont">4</strong>) are expressed in <em>μ</em>g/ml (instead of <em>μ</em>M).</p></dd><dd class="fullsizeTable"><a title="Full-size table - Opens new window" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=MiamiCaptionURL&amp;_method=retrieve&amp;_eid=1-s2.0-S0166354298000254&amp;_image=TBL1&amp;_ba=&amp;_fmt=full&amp;_orig=na&amp;_issn=01663542&amp;_pii=S0166354298000254&amp;_isTablePopup=Y&amp;_acct=C000005418&amp;_version=1&amp;_urlVersion=0&amp;_userid=62921&amp;md5=2493de2befaddaaf30d6585ad40d0984">Full-size table</a></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Table options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#TBL1" class="viewWS" title="View in workspace">View in workspace</a></li><li><div class="downloadCsv"><a title="Download as CSV" href="#">Download as CSV</a></div></li></ul></dd></dl></div></div><!--VALIDHTML--><h2 class="svArticle" id="section_lbl3">3. Interaction of NNRTIs with their pocket site at the HIV-1 RT</h2><p class="svArticle section" id="">Whereas the ddN analogues (i.e. AZT, ddI, etc.), following their intracellular phosphorylation to the triphosphate form, interact with the substrate binding site of the HIV RT, the NNRTIs block the HIV-1 RT reaction through interaction with an allosterically located, non-substrate binding site (<a href="#BIB48" id="bBIB48" class="intra_ref">De Clercq, 1996a</a>&nbsp;and&nbsp;<a href="#BIB49" id="bBIB49" class="intra_ref">De Clercq, 1996b</a>). This NNRTI-binding site (`pocket') is located at a close (about 10 Å) distance from the substrate-binding site (<span id="bBIB133"><a href="#BIB133" id="ancbBIB133" class="intra_ref">Tantillo et al., 1994</a></span>). It is not only spatially but also functionally (<a href="#BIB46" id="bBIB46" class="intra_ref">Debyser et al., 1992</a>&nbsp;and&nbsp;<a href="#BIB58" id="bBIB58" class="intra_ref">Dueweke et al., 1992</a>) associated with the substrate-binding site. The cooperative interaction between these two sites (<span id="bBIB129"><a href="#BIB129" id="ancbBIB129" class="intra_ref">Spence et al., 1995</a></span>) provides a means to increase the effectiveness of NRTIs and NNRTIs by using them in combination therapy.</p><!--VALIDHTML--><p class="svArticle section" id="">Several studies have revealed a common mode of binding for the chemically diverse NNRTIs with their target site at the HIV-1 RT (<span id="bBIB113"><a href="#BIB113" id="ancbBIB113" class="intra_ref">Ren et al., 1995a</a></span>). The NNRTIs cause a repositioning of the three-stranded <em>β</em>-sheet in the p66 subunit (containing the catalytic aspartic acid residues 110, 185 and 186) (<span id="bBIB62"><a href="#BIB62" id="ancbBIB62" class="intra_ref">Esnouf et al., 1995</a></span>). This suggests that the NNRTIs inhibit HIV-1 RT by locking the active catalytic site in an inactive conformation, reminiscent of the conformation observed in the inactive p51 subunit (<span id="bBIB62"><a href="#BIB62" id="ancbBIB62" class="intra_ref">Esnouf et al., 1995</a></span>). When bound into their pocket at the HIV-1 RT, the NNRTIs [i.e. <em>α</em>-APA R95846 (<span id="bBIB54"><a href="#BIB54" id="ancbBIB54" class="intra_ref">Ding et al., 1995a</a></span>), TIBO R86183 (<span id="bBIB55"><a href="#BIB55" id="ancbBIB55" class="intra_ref">Ding et al., 1995b</a></span>), 9-chloro-TIBO (R82913) (<span id="bBIB114"><a href="#BIB114" id="ancbBIB114" class="intra_ref">Ren et al., 1995b</a></span>) and nevirapine (<span id="bBIB87"><a href="#BIB87" id="ancbBIB87" class="intra_ref">Kroeger Smith et al., 1995</a></span>)] maintain a very similar conformational `butterfly-like' shape. They roughly overlay each other in the binding pocket and appear to function as <em>π</em>-electron donors to aromatic side-chain residues surrounding the pocket (<span id="bBIB87"><a href="#BIB87" id="ancbBIB87" class="intra_ref">Kroeger Smith et al., 1995</a></span>).</p><!--VALIDHTML--><p class="svArticle section" id="">The bulky U-90152 (delavirdine) occupies the same pocket as other NNRTIs, but the complex is stabilized quite differently, in particular by hydrogen bonding to the main chain of Lys-103 and extensive hydrophobic contacts with Pro-236. When bound, part of U-90152 protrudes into the solvent creating a channel between Pro-236 and the polypeptide segments 225–226 and 105–106, thus providing evidence for the entry mode of NNRTIs (<span id="bBIB63"><a href="#BIB63" id="ancbBIB63" class="intra_ref">Esnouf et al., 1997a</a></span>). The suggested model (<span id="bFIG6"><a href="#FIG6" id="ancbFIG6" class="intra_ref">Fig. 6</a></span>) also allows predictions on resistance mutations (notably P236L, which occurs characteristically for BHAPs) and chemical modifications, which may make the binding more resilient to mutations in the HIV-1 RT (<span id="bBIB63"><a href="#BIB63" id="ancbBIB63" class="intra_ref">Esnouf et al., 1997a</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG6"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG6" data-t="f"><dt class="autoScroll" data-style="height:821px;width:578px;"><a class="figureLink" href="#gr6v7" title="Full-size image (247 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (247 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr6v7.sml" data-fulleid="1-s2.0-S0166354298000254-gr6v7.jpg" data-thumbheight="92" data-thumbwidth="65" data-fullheight="821" data-fullwidth="578" border="0" height="821" width="578"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr6v7.sml" data-fulleid="1-s2.0-S0166354298000254-gr6v7.jpg"><img class="figure large" border="0" alt="Full-size image (247 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr6v7.jpg" data-thumbEID="1-s2.0-S0166354298000254-gr6v7.sml" data-fullEID="1-s2.0-S0166354298000254-gr6v7.jpg"></noscript></a></dt><dd id="labelCaptionFIG6"><p class="caption">Fig. 6.&nbsp;<span id="">Positioning of U-90152 in the NNRTI-binding pocket (according to <span id="FIG6bBIB63"><a href="#BIB63" id="ancFIG6bBIB63" class="intra_ref">Esnouf et al., 1997a</a></span>). The inhibitor is shown as an atom-colored ball-and-stick model with the surrounding protein structure as thin grey sticks. The green face of the surface points toward the protein, the blue face toward the solvent. This is the first RT–NNRTI complex structure to show the channel connecting the pocket to the solvent and may indicate the mode of entry into the (normally buried) pocket for all NNRTIs.<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG6" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr6v7.jpg" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr6v7.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">The binding of the thiocarboxanilide UC-781 in its HIV-1 RT pocket is shown in <span id="bFIG7"><a href="#FIG7" id="ancbFIG7" class="intra_ref">Fig. 7</a></span> (<span id="bBIB64"><a href="#BIB64" id="ancbBIB64" class="intra_ref">Esnouf et al., 1997b</a></span>). The thiocarboxanilides bind to their pocket in a similar fashion as the other NNRTIs, i.e. through hydrogen binding with the main chain oxygen of Lys-101 and hydrophobic interactions with Leu-100, Val-106, Val-179, Tyr-188, Phe-227, Leu-234 and His-235. The thiocarboxanilide UC-781 also makes important hydrophobic interactions with Trp-229 (<span id="bBIB64"><a href="#BIB64" id="ancbBIB64" class="intra_ref">Esnouf et al., 1997b</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG7"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG7" data-t="f"><dt class="autoScroll" data-style="height:821px;width:578px;"><a class="figureLink" href="#gr6v7" title="Full-size image (247 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (247 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr6v7.sml" data-fulleid="1-s2.0-S0166354298000254-gr6v7.jpg" data-thumbheight="92" data-thumbwidth="65" data-fullheight="821" data-fullwidth="578" border="0" height="821" width="578"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr6v7.sml" data-fulleid="1-s2.0-S0166354298000254-gr6v7.jpg"><img class="figure large" border="0" alt="Full-size image (247 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr6v7.jpg" data-thumbEID="1-s2.0-S0166354298000254-gr6v7.sml" data-fullEID="1-s2.0-S0166354298000254-gr6v7.jpg"></noscript></a></dt><dd id="labelCaptionFIG7"><p class="caption">Fig. 7.&nbsp;<span id="">Schematic diagram of the features stabilizing the HIV-1 RT complex with thiocarboxanilide UC-781 (according to <span id="FIG7bBIB64"><a href="#BIB64" id="ancFIG7bBIB64" class="intra_ref">Esnouf et al., 1997b</a></span>). Thiocarboxanilide UC-781 is shown using atom-colored spheres. The hydrogen bond between UC-781 and the main chain of Lys-101 and the two methyl group–aromatic ring interactions are shown explicitly. Other major hydrophobic contacts are shown with bold green lines, minor ones with faint green lines. Modified from <span id="FIG7bBIB64"><a href="#BIB64" id="ancFIG7bBIB64" class="intra_ref">Esnouf et al. (1997b)</a></span>.<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG7" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr6v7.jpg" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr6v7.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id=""><span id="bFIG8"><a href="#FIG8" id="ancbFIG8" class="intra_ref">Fig. 8</a></span> shows how binding of an NNRTI, in this case UC-781, can affect parts of the structure of HIV-1 RT (<span id="bBIB64"><a href="#BIB64" id="ancbBIB64" class="intra_ref">Esnouf et al., 1997b</a></span>). Binding of the NNRTI causes side-chain rearrangement of tyrosine residues 181 and 188, and repositioning of the catalytic aspartic acid residues, as compared to the unliganded RT structure (<span id="bBIB62"><a href="#BIB62" id="ancbBIB62" class="intra_ref">Esnouf et al., 1995</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG8"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG8" data-t="f"><dt class="autoScroll" data-style="height:839px;width:647px;"><a class="figureLink" href="#gr8v9" title="Full-size image (288 K)"><img style="display: inline;" class="imgLazyJSB figure large smallImg" alt="Full-size image (288 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr8v9.sml" data-fulleid="1-s2.0-S0166354298000254-gr8v9.jpg" data-thumbheight="93" data-thumbwidth="72" data-fullheight="839" data-fullwidth="647" border="0"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr8v9.sml" data-fulleid="1-s2.0-S0166354298000254-gr8v9.jpg"><img class="figure large" border="0" alt="Full-size image (288 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr8v9.jpg" data-thumbEID="1-s2.0-S0166354298000254-gr8v9.sml" data-fullEID="1-s2.0-S0166354298000254-gr8v9.jpg"></noscript></a></dt><dd id="labelCaptionFIG8"><p class="caption">Fig. 8.&nbsp;<span id="">Unliganded versus liganded HIV-1 RT structure (<a href="#BIB62" id="bBIB62" class="intra_ref">Esnouf et al., 1995</a>&nbsp;and&nbsp;<a href="#BIB64" id="bBIB64" class="intra_ref">Esnouf et al., 1997b</a>). Thiocarboxanilide UC-781 is shown as an atom-colored ball-and-stick model with large atom spheres and the carbon atoms in dary cyan. The three <em>β</em>-strands of RT (left to right named <em>β</em>7, <em>β</em>8 and <em>β</em>4, respectively) are shown as atom-colored ball-and-stick models with the carbon atoms in bright cyan; the equivalent structure from the unliganded RT structure (<span id="FIG8bBIB62"><a href="#BIB62" id="ancFIG8bBIB62" class="intra_ref">Esnouf et al., 1995</a></span>) is shown in pale yellow. The figure was drawn using BobScript (<span id="FIG8bBIB61"><a href="#BIB61" id="ancFIG8bBIB61" class="intra_ref">Esnouf, 1997</a></span>).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG8" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr8v9.jpg" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr8v9.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">Structural modelling studies have demonstrated that, despite their diverse structures, the conformations adopted by the NNRTIs, when bound to HIV-1 RT, lead to very similar features of binding. <span id="bFIG9"><a href="#FIG9" id="ancbFIG9" class="intra_ref">Fig. 9</a></span> shows superposition of the thiocarboxanilide UC-781 (<span id="bBIB64"><a href="#BIB64" id="ancbBIB64" class="intra_ref">Esnouf et al., 1997b</a></span>) and the quinoxaline S2720, relative to the structure of the surrounding protein in the models of the NNRTI–RT complexes.</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG9"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG9" data-t="f"><dt class="autoScroll" data-style="height:839px;width:647px;"><a class="figureLink" href="#gr8v9" title="Full-size image (288 K)"><img style="display: inline;" class="imgLazyJSB figure large smallImg" alt="Full-size image (288 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr8v9.sml" data-fulleid="1-s2.0-S0166354298000254-gr8v9.jpg" data-thumbheight="93" data-thumbwidth="72" data-fullheight="839" data-fullwidth="647" border="0"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr8v9.sml" data-fulleid="1-s2.0-S0166354298000254-gr8v9.jpg"><img class="figure large" border="0" alt="Full-size image (288 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr8v9.jpg" data-thumbEID="1-s2.0-S0166354298000254-gr8v9.sml" data-fullEID="1-s2.0-S0166354298000254-gr8v9.jpg"></noscript></a></dt><dd id="labelCaptionFIG9"><p class="caption">Fig. 9.&nbsp;<span id="">Superposition of thiocarboxanilide UC-781 and quinoxaline S2720 within the HIV-1 RT `pocket' site (<span id="FIG9bBIB64"><a href="#BIB64" id="ancFIG9bBIB64" class="intra_ref">Esnouf et al., 1997b</a></span>). Atom-colored ball-and-stick models are shown for the thiocarboxanilide UC-781 (pale grey carbon atoms) and for the quinoxaline S2720 (dark grey carbon atoms). The positions of the sulfur and chlorine atoms and of the nitrogens involved in hydrogen bonding superimpose very well. The six-membered aromatic rings also occupy equivalent positions. Finally, the UC-781 ether group and the S2720 ester group adopt conformations that allow terminal methyl groups to interact strongly with the aromatic ring of Trp-229. The figure was drawn using BobScript (<span id="FIG9bBIB61"><a href="#BIB61" id="ancFIG9bBIB61" class="intra_ref">Esnouf, 1997</a></span>).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG9" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr8v9.jpg" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr8v9.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><h2 class="svArticle" id="section_lbl4">4. HIV-1 resistance to NNRTIs</h2><p class="svArticle section" id="">Inevitably, the rapid replication of HIV and its inherent genetic variability must lead to the generation of viral variants that exhibit drug resistance (<span id="bBIB124"><a href="#BIB124" id="ancbBIB124" class="intra_ref">Schinazi et al., 1997</a></span>). NNRTIs are notorious for rapidly triggering the emergence of drug-resistant HIV-1 variants. The first RT mutations shown to be associated with, and to account for, HIV-1 resistance to NNRTIs were the K103N and Y181C mutations, engendering resistance to pyridinone (<span id="bBIB102"><a href="#BIB102" id="ancbBIB102" class="intra_ref">Nunberg et al., 1991</a></span>), nevirapine (<span id="bBIB115"><a href="#BIB115" id="ancbBIB115" class="intra_ref">Richman et al., 1991a</a></span>) and TIBO R82150 (<span id="bBIB95"><a href="#BIB95" id="ancbBIB95" class="intra_ref">Mellors et al., 1992</a></span>). In fact, the mutations K103N and Y181C have been observed with virtually all the NNRTIs (<span id="bFIG10"><a href="#FIG10" id="ancbFIG10" class="intra_ref">Fig. 10</a></span>), except for the quinoxalines (i.e. HBY 097). The latter preferentially induce mutations at the RT position 190 (i.e. G190E) (<span id="bBIB82"><a href="#BIB82" id="ancbBIB82" class="intra_ref">Kleim et al., 1994</a></span>), particularly under high selective pressure [whereas under low selective pressure, mutations L100I, K103N, V106A/I/L, Y181C and G190A/T/V are induced (<span id="bBIB85"><a href="#BIB85" id="ancbBIB85" class="intra_ref">Kleim et al., 1997</a></span>)]. Concomitantly with the G190E mutation, HBY 097 induces the mutations L74V and V75I (<a href="#BIB84" id="bBIB84" class="intra_ref">Kleim et al., 1996</a>&nbsp;and&nbsp;<a href="#BIB27" id="bBIB27" class="intra_ref">Boyer et al., 1998</a>). Other `specific' NNRTI mutations include L100I [TIBO 82150 (<span id="bBIB96"><a href="#BIB96" id="ancbBIB96" class="intra_ref">Mellors et al., 1993</a></span>)], E138K [TSAO-T (<a href="#BIB26" id="bBIB26" class="intra_ref">Boyer et al., 1994</a>&nbsp;and&nbsp;<a href="#BIB76" id="bBIB76" class="intra_ref">Jonckheere et al., 1994</a>)], and P236L [BHAPs (<span id="bBIB60"><a href="#BIB60" id="ancbBIB60" class="intra_ref">Dueweke et al., 1993b</a></span>)]. Resistance to the HEPT derivatives (i.e. MKC-442) can be associated with mutations K103N, V108I and Y181C (<span id="bBIB126"><a href="#BIB126" id="ancbBIB126" class="intra_ref">Seki et al., 1995</a></span>) or yet others (<span id="bBIB32"><a href="#BIB32" id="ancbBIB32" class="intra_ref">Buckheit et al., 1995</a></span>), although MKC-442 (I-EBU) still retains sufficient activity against the Y181C mutant (EC<sub>50</sub>: 0.22 <em>μ</em>M) as compared to the wild-type (EC<sub>50</sub>: 0.002 <em>μ</em>M) (<span id="bBIB15"><a href="#BIB15" id="ancbBIB15" class="intra_ref">Balzarini et al., 1995a</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG10"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG10" data-t="f"><dt class="autoScroll" data-style="height:304px;width:500px;"><a class="figureLink" href="#gr10" title="Full-size image (10 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (10 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr10.sml" data-fulleid="1-s2.0-S0166354298000254-gr10.gif" data-thumbheight="76" data-thumbwidth="125" data-fullheight="304" data-fullwidth="500" border="0" height="304" width="500"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr10.sml" data-fulleid="1-s2.0-S0166354298000254-gr10.gif"><img class="figure large" border="0" alt="Full-size image (10 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr10.gif" data-thumbEID="1-s2.0-S0166354298000254-gr10.sml" data-fullEID="1-s2.0-S0166354298000254-gr10.gif"></noscript></a></dt><dd id="labelCaptionFIG10"><p class="caption">Fig. 10.&nbsp;<span id="">Mutations in the HIV-1 RT that confer resistance to the non-nucleoside reverse transcriptase inhibitors (NNRTIs) (see also <span id="FIG10bBIB124"><a href="#BIB124" id="ancFIG10bBIB124" class="intra_ref">Schinazi et al., 1997</a></span>).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG10" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr10.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr10.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">The emergence of NNRTI resistance mutations (which, as a rule, are located at the amino acid residues aligning the NNRTI-binding `pocket' site) is generally felt as compromising the clinical utility of the NNRTIs. Yet, it should be recognized that several NNRTI classes, viz. quinoxalines (i.e. S-2720, HBY 097) and thiocarboxanilides (i.e. UC-781), still retain pronounced activity against HIV-1 RT mutants containing the L100I, K103N, V106A and Y181C mutation (<span id="bTBL2"><a href="#TBL2" id="ancbTBL2" class="intra_ref">Table 2</a></span>) (<a href="#BIB16" id="bBIB16" class="intra_ref">Balzarini et al., 1995b</a>&nbsp;and&nbsp;<a href="#BIB19" id="bBIB19" class="intra_ref">Balzarini et al., 1996b</a>). Also DMP 266 (efavirenz) is equally active against the V108I, V179D, Y181C mutant wild-type HIV-1 (<span id="bBIB143"><a href="#BIB143" id="ancbBIB143" class="intra_ref">Young et al., 1995</a></span>). The thiocarboxanilides are only 10- to 20-fold less active against those HIV-1 mutants (i.e. L100I, V106A, E138K and V179D) that they select for in vitro (<span id="bBIB19"><a href="#BIB19" id="ancbBIB19" class="intra_ref">Balzarini et al., 1996b</a></span>). More remarkably, the P236L mutation that confers resistance to BHAP U-90152 (delavirdine) causes hypersensitivity to other NNRTIs such as nevirapine, TIBO and pyridinone (<span id="bBIB60"><a href="#BIB60" id="ancbBIB60" class="intra_ref">Dueweke et al., 1993b</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="table_TBL2"><div class="textboxdefault"><dl id="TBL2" data-t="t" class="table " data-label="Table 2"><dd class="lblCap"><p class="caption"><span class="label">Table 2.
        </span>Antiviral activity spectrum of NNRTIs&nbsp;<span id="bTBLFN2"><a href="#TBLFN2" id="ancbTBLFN2" class="intra_ref"><sup>a</sup></a></span></p></dd><dd class="table"><table><colgroup><col><col><col><col><col><col><col><col></colgroup><thead><tr><th rowspan="3" colspan="1">NNRTI</th><th rowspan="1" colspan="7">Active against&nbsp;<sup>b</sup><hr></th></tr><tr><th rowspan="2" colspan="1">Wild-type (HIV-1 III<sub>B</sub>)</th><th rowspan="1" colspan="6">Mutant<hr></th></tr><tr><th rowspan="1" colspan="1">HIV-1 L100I</th><th rowspan="1" colspan="1">HIV-1 103N</th><th rowspan="1" colspan="1">HIV-1 106A</th><th rowspan="1" colspan="1">HIV-1 E138K</th><th rowspan="1" colspan="1">HIV-1 Y181C</th><th rowspan="1" colspan="1">HIV-1 Y188H</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">TIBO R82913</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td></tr><tr><td rowspan="1" colspan="1">I-EBU (MKC-442)</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td></tr><tr><td rowspan="1" colspan="1">Nevirapine</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td></tr><tr><td rowspan="1" colspan="1">Pyridinone (L-697,661)</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td></tr><tr><td rowspan="1" colspan="1">BHAP U-88204</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td></tr><tr><td rowspan="1" colspan="1">BHAP U-90152 (Delavirdine)</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td></tr><tr><td rowspan="1" colspan="1">TSAO-m<sup>3</sup>T</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">□</td></tr><tr><td rowspan="1" colspan="1">Quinoxaline S-2720</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td></tr><tr><td rowspan="1" colspan="1">Thiocarboxanilide UC-10</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">□</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td></tr><tr><td rowspan="1" colspan="1">Quinoxaline HBY 097</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td></tr><tr><td rowspan="1" colspan="1">Thiocarboxanilide UC-781</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td></tr><tr><td rowspan="1" colspan="1">DMP 266 (Efavirenz)</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td><td rowspan="1" colspan="1">■</td></tr></tbody></table></dd><dd><dl id="TBLFN2" data-t="n" class="tblFootnote"><dt>a</dt><dd><p>Data from <a href="#BIB16" id="bBIB16" class="intra_ref">Balzarini et al., 1995b</a>, <a href="#BIB17" id="bBIB17" class="intra_ref">Balzarini et al., 1995c</a>&nbsp;and&nbsp;<a href="#BIB19" id="bBIB19" class="intra_ref">Balzarini et al., 1996b</a>and unpublished.</p><p><sup>b</sup>■, EC<sub>50</sub>≤1 <em>μ</em>M; □, EC<sub>50</sub>&gt;1 <em>μ</em>M.</p></dd></dl></dd><dd class="fullsizeTable"><a title="Full-size table - Opens new window" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=MiamiCaptionURL&amp;_method=retrieve&amp;_eid=1-s2.0-S0166354298000254&amp;_image=TBL2&amp;_ba=&amp;_fmt=full&amp;_orig=na&amp;_issn=01663542&amp;_pii=S0166354298000254&amp;_isTablePopup=Y&amp;_acct=C000005418&amp;_version=1&amp;_urlVersion=0&amp;_userid=62921&amp;md5=1bb1fc96b8a20f840716d9c625457c17">Full-size table</a></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Table options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#TBL2" class="viewWS" title="View in workspace">View in workspace</a></li><li><div class="downloadCsv"><a title="Download as CSV" href="#">Download as CSV</a></div></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">Recently, a novel mutation (P225H) was identified that consistently appeared in a V106A mutant background and conferred additional resistance to all NNRTIs, except for delavirdine, which actually showed hypersensitivity towards the P225H mutant (<span id="bBIB110"><a href="#BIB110" id="ancbBIB110" class="intra_ref">Pelemans et al., 1997</a></span>). Another novel mutation (F227L) that arose in a V106A mutant background was found to confer high-level resistance to virtually all NNRTIs that were examined (<span id="bBIB22"><a href="#BIB22" id="ancbBIB22" class="intra_ref">Balzarini et al., 1998a</a></span>). It has become increasingly clear that combinations of different RT mutations (i.e. L100I and K103N, or K101D and K103N, or K103N and Y181C) are required for engendering high-level resistance to NNRTIs. It is not clear, however, whether such double-mutants readily arise in vivo, in patients under NNRTI treatment.</p><!--VALIDHTML--><p class="svArticle section" id="">With nevirapine, the most common resistance mutation observed in vivo is Y181C, and this mutation is prevented from emerging by coadministration of AZT (<span id="bBIB117"><a href="#BIB117" id="ancbBIB117" class="intra_ref">Richman et al., 1994</a></span>). Vice versa, the Y181C mutation (<span id="bBIB88"><a href="#BIB88" id="ancbBIB88" class="intra_ref">Larder, 1992</a></span>) or L100I mutation (<span id="bBIB34"><a href="#BIB34" id="ancbBIB34" class="intra_ref">Byrnes et al., 1994</a></span>) in an AZT resistance background (T215Y) significantly suppress (phenotypic) resistance to AZT. Concomitant combination of 3TC with HBY 097 prevents the emergence of virus resistance to HBY 097 (<span id="bBIB21"><a href="#BIB21" id="ancbBIB21" class="intra_ref">Balzarini et al., 1997</a></span>). In fact, an AZT-resistant HIV-1 strain was found to retain marked sensitivity to HBY 097 when subcultured in the combined presence of HBY 097 and 3TC (<span id="bBIB23"><a href="#BIB23" id="ancbBIB23" class="intra_ref">Balzarini et al., 1998b</a></span>).</p><!--VALIDHTML--><h2 class="svArticle" id="section_lbl5">5. Optimization of NNRTI treatment regimens</h2><p class="svArticle section" id="">The mutually antagonistic effects of different resistance mutations (i.e. Y181C or L100I versus T215Y), and the hypersensitivity that is seen under some conditions (i.e. with the P236L mutation towards some NNRTIs), argues in favor of the combined use of NNRTIs with NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors), and different NNRTIs with one another. While achieving synergism in their anti-HIV action, different drugs combined may also reduce the risk of HIV drug resistance development and diminish toxic side-effects (through reduction of the individual doses). The compounds should not be given in sequential order (<span id="bBIB137"><a href="#BIB137" id="ancbBIB137" class="intra_ref">Wainberg et al., 1996</a></span>), as such procedure may enable the virus to acquire resistance mutations to all the compounds (<span id="bBIB20"><a href="#BIB20" id="ancbBIB20" class="intra_ref">Balzarini et al., 1996c</a></span>). Instead, concomitant combination therapy, as demonstrated particularly with 3TC and NNRTIs (<span id="bBIB20"><a href="#BIB20" id="ancbBIB20" class="intra_ref">Balzarini et al., 1996c</a></span>), should be recommended.</p><!--VALIDHTML--><p class="svArticle section" id="">Synergistic anti-HIV activity may be expected if NNRTIs are combined with NRTIs. For example, synergistic anti-HIV activity has been described for combinations of AZT with any of the NNRTIs, i.e. TIBO R82913 or R86183 (tivirapine) (<span id="bBIB31"><a href="#BIB31" id="ancbBIB31" class="intra_ref">Buckheit et al., 1994b</a></span>), nevirapine (<span id="bBIB116"><a href="#BIB116" id="ancbBIB116" class="intra_ref">Richman et al., 1991b</a></span>), delavirdine (<span id="bBIB40"><a href="#BIB40" id="ancbBIB40" class="intra_ref">Chong et al., 1994</a></span>), or MKC-442 (<a href="#BIB144" id="bBIB144" class="intra_ref">Yuasa et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB28" id="bBIB28" class="intra_ref">Brennan et al., 1995</a>). Synergistic anti-HIV activity has also been reported for the combination of delavirdine with protease inhibitors (i.e. U-75875) or interferon-<em>α</em> (<span id="bBIB105"><a href="#BIB105" id="ancbBIB105" class="intra_ref">Pagano and Chong, 1995</a></span>) and for the combination of HEPT with interferon-<em>α</em> (<span id="bBIB75"><a href="#BIB75" id="ancbBIB75" class="intra_ref">Ito et al., 1991</a></span>). Thiocarboxanilides (i.e. UC-781) show an additive inhibitory effect on HIV-1 replication when combined with other antiretroviral drugs (RT inhibitors or HIV protease inhibitors) (<span id="bBIB9"><a href="#BIB9" id="ancbBIB9" class="intra_ref">Balzarini and De Clercq, 1997</a></span>). The different drug combinations that have proved to confer an additive/synergistic anti-HIV activity in vitro and/or in vivo (the latter, in patients) are illustrated in <span id="bFIG11"><a href="#FIG11" id="ancbFIG11" class="intra_ref">Fig. 11</a></span>.</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG11"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG11" data-t="f"><dt class="autoScroll" data-style="height:316px;width:337px;"><a class="figureLink" href="#gr11" title="Full-size image (13 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (13 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr11.sml" data-fulleid="1-s2.0-S0166354298000254-gr11.gif" data-thumbheight="94" data-thumbwidth="100" data-fullheight="316" data-fullwidth="337" border="0" height="316" width="337"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr11.sml" data-fulleid="1-s2.0-S0166354298000254-gr11.gif"><img class="figure large" border="0" alt="Full-size image (13 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr11.gif" data-thumbEID="1-s2.0-S0166354298000254-gr11.sml" data-fullEID="1-s2.0-S0166354298000254-gr11.gif"></noscript></a></dt><dd id="labelCaptionFIG11"><p class="caption">Fig. 11.&nbsp;<span id="">Additive/synergistic anti-drug interactions shown in vitro (<a href="#BIB116" id="bBIB116" class="intra_ref">Richman et al., 1991b</a>, <a href="#BIB144" id="bBIB144" class="intra_ref">Yuasa et al., 1993</a>, <a href="#BIB40" id="bBIB40" class="intra_ref">Chong et al., 1994</a>, <a href="#BIB17" id="bBIB17" class="intra_ref">Balzarini et al., 1995c</a>, <a href="#BIB18" id="bBIB18" class="intra_ref">Balzarini et al., 1996a</a>, <a href="#BIB28" id="bBIB28" class="intra_ref">Brennan et al., 1995</a>, <a href="#BIB104" id="bBIB104" class="intra_ref">Okamoto et al., 1996</a>&nbsp;and&nbsp;<a href="#BIB9" id="bBIB9" class="intra_ref">Balzarini and De Clercq, 1997</a>) and in vivo (<a href="#BIB130" id="bBIB130" class="intra_ref">Staszewski et al., 1995</a>, <a href="#BIB132" id="bBIB132" class="intra_ref">Staszewski et al., 1996b</a>, <a href="#BIB38" id="bBIB38" class="intra_ref">Carr et al., 1996</a>, <a href="#BIB42" id="bBIB42" class="intra_ref">D'Aquila et al., 1996</a>, <a href="#BIB44" id="bBIB44" class="intra_ref">Davey et al., 1996</a>, <a href="#BIB125" id="bBIB125" class="intra_ref">Schooley et al., 1996</a>, <a href="#BIB35" id="bBIB35" class="intra_ref">CAESAR Coordinating Committee, 1997</a>, <a href="#BIB90" id="bBIB90" class="intra_ref">Luzuriaga et al., 1997</a>, <a href="#BIB94" id="bBIB94" class="intra_ref">Mayers et al., 1997</a>&nbsp;and&nbsp;<a href="#BIB128" id="bBIB128" class="intra_ref">Skowron et al., 1998</a>; M. Myers, personal communication, 1998; G. Tarpley, personal communication, 1998).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG11" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr11.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr11.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">In contrast with the ddN analogues (AZT, ddI, etc.), the NNRTIs TIBO, BHAP and nevirapine were found to completely suppress HIV-1 infection, if added to the cells at a sufficiently high concentration (1–10 <em>μ</em>M, or 100 times their EC<sub>50</sub>) (<span id="bBIB13"><a href="#BIB13" id="ancbBIB13" class="intra_ref">Balzarini et al., 1993</a></span>). The infected cells could apparently be cleared from virus by the NNRTIs when used at these `knocking-out' concentrations, and the resultant healthy cell culture could be subsequently maintained without drug with no evidence of latent proviral DNA ( <a href="#BIB136" id="bBIB136" class="intra_ref">Vasudevachari et al., 1992</a>&nbsp;and&nbsp;<a href="#BIB13" id="bBIB13" class="intra_ref">Balzarini et al., 1993</a>). The more potent quinoxaline (<span id="bBIB14"><a href="#BIB14" id="ancbBIB14" class="intra_ref">Balzarini et al., 1994</a></span>) and thiocarboxanilide (<span id="bBIB19"><a href="#BIB19" id="ancbBIB19" class="intra_ref">Balzarini et al., 1996b</a></span>) derivatives were found to achieve this `knocking out' effect at even lower concentrations (0.1–1 <em>μ</em>M) (<span id="bFIG12"><a href="#FIG12" id="ancbFIG12" class="intra_ref">Fig. 12</a></span>), that is concentrations that should be readily attainable in the plasma following systemic administration to patients. Also, DMP 266 (efavirenz) was found to completely suppress virus replication in peripheral blood mononuclear cells (PBMC) at a concentration of 0.96 <em>μ</em>M, and no regrowth of virus occurred in the presence of compound after 10 weeks or in the absence of compound for 3 additional weeks (<span id="bBIB140"><a href="#BIB140" id="ancbBIB140" class="intra_ref">Winslow et al., 1996</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG12"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG12" data-t="f"><dt class="autoScroll" data-style="height:837px;width:510px;"><a class="figureLink" href="#gr12v13" title="Full-size image (251 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (251 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr12v13.sml" data-fulleid="1-s2.0-S0166354298000254-gr12v13.jpg" data-thumbheight="94" data-thumbwidth="57" data-fullheight="837" data-fullwidth="510" border="0" height="837" width="510"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr12v13.sml" data-fulleid="1-s2.0-S0166354298000254-gr12v13.jpg"><img class="figure large" border="0" alt="Full-size image (251 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr12v13.jpg" data-thumbEID="1-s2.0-S0166354298000254-gr12v13.sml" data-fullEID="1-s2.0-S0166354298000254-gr12v13.jpg"></noscript></a></dt><dd id="labelCaptionFIG12"><p class="caption">Fig. 12.&nbsp;<span id="">Suppression of virus breakthrough in CEM cells infected with HIV-1 III<sub>B</sub> and treated with individual drugs at different concentrations. The delay in virus breakthrough corresponds to the number of days required for 50% viral cytopathicity to develop. Data taken from <a href="#BIB14" id="bBIB14" class="intra_ref">Balzarini et al., 1994</a>, <a href="#BIB17" id="bBIB17" class="intra_ref">Balzarini et al., 1995c</a>, <a href="#BIB18" id="bBIB18" class="intra_ref">Balzarini et al., 1996a</a>&nbsp;and&nbsp;<a href="#BIB19" id="bBIB19" class="intra_ref">Balzarini et al., 1996b</a>.<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG12" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr12v13.jpg" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr12v13.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">If, furthermore, the NNRTIs are used in combination with the ddN analogues, i.e. delavirdine combined with AZT (<span id="bBIB59"><a href="#BIB59" id="ancbBIB59" class="intra_ref">Dueweke et al., 1993a</a></span>), or MKC-442 combined with AZT (<span id="bBIB104"><a href="#BIB104" id="ancbBIB104" class="intra_ref">Okamoto et al., 1996</a></span>), or delavirdine combined with 3TC (<span id="bBIB18"><a href="#BIB18" id="ancbBIB18" class="intra_ref">Balzarini et al., 1996a</a></span>), or MKC-442 combined with 3TC (<span id="bBIB18"><a href="#BIB18" id="ancbBIB18" class="intra_ref">Balzarini et al., 1996a</a></span>), or thiocarboxanilides combined with other NNRTIs (<span id="bBIB17"><a href="#BIB17" id="ancbBIB17" class="intra_ref">Balzarini et al., 1995c</a></span>), the drugs are able to suppress virus breakthrough for a much longer time, and at much lower concentrations than when the compounds are used individually (<span id="bFIG13"><a href="#FIG13" id="ancbFIG13" class="intra_ref">Fig. 13</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG13"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG13" data-t="f"><dt class="autoScroll" data-style="height:837px;width:510px;"><a class="figureLink" href="#gr12v13" title="Full-size image (251 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (251 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr12v13.sml" data-fulleid="1-s2.0-S0166354298000254-gr12v13.jpg" data-thumbheight="94" data-thumbwidth="57" data-fullheight="837" data-fullwidth="510" border="0" height="837" width="510"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr12v13.sml" data-fulleid="1-s2.0-S0166354298000254-gr12v13.jpg"><img class="figure large" border="0" alt="Full-size image (251 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr12v13.jpg" data-thumbEID="1-s2.0-S0166354298000254-gr12v13.sml" data-fullEID="1-s2.0-S0166354298000254-gr12v13.jpg"></noscript></a></dt><dd id="labelCaptionFIG13"><p class="caption">Fig. 13.&nbsp;<span id="">Suppression of virus breakthrough in CEM cells infected with HIV-1 III<sub>B</sub> and treated with dual drug combinations at different concentrations: 3TC+delavirdine or 3TC+MKC-442. For some dual drug combinations [i.e. 3TC (at 0.1 <em>μ</em>g/ml) with MKC-442 (at 0.02 or 0.04 <em>μ</em>g/ml) or delavirdine (at 0.04 <em>μ</em>g/ml)], the cell cultures remained p24 negative when the drugs were removed on day 52 and the cells were further passaged in the absence of the compounds. The delay in virus breakthrough corresponds to the number of days required for 50% viral cytopathicity to develop. Data taken from <span id="FIG13bBIB18"><a href="#BIB18" id="ancFIG13bBIB18" class="intra_ref">Balzarini et al. (1996a)</a></span>.<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG13" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr12v13.jpg" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr12v13.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">Thus, when optimizing the NNRTI-containing drug treatment regimens, the drugs, in combination, should be administered from the start at the highest possible doses so as to achieve complete virus suppression and prevent virus drug resistance from arising.</p><!--VALIDHTML--><h2 class="svArticle" id="section_lbl6">6. In vivo efficacy of NNRTIs</h2><p class="svArticle section" id="">Given their high specificity as inhibitors of HIV-1 infection (for which there is no adequate animal model), NNRTIs have only rarely been studied in animal retrovirus models. When evaluated in HIV-1-infected hu-PBL-SCID mice, the NNRTIs delavirdine (BHAP U-90152) and thiocarboxanilide UC-781 protected the mice against HIV-1 infection (<span id="bBIB19"><a href="#BIB19" id="ancbBIB19" class="intra_ref">Balzarini et al., 1996b</a></span>). Similarly, nevirapine proved effective in preventing HIV-1 infection in chimpanzees (<span id="bBIB68"><a href="#BIB68" id="ancbBIB68" class="intra_ref">Grob et al., 1997</a></span>).</p><!--VALIDHTML--><p class="svArticle section" id="">In humans, several NNRTIs have been the subject of short-term clinical studies: TIBO R82913 (<a href="#BIB112" id="bBIB112" class="intra_ref">Pialoux et al., 1991</a>&nbsp;and&nbsp;<a href="#BIB53" id="bBIB53" class="intra_ref">De Wit et al., 1992</a>), pyridinone L-697,661 (<a href="#BIB43" id="bBIB43" class="intra_ref">Davey et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB121" id="bBIB121" class="intra_ref">Saag et al., 1993</a>), nevirapine (<span id="bBIB70"><a href="#BIB70" id="ancbBIB70" class="intra_ref">Havlir et al., 1995a</a></span>), <em>α</em>-APA R089439 (loviride) (<span id="bBIB131"><a href="#BIB131" id="ancbBIB131" class="intra_ref">Staszewski et al., 1996a</a></span>), MKC-442 (<span id="bBIB101"><a href="#BIB101" id="ancbBIB101" class="intra_ref">Moxham et al., 1997</a></span>) and HBY 097 (<span id="bBIB120"><a href="#BIB120" id="ancbBIB120" class="intra_ref">Rübsamen-Waigmann et al., 1997</a></span>). As a rule, the NNRTIs were very well tolerated [although rash developed in about half of the patients treated with nevirapine (<span id="bBIB70"><a href="#BIB70" id="ancbBIB70" class="intra_ref">Havlir et al., 1995a</a></span>)]; they efficiently suppressed plasma viral load [up to 1.38 log<sub>10</sub> (<span id="bBIB120"><a href="#BIB120" id="ancbBIB120" class="intra_ref">Rübsamen-Waigmann et al., 1997</a></span>)], but could not prevent the emergence of drug-resistant virus strains ( <a href="#BIB43" id="bBIB43" class="intra_ref">Davey et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB70" id="bBIB70" class="intra_ref">Havlir et al., 1995a</a>). As shown for pyridinone L-697,661, suppression of virus replication was only transient: this suppressive effect disappeared coincidentally with the emergence of resistant virus (within 6-12 weeks) ( <a href="#BIB43" id="bBIB43" class="intra_ref">Davey et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB121" id="bBIB121" class="intra_ref">Saag et al., 1993</a>). Even following high-dose nevirapine (400 mg/day) therapy, nevirapine-resistant virus was isolated from all subjects tested at 12 weeks (<span id="bBIB70"><a href="#BIB70" id="ancbBIB70" class="intra_ref">Havlir et al., 1995a</a></span>), and by that time plasma HIV-1 RNA load had returned to baseline values (<span id="bBIB51"><a href="#BIB51" id="ancbBIB51" class="intra_ref">De Jong et al., 1997</a></span>). Although some patients treated with high-dose nevirapine (i.e. 400 mg daily) may experience sustained reduction in plasma HIV RNA despite the presence of resistant virus (<span id="bBIB71"><a href="#BIB71" id="ancbBIB71" class="intra_ref">Havlir et al., 1995b</a></span>), this does not seem to hold true in previously untreated HIV-1-infected persons (<span id="bBIB51"><a href="#BIB51" id="ancbBIB51" class="intra_ref">De Jong et al., 1997</a></span>).</p><!--VALIDHTML--><p class="svArticle section" id="">Although monotherapy with NNRTIs may rapidly lead to the emergence of drug-resistant HIV strains (<a href="#BIB43" id="bBIB43" class="intra_ref">Davey et al., 1993</a>&nbsp;and&nbsp;<a href="#BIB121" id="bBIB121" class="intra_ref">Saag et al., 1993</a>), the rate of emergence of NNRTI-resistant virus can be markedly reduced in subjects receiving the NNRTI (i.e. pyridinone L-697,661) concomitantly with AZT (<a href="#BIB130" id="bBIB130" class="intra_ref">Staszewski et al., 1995</a>&nbsp;and&nbsp;<a href="#BIB125" id="bBIB125" class="intra_ref">Schooley et al., 1996</a>). As could be predicted from the in vitro studies (see above), NNRTIs such as nevirapine (<span id="bBIB38"><a href="#BIB38" id="ancbBIB38" class="intra_ref">Carr et al., 1996</a></span>) and delavirdine (<span id="bBIB44"><a href="#BIB44" id="ancbBIB44" class="intra_ref">Davey et al., 1996</a></span>) achieve higher efficacy in HIV-1-infected patients when combined with ddN analogues such as AZT than when used alone. If these combinations (AZT with nevirapine, or AZT with delavirdine) are extended by yet another drug (i.e. ddI), the efficacy (in both immunological and virological terms) is further increased (<a href="#BIB44" id="bBIB44" class="intra_ref">Davey et al., 1996</a>&nbsp;and&nbsp;<a href="#BIB42" id="bBIB42" class="intra_ref">D'Aquila et al., 1996</a>). Combined treatment of nevirapine with AZT and ddI has also proved efficacious in providing a sustained reduction of the plasma HIV-1 RNA load in infants (<span id="bBIB90"><a href="#BIB90" id="ancbBIB90" class="intra_ref">Luzuriaga et al., 1997</a></span>). The latter authors also stated that “therapy with potent combinations of antiretroviral drugs should be started as early as possible in infants with maternally acquired infection (probably within the first 2 to 4 weeks), to minimize the likelihood that antiretroviral resistance will emerge and to maximize the opportunity for long-term control of HIV-1 replication” (<span id="bBIB90"><a href="#BIB90" id="ancbBIB90" class="intra_ref">Luzuriaga et al., 1997</a></span>).</p><!--VALIDHTML--><p class="svArticle section" id="">From a comprehensive study of 1330 HIV-1-infected patients enrolled in several antiretroviral treatment trials (<span id="bBIB92"><a href="#BIB92" id="ancbBIB92" class="intra_ref">Marschner et al., 1998</a></span>), it appeared that having either a reduction in HIV-1 RNA level or an increase in CD4 lymphocyte count, or both, are associated with a delay in clinical disease progression. This implies that patient prognosis can be assessed using both HIV-1 RNA and CD4 cell responses to therapy (<span id="bBIB92"><a href="#BIB92" id="ancbBIB92" class="intra_ref">Marschner et al., 1998</a></span>). In fact, the characteristic responses of CD4 cell counts (increase) and HIV RNA plasma levels (decrease) following therapy could be depicted as a mirror image (<span id="bBIB69"><a href="#BIB69" id="ancbBIB69" class="intra_ref">Havlir and Richman, 1996</a></span>): the magnitude of the CD4 cell response tends to mirror the magnitude of the viral RNA response (although the peak response in CD4 cell counts lags behind the maximum reduction in plasma HIV RNA levels) (<span id="bFIG14"><a href="#FIG14" id="ancbFIG14" class="intra_ref">Fig. 14</a></span>). Pictured here are the responses of CD4 cell counts and plasma HIV RNA levels towards monotherapy (AZT), bitherapy (AZT+3TC) and tritherapy (AZT+3TC+protease inhibitor), but it is obvious that similar patterns may also be seen in response to NNRTI-containing drug regimens.</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG14"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG14" data-t="f"><dt class="autoScroll" data-style="height:392px;width:330px;"><a class="figureLink" href="#gr14" title="Full-size image (8 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (8 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr14.sml" data-fulleid="1-s2.0-S0166354298000254-gr14.gif" data-thumbheight="94" data-thumbwidth="79" data-fullheight="392" data-fullwidth="330" border="0" height="392" width="330"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr14.sml" data-fulleid="1-s2.0-S0166354298000254-gr14.gif"><img class="figure large" border="0" alt="Full-size image (8 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr14.gif" data-thumbEID="1-s2.0-S0166354298000254-gr14.sml" data-fullEID="1-s2.0-S0166354298000254-gr14.gif"></noscript></a></dt><dd id="labelCaptionFIG14"><p class="caption">Fig. 14.&nbsp;<span id="">Idealized response to tri-, di- and monotherapy, as exemplified for AZT (·&nbsp;·&nbsp;·), AZT+3TC (-&nbsp;-&nbsp;-) and AZT+3TC+protease inhibitor (———). According to <span id="FIG14bBIB69"><a href="#BIB69" id="ancFIG14bBIB69" class="intra_ref">Havlir and Richman (1996)</a></span>, modified.<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG14" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr14.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr14.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">From <span id="bFIG15"><a href="#FIG15" id="ancbFIG15" class="intra_ref">Fig. 15</a></span> it is clear that extension of the dual-drug (AZT+ddI) therapy to the triple-drug (AZT+ddI+nevirapine) regimen resulted in higher CD4 cell counts paralleled by lower plasma HIV-1 RNA levels, thus attesting to the immunologic and virologic benefit afforded by the addition of nevirapine to the combination of AZT and ddI (<span id="bBIB42"><a href="#BIB42" id="ancbBIB42" class="intra_ref">D'Aquila et al., 1996</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG15"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG15" data-t="f"><dt class="autoScroll" data-style="height:536px;width:331px;"><a class="figureLink" href="#gr15" title="Full-size image (14 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (14 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr15.sml" data-fulleid="1-s2.0-S0166354298000254-gr15.gif" data-thumbheight="92" data-thumbwidth="57" data-fullheight="536" data-fullwidth="331" border="0" height="536" width="331"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr15.sml" data-fulleid="1-s2.0-S0166354298000254-gr15.gif"><img class="figure large" border="0" alt="Full-size image (14 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr15.gif" data-thumbEID="1-s2.0-S0166354298000254-gr15.sml" data-fullEID="1-s2.0-S0166354298000254-gr15.gif"></noscript></a></dt><dd id="labelCaptionFIG15"><p class="caption">Fig. 15.&nbsp;<span id="">Triple-drug combination (AZT+ddI+nevirapine; ·&nbsp;·&nbsp;·) versus double-drug combination (AZT+ddI; ———). According to <span id="FIG15bBIB42"><a href="#BIB42" id="ancFIG15bBIB42" class="intra_ref">D'Aquila et al. (1996)</a></span>.<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG15" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr15.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr15.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">As already mentioned above, the triple-drug combination AZT+ddI+delavirdine proved more potent than either two-drug combinations or monotherapy (<span id="bBIB44"><a href="#BIB44" id="ancbBIB44" class="intra_ref">Davey et al., 1996</a></span>). Similarly, the triple-drug combination AZT+3TC+delavirdine proved superior to the double-drug combination AZT+3TC, which in turn, proved more efficacious than the double-drug combination AZT+delavirdine, when monitored either virologically (decrease of HIV RNA plasma levels) or immunologically (increase of CD4 cell counts) (<span id="bFIG16"><a href="#FIG16" id="ancbFIG16" class="intra_ref">Fig. 16</a></span>) (G. Tarpley, personal communication, 1998).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG16"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG16" data-t="f"><dt class="autoScroll" data-style="height:532px;width:498px;"><a class="figureLink" href="#gr16" title="Full-size image (18 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (18 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr16.sml" data-fulleid="1-s2.0-S0166354298000254-gr16.gif" data-thumbheight="93" data-thumbwidth="87" data-fullheight="532" data-fullwidth="498" border="0" height="532" width="498"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr16.sml" data-fulleid="1-s2.0-S0166354298000254-gr16.gif"><img class="figure large" border="0" alt="Full-size image (18 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr16.gif" data-thumbEID="1-s2.0-S0166354298000254-gr16.sml" data-fullEID="1-s2.0-S0166354298000254-gr16.gif"></noscript></a></dt><dd id="labelCaptionFIG16"><p class="caption">Fig. 16.&nbsp;<span id="">Protocol 0021 Pt 2 (G. Tarpley, personal communication, 1998). ■, AZT+3TC; □, AZT+delavirdine; •, AZT+3TC+delavirdine. *<em>P</em>≤0.05.<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG16" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr16.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr16.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">In the CAESAR Trial (a large randomized trial, involving more than 3000 patients) the addition of 3TC, or 3TC+loviride, to AZT-containing treatment regimens (AZT monotherapy, or AZT+ddC, or AZT+ddI combination therapy),was found to slow the progression of HIV disease and improve survival (<span id="bBIB35"><a href="#BIB35" id="ancbBIB35" class="intra_ref">CAESAR Coordinating Committee, 1997</a></span>); and again the incremental benefit resulting from the addition of 3TC and loviride was reflected by the increase in CD4 cell counts and decrease of plasma HIV RNA levels (<span id="bFIG17"><a href="#FIG17" id="ancbFIG17" class="intra_ref">Fig. 17</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG17"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG17" data-t="f"><dt class="autoScroll" data-style="height:470px;width:502px;"><a class="figureLink" href="#gr17" title="Full-size image (17 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (17 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr17.sml" data-fulleid="1-s2.0-S0166354298000254-gr17.gif" data-thumbheight="94" data-thumbwidth="100" data-fullheight="470" data-fullwidth="502" border="0" height="470" width="502"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr17.sml" data-fulleid="1-s2.0-S0166354298000254-gr17.gif"><img class="figure large" border="0" alt="Full-size image (17 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr17.gif" data-thumbEID="1-s2.0-S0166354298000254-gr17.sml" data-fullEID="1-s2.0-S0166354298000254-gr17.gif"></noscript></a></dt><dd id="labelCaptionFIG17"><p class="caption">Fig. 17.&nbsp;<span id="">CAESER trial (<span id="FIG17bBIB35"><a href="#BIB35" id="ancFIG17bBIB35" class="intra_ref">CAESAR Coordinating Committee, 1997</a></span>). Median (±S.E.) changes from baseline in CD4 counts, and log<sub>10</sub> copies per ml HIV RNA, per treatment group. Current treatment (AZT, or AZT+ddC, or AZT+ddI) to which was added either placebo (•), or 3TC (□), or 3TC+loviride (○).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG17" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr17.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr17.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">In another study, (VAN Study, 22 patients enrolled), HIV patients were treated with the combination 3TC+indinavir+nevirapine (M. Myers, personal communication, 1998): this triple-drug combination resulted in a pronounced (3&nbsp;log<sub>10</sub>) reduction in plasma HIV RNA levels, which, again, was virtually mirrored by an equivalent increase in CD4 cell counts (<span id="bFIG18"><a href="#FIG18" id="ancbFIG18" class="intra_ref">Fig. 18</a></span>). In yet another small study (dNN Study, 25 patients enrolled), the combination d4T+nelfinavir+nevirapine was investigated (<span id="bBIB128"><a href="#BIB128" id="ancbBIB128" class="intra_ref">Skowron et al., 1998</a></span>); and this, again, resulted in a marked reduction in viral load mirrored by a substantial increase in CD4 cell counts (<span id="bFIG19"><a href="#FIG19" id="ancbFIG19" class="intra_ref">Fig. 19</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG18"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG18" data-t="f"><dt class="autoScroll" data-style="height:440px;width:338px;"><a class="figureLink" href="#gr18" title="Full-size image (6 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (6 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr18.sml" data-fulleid="1-s2.0-S0166354298000254-gr18.gif" data-thumbheight="92" data-thumbwidth="71" data-fullheight="440" data-fullwidth="338" border="0" height="440" width="338"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr18.sml" data-fulleid="1-s2.0-S0166354298000254-gr18.gif"><img class="figure large" border="0" alt="Full-size image (6 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr18.gif" data-thumbEID="1-s2.0-S0166354298000254-gr18.sml" data-fullEID="1-s2.0-S0166354298000254-gr18.gif"></noscript></a></dt><dd id="labelCaptionFIG18"><p class="caption">Fig. 18.&nbsp;<span id="">VAN Study. One-year follow-up of HIV patients treated with 3TC, indinavir and nelfinavir in combination (<em>N</em>=22). According to Harris et al. (M. Myers, personal communication, 1998).<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG18" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr18.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr18.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG19"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG19" data-t="f"><dt class="autoScroll" data-style="height:434px;width:338px;"><a class="figureLink" href="#gr19" title="Full-size image (7 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (7 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr19.sml" data-fulleid="1-s2.0-S0166354298000254-gr19.gif" data-thumbheight="94" data-thumbwidth="73" data-fullheight="434" data-fullwidth="338" border="0" height="434" width="338"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr19.sml" data-fulleid="1-s2.0-S0166354298000254-gr19.gif"><img class="figure large" border="0" alt="Full-size image (7 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr19.gif" data-thumbEID="1-s2.0-S0166354298000254-gr19.sml" data-fullEID="1-s2.0-S0166354298000254-gr19.gif"></noscript></a></dt><dd id="labelCaptionFIG19"><p class="caption">Fig. 19.&nbsp;<span id="">ddN Study. d4T, nelfinavir and nevirapine in combination (<em>N</em>=25). According to <span id="FIG19bBIB128"><a href="#BIB128" id="ancFIG19bBIB128" class="intra_ref">Skowron et al. (1998)</a></span>.<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG19" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr19.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr19.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">Also efavirenz (DMP 266) has been the subject of combination studies with AZT and 3TC, and with indinavir. In the latter study (101 patients enrolled), the patients receiving indinavir were allowed to add d4T+efavirenz from week 12 onwards (<span id="bBIB94"><a href="#BIB94" id="ancbBIB94" class="intra_ref">Mayers et al., 1997</a></span>). The combination of indinavir with efavirenz conferred a more pronounced immunologic and virologic response than indinavir alone, and this response was sustained for the whole follow-up period (48 weeks) (<span id="bFIG20"><a href="#FIG20" id="ancbFIG20" class="intra_ref">Fig. 20</a></span>).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="figure_FIG20"><div class="
                    textboxdefault
                "><dl class="figure" id="FIG20" data-t="f"><dt class="autoScroll" data-style="height:729px;width:519px;"><a class="figureLink" href="#gr20" title="Full-size image (27 K)"><img style="display: inline;" class="imgLazyJSB figure large" alt="Full-size image (27 K)" src="grey_pxl.gif" data-thumbeid="1-s2.0-S0166354298000254-gr20.sml" data-fulleid="1-s2.0-S0166354298000254-gr20.gif" data-thumbheight="93" data-thumbwidth="66" data-fullheight="729" data-fullwidth="519" border="0" height="729" width="519"><noscript class="figure large" border="0" alt="Full-size image" data-thumbeid="1-s2.0-S0166354298000254-gr20.sml" data-fulleid="1-s2.0-S0166354298000254-gr20.gif"><img class="figure large" border="0" alt="Full-size image (27 K)" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr20.gif" data-thumbEID="1-s2.0-S0166354298000254-gr20.sml" data-fullEID="1-s2.0-S0166354298000254-gr20.gif"></noscript></a></dt><dd id="labelCaptionFIG20"><p class="caption">Fig. 20.&nbsp;<span id="">Combination of efavirenz (DMP 266) with indinavir. Patients receiving indinavir were allowed to add d4T+DMP 266 from week 12 onwards. □, efavirenz 200 mg qd+indinavir 1000 mg q 8 h; ○, indinavir 800 mg/1000 mg q 8 h. *&nbsp;Number of patients receiving d4T+DMP 266 in addition to indinavir. According to <span id="FIG20bBIB94"><a href="#BIB94" id="ancFIG20bBIB94" class="intra_ref">Mayers et al. (1997)</a></span>.<!--Comment--></span><!--caption--></p></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Figure options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#FIG20" class="viewWS" title="View in workspace">View in workspace</a></li><li><a href="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0166354298000254-gr20.gif" title="View full-size image - Opens in new window">Download full-size image</a></li><li><a class="ppt" title="Download as PowerPoint slide" href="http://services.elsevier.com.libgate.library.nuigalway.ie/SDWebExport/export/figure/S0166354298000254/1-s2.0-S0166354298000254-gr20.sml/ppt">Download as PowerPoint slide</a></li></ul></dd></dl></div></div><!--VALIDHTML--><p class="svArticle section" id="">As a rule, triple-drug therapy may thus be considered as superior to dual-drug therapy, which, in turn, can be considered as superior to single-drug therapy. It could a priori be expected that quadruple-drug therapy may even be more effective than triple-, and quintuple- more effective than quadruple-, and sextuple- more so than quintuple-drug therapy. Such multiple-drug regimens should, of course, be carefully monitored for toxic side effects and drug interactions. While possible interactions between NNRTIs and ddN analogues are neither known nor anticipated, interactions between NNRTIs and protease inhibitors are likely to occur, since they are both hepatically metabolized (<span id="bBIB123"><a href="#BIB123" id="ancbBIB123" class="intra_ref">Sahai, 1996</a></span>). In this respect, delavirdine acts as a cytochrome P450 CYP3A4 inhibitor and may thus increase the plasma levels of the protease inhibitors (i.e. saquinavir). Vice versa, nevirapine rather acts as an inducer of the P450 enzyme and may thus decrease the plasma levels of the hepatically metabolized drugs (<span id="bBIB123"><a href="#BIB123" id="ancbBIB123" class="intra_ref">Sahai, 1996</a></span>).</p><!--VALIDHTML--><h2 class="svArticle" id="section_lbl7">7. Conclusion</h2><p class="svArticle section" id="">HIV-1 viremia, the hallmark of HIV infection is sustained by a highly dynamic process involving continuous rounds of de novo virus replication and cell turnover (<a href="#BIB72" id="bBIB72" class="intra_ref">Ho et al., 1995</a>&nbsp;and&nbsp;<a href="#BIB138" id="bBIB138" class="intra_ref">Wei et al., 1995</a>). Productively infected cells have, on average, a life-span of 2.2 days (half-life=1.6 days) and plasma virions have a mean life-span of 0.3 days (half-life=0.24 days). The average total HIV-1 production is approximately 1010 virions/day, and the minimum duration of the HIV-1 life-cycle in vivo is 1.2 days on average (<span id="bBIB111"><a href="#BIB111" id="ancbBIB111" class="intra_ref">Perelson et al., 1996</a></span>). Virus replication is the driving force in the progression to AIDS. Low viral load is associated with long-term non-progression to AIDS (<a href="#BIB37" id="bBIB37" class="intra_ref">Cao et al., 1995</a>&nbsp;and&nbsp;<a href="#BIB106" id="bBIB106" class="intra_ref">Pantaleo et al., 1995</a>), and, while both plasma HIV RNA levels and CD4 cell counts are valid predictors of the clinical progression of HIV disease (<a href="#BIB103" id="bBIB103" class="intra_ref">O'Brien et al., 1996</a>&nbsp;and&nbsp;<a href="#BIB122" id="bBIB122" class="intra_ref">Saag et al., 1996</a>), plasma viral load is a more accurate predictor of progression to AIDS than the number of CD4 cells (<span id="bBIB97"><a href="#BIB97" id="ancbBIB97" class="intra_ref">Mellors et al., 1996</a></span>). Furthermore, the clinical course of HIV-1 infection may already be determined at the earliest phase of the disease, and this necessitates initiation of definitive treatment very early in HIV-1 infection (<span id="bBIB41"><a href="#BIB41" id="ancbBIB41" class="intra_ref">Craib et al., 1997</a></span>).</p><!--VALIDHTML--><p class="svArticle section" id="">In view of all these considerations, and the remarks made above on the optimization of drug treatment regimens, a few recommendations could be formulated so as to ensure a successful treatment of HIV infections. These recommendations (<span id="bTBL3"><a href="#TBL3" id="ancbTBL3" class="intra_ref">Table 3</a></span>) concern NNRTIs as well as any other anti-HIV drugs. It would be of paramount importance that the NNRTI-containing drug regimens should be started as soon as possible after HIV infection, and that the individual compounds should be used at the highest possible doses so as to completely suppress virus replication (and prevent drug-resistant virus strains from emerging) for as long a time as necessary. How long the treatment should be continued, and whether it could be discontinued or adjusted at certain time points, remain unsettled issues. Fact is that, despite prolonged suppression of plasma viremia, replication-competent virus could still be recovered from resting CD4 T-lymphocytes (<a href="#BIB65" id="bBIB65" class="intra_ref">Finzi et al., 1997</a>&nbsp;and&nbsp;<a href="#BIB142" id="bBIB142" class="intra_ref">Wong et al., 1997</a>), even after 30 months of highly active anti-retroviral therapy. It thus appears that with the current drug treatment regimes, virus replication may be suppressed, resistance development prevented, and progression to AIDS arrested, albeit without eradication of the virus from its reservoir(s).</p><!--VALIDHTML--><div class="figTblUpiOuter svArticle" id="table_TBL3"><div class="textboxdefault"><dl id="TBL3" data-t="t" class="table " data-label="Table 3"><dd class="lblCap"><p class="caption"><span class="label">Table 3.
        </span>Recommendations for clinical use of anti-HIV drugs, including NNRTIs</p></dd><dd class="table"><table><colgroup><col></colgroup><tbody><tr><td rowspan="1" colspan="1">&nbsp;1. Use different compounds in multiple (double, triple, quadruple, etc.) drug combinations</td></tr><tr><td rowspan="1" colspan="1">&nbsp;2. At sufficiently high (but subtoxic) doses</td></tr><tr><td rowspan="1" colspan="1">&nbsp;3. Starting as soon as possible after the HIV infection</td></tr><tr><td rowspan="1" colspan="1">&nbsp;4. With the aim to achieve complete suppression of virus replication (viral load below detection limit)</td></tr><tr><td rowspan="1" colspan="1">&nbsp;5. And to prevent the development of virus–drug resistance</td></tr><tr><td rowspan="1" colspan="1">&nbsp;6. Ensuring full compliance (patient taking his/her medicine)</td></tr><tr><td rowspan="1" colspan="1">&nbsp;7. While improving on the convenience of drug dosing (preferably once daily)</td></tr><tr><td rowspan="1" colspan="1">&nbsp;8. Minimizing adverse side-effects of the drug</td></tr><tr><td rowspan="1" colspan="1">&nbsp;9. Continuing drug treatment as long as required for a sustained suppression (and, ideally, eradication of the virus from the organs and from the organism)</td></tr><tr><td rowspan="1" colspan="1">10. Making the anti-HIV drugs widely available (at affordable costs)</td></tr></tbody></table></dd><dd class="fullsizeTable"><a title="Full-size table - Opens new window" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=MiamiCaptionURL&amp;_method=retrieve&amp;_eid=1-s2.0-S0166354298000254&amp;_image=TBL3&amp;_ba=&amp;_fmt=full&amp;_orig=na&amp;_issn=01663542&amp;_pii=S0166354298000254&amp;_isTablePopup=Y&amp;_acct=C000005418&amp;_version=1&amp;_urlVersion=0&amp;_userid=62921&amp;md5=7bff4c45b244f9520e3a40ddd338cd91">Full-size table</a></dd><dd class="menuButtonLinks"><div class="btnHolder"><a class="menuTitle" href="#">Table options</a><div class="down_Btn"></div></div><ul class="menuButton"><li><a href="#TBL3" class="viewWS" title="View in workspace">View in workspace</a></li><li><div class="downloadCsv"><a title="Download as CSV" href="#">Download as CSV</a></div></li></ul></dd></dl></div></div><!--VALIDHTML--><div class="articleText svArticle"><div class="articleText_indent"><h2 class="h2 secHeading" id="ack001">Acknowledgements</h2><p class="svArticle section" id="">The dedicated editorial assistance of Christiane Callebaut is gratefully acknowledged. E. De Clercq is titular of the Professor P. De Somer Chair for Microbiology.</p></div></div><!--VALIDHTML--><script type="text/javascript">

              prs.rt("ref_start");
            </script><h2 id="bibl001">References</h2><ol class="references"><li id="BIB1" data-t="r"><ul class="reference" id="bibsbref1"><li class="referenceLabel"><a href="#BIB1" class="label intra_ref">Ahgren et al., 1995</a></li><li class="author">C. Ahrgren, K. Backro, F.W. Bell, A.S. Cantrell, M. Clemens, J.M. Colacino, J.B. Deeter, J.A. Engelhardt, M. Högberg, S.R. Jaskunas, N.G. Johansson, C.L. Jordan, J.S. Kasher, M.D. Kinnick, P. Lind, C. Lopez, J.M. Morin Jr., M.A. Muesing, R. Noreen, B. Öberg, C.J. Paget, J.A. Palkowitz, C.A. Parrish, P. Pranc, M.K. Rippy, C. Rydergard, C. Sahlberg, S. Swanson, R.J. Ternansky, T. Unge, R.T. Vasileff, L. Vrang, S.J. West, H. Zhang, X.-X. Zhou</li><li class="title"><p>The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase</p></li><li class="source"><p>Antimicrob. Agents Chemother., 39 (1995), pp. 1329–1335</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref1" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref1'] = new Array();
        </script></li><li id="BIB2" data-t="r"><ul class="reference" id="bibsbref2"><li class="referenceLabel"><a href="#BIB2" class="label intra_ref">Althaus et al., 1996</a></li><li class="author">I.W. Althaus, K.-C. Chou, R.J. Lemay, K.M. Franks, M.R. Deibel, F.J. Kezdy, L. Resnick, M.E. Busso, A.G. So, K.M. Downey, D.L. Romero, R.C. Thomas, P.A. Aristoff, W.G. Tarpley, F. Reusser</li><li class="title"><p>The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase</p></li><li class="source"><p>Biochem. Pharmacol., 51 (1996), pp. 743–750</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref2" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref2'] = new Array();
        </script></li><li id="BIB3" data-t="r"><ul class="reference" id="bibsbref3"><li class="referenceLabel"><a href="#BIB3" class="label intra_ref">Antonucci et al., 1995</a></li><li class="author">T. Antonucci, J.S. Warmus, J.C. Hodges, D.G. Nickell</li><li class="title"><p>Characterization of the antiviral activity of highly substituted pyrroles: a novel class of non-nucleoside HIV-1 reverse transcriptase inhibitor</p></li><li class="source"><p>Antiviral Chem. Chemother., 6 (1995), pp. 98–108</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref3" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref3'] = new Array();
        </script></li><li id="BIB4" data-t="r"><ul class="reference" id="bibsbref4"><li class="referenceLabel"><a href="#BIB4" class="label intra_ref">Artico et al., 1993</a></li><li class="author">M. Artico, S. Massa, A. Mai, M.E. Marongiu, G. Piras, E. Tramontano, P. La Colla</li><li class="title"><p>3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus type 1</p></li><li class="source"><p>Antiviral Chem. Chemother., 4 (1993), pp. 361–368</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref4" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref4'] = new Array();
        </script></li><li id="BIB5" data-t="r"><ul class="reference" id="bibsbref5"><li class="referenceLabel"><a href="#BIB5" class="label intra_ref">Baba et al., 1989</a></li><li class="author">M. Baba, H. Tanaka, E. De Clercq, R. Pauwels, J. Balzarini, D. Schols, H. Nakashima, C.-F. Perno, R.T. Walker, T. Miyasaka</li><li class="title"><p>Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative</p></li><li class="source"><p>Biochem. Biophys. Res. Commun., 165 (1989), pp. 1375–1381</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref5" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref5'] = new Array();
        </script></li><li id="BIB6" data-t="r"><ul class="reference" id="bibsbref6"><li class="referenceLabel"><a href="#BIB6" class="label intra_ref">Baba et al., 1991a</a></li><li class="author">M. Baba, E. De Clercq, H. Tanaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, K. Umezu, H. Nakashima, S. Mori, S. Shigeta, R.T. Walker, T. Miyasaka</li><li class="title"><p>Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 88 (1991), pp. 2356–2360</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref6" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref6'] = new Array();
        </script></li><li id="BIB7" data-t="r"><ul class="reference" id="bibsbref7"><li class="referenceLabel"><a href="#BIB7" class="label intra_ref">Baba et al., 1991b</a></li><li class="author">M. Baba, E. De Clercq, H. Tanaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, K. Umezu, R.T. Walker, S. Mori, M. Ito, S. Shigeta, T. Miyasaka</li><li class="title"><p>Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives</p></li><li class="source"><p>Mol. Pharmacol., 39 (1991), pp. 805–810</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref7" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref7'] = new Array();
        </script></li><li id="BIB8" data-t="r"><ul class="reference" id="bibsbref8"><li class="referenceLabel"><a href="#BIB8" class="label intra_ref">Baba et al., 1994</a></li><li class="author">M.M. Baba, S. Shigeta, S. Yuasa, H. Takashima, K. Sekiya, M. Ubasawa, H. Tanaka, T. Miyasaka, R.T. Walker, E. De Clercq</li><li class="title"><p>Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro</p></li><li class="source"><p>Antimicrob. Agents Chemother., 38 (1994), pp. 688–692</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref8" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref8'] = new Array();
        </script></li><li id="BIB9" data-t="r"><ul class="reference" id="bibsbref9"><li class="referenceLabel"><a href="#BIB9" class="label intra_ref">Balzarini and De Clercq, 1997</a></li><li class="author">J. Balzarini, E. De Clercq</li><li class="title"><p>The thiocarboxanilides UC-10 and UC-781 have an additive inhibitory effect against human immunodeficiency virus type 1 reverse transcriptase and replication in cell culture when combined with other antiretroviral drugs</p></li><li class="source"><p>Antiviral Chem. Chemother., 8 (1997), pp. 197–204</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref9" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref9'] = new Array();
        </script></li><li id="BIB10" data-t="r"><ul class="reference" id="bibsbref10"><li class="referenceLabel"><a href="#BIB10" class="label intra_ref">Balzarini et al., 1992a</a></li><li class="author">J. Balzarini, M.-J. Pérez-Pérez, A. San-Félix, D. Schols, C.-F. Perno, A.-M. Vandamme, M.-J. Camarasa, E. De Clercq</li><li class="title"><p>2′,5′-Bis-<em>O</em>-(tert.-butyldimethylsilyl)-3′-spiro-5′′(4′′amino-1′′,2′′oxathiole-2′′,2′′-dioxide)pyrimidine (TSAO) nucleoside analogues: novel highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 89 (1992), pp. 4392–4396</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref10" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref10'] = new Array();
        </script></li><li id="BIB11" data-t="r"><ul class="reference" id="bibsbref11"><li class="referenceLabel"><a href="#BIB11" class="label intra_ref">Balzarini et al., 1992b</a></li><li class="author">J. Balzarini, M.-J. Perez-Perez, A. San-Felix, S. Velazquez, M.-J. Camarasa, E. De Clercq</li><li class="title"><p>[2′,5′-Bis-<em>O</em>-(tert-butyldimethylsilyl)]-3′-spiro-5′′-[4′′-amino-1′′,2′′-oxathiole-2′′,2′′-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1</p></li><li class="source"><p>Antimicrob. Agents Chemother., 36 (1992), pp. 1073–1080</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref11" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref11'] = new Array();
        </script></li><li id="BIB12" data-t="r"><ul class="reference" id="bibsbref12"><li class="referenceLabel"><a href="#BIB12" class="label intra_ref">Balzarini et al., 1992c</a></li><li class="author">J. Balzarini, M.-J. Pérez-Pérez, A. San-Félix, M.-J. Camarasa, P.J. Barr, E. De Clercq</li><li class="title"><p>Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-<em>O</em>-(tert-butyldimethylsilyl)-<em>β</em>-<span class="smallcaps">d</span>-ribofuranosyl]-3′-spiro-5′′-(4′′-amino-1′′,2′′-oxathiole-2′′,2′′-di-oxide)thymine (TSAO-T)</p></li><li class="source"><p>J. Biol. Chem., 267 (1992), pp. 11831–11838</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref12" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref12'] = new Array();
        </script></li><li id="BIB13" data-t="r"><ul class="reference" id="bibsbref13"><li class="referenceLabel"><a href="#BIB13" class="label intra_ref">Balzarini et al., 1993</a></li><li class="author">J. Balzarini, A. Karlsson, M.-J. Pérez-Pérez, M.-J. Camarasa, E. De Clercq</li><li class="title"><p>Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus</p></li><li class="source"><p>Virology, 196 (1993), pp. 576–585</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref13" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref13'] = new Array();
        </script></li><li id="BIB14" data-t="r"><ul class="reference" id="bibsbref14"><li class="referenceLabel"><a href="#BIB14" class="label intra_ref">Balzarini et al., 1994</a></li><li class="author">J. Balzarini, A. Karlsson, C. Meichsner, A. Paessens, G. Riess, E. De Clercq, J.-P. Kleim</li><li class="title"><p>Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720</p></li><li class="source"><p>J. Virol., 68 (1994), pp. 7986–7992</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref14" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref14'] = new Array();
        </script></li><li id="BIB15" data-t="r"><ul class="reference" id="bibsbref15"><li class="referenceLabel"><a href="#BIB15" class="label intra_ref">Balzarini et al., 1995a</a></li><li class="author">J. Balzarini, W.G. Brouwer, E.E. Felauer, E. De Clercq, A. Karlsson</li><li class="title"><p>Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains</p></li><li class="source"><p>Antiviral Res., 27 (1995), pp. 219–236</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref15" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref15'] = new Array();
        </script></li><li id="BIB16" data-t="r"><ul class="reference" id="bibsbref16"><li class="referenceLabel"><a href="#BIB16" class="label intra_ref">Balzarini et al., 1995b</a></li><li class="author">J. Balzarini, M. Baba, E. De Clercq</li><li class="title"><p>Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains</p></li><li class="source"><p>Antimicrob. Agents Chemother., 39 (1995), pp. 998–1002</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref16" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref16'] = new Array();
        </script></li><li id="BIB17" data-t="r"><ul class="reference" id="bibsbref17"><li class="referenceLabel"><a href="#BIB17" class="label intra_ref">Balzarini et al., 1995c</a></li><li class="author">J. Balzarini, M.-J. Pérez-Pérez, S. Vélazquez, A. San-Félix, M.-J. Camarasa, E. De Clercq, A. Karlsson</li><li class="title"><p>Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives)</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 92 (1995), pp. 5470–5474</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref17" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref17'] = new Array();
        </script></li><li id="BIB18" data-t="r"><ul class="reference" id="bibsbref18"><li class="referenceLabel"><a href="#BIB18" class="label intra_ref">Balzarini et al., 1996a</a></li><li class="author">J. Balzarini, H. Pelemans, M.-J. Pérez-Pérez, A. San-Félix, M.-J. Camarasa, A. Karlsson</li><li class="title"><p>Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine</p></li><li class="source"><p>Mol. Pharmacol., 49 (1996), pp. 882–890</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref18" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref18'] = new Array();
        </script></li><li id="BIB19" data-t="r"><ul class="reference" id="bibsbref19"><li class="referenceLabel"><a href="#BIB19" class="label intra_ref">Balzarini et al., 1996b</a></li><li class="author">J. Balzarini, H. Pelemans, S. Aquaro, C.-F. Perno, M. Witvrouw, D. Schols, E. De Clercq, A. Karlsson</li><li class="title"><p>Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication</p></li><li class="source"><p>Mol. Pharmacol., 50 (1996), pp. 394–401</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref19" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref19'] = new Array();
        </script></li><li id="BIB20" data-t="r"><ul class="reference" id="bibsbref20"><li class="referenceLabel"><a href="#BIB20" class="label intra_ref">Balzarini et al., 1996c</a></li><li class="author">J. Balzarini, H. Pelemans, A. Karlsson, E. De Clercq, J.-P. Kleim</li><li class="title"><p>Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 93 (1996), pp. 13152–13157</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref20" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref20'] = new Array();
        </script></li><li id="BIB21" data-t="r"><ul class="reference" id="bibsbref21"><li class="referenceLabel"><a href="#BIB21" class="label intra_ref">Balzarini et al., 1997</a></li><li class="author">J. Balzarini, H. Pelemans, G. Riess, M. Roesner, I. Winkler, E. De Clercq, J.-P. Kleim</li><li class="title"><p>Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine</p></li><li class="source"><p>J. Infect. Dis., 176 (1997), pp. 1392–1397</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref21" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref21'] = new Array();
        </script></li><li id="BIB22" data-t="r"><ul class="reference" id="bibsbref22"><li class="referenceLabel"><a href="#BIB22" class="label intra_ref">Balzarini et al., 1998a</a></li><li class="author">J. Balzarini, H. Pelemans, R. Esnouf, E. De Clercq</li><li class="title"><p>A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781</p></li><li class="source"><p>AIDS Res. Hum. Retroviruses, 14 (1998), pp. 255–260</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref22" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref22'] = new Array();
        </script></li><li id="BIB23" data-t="r"><ul class="reference" id="bibsbref23"><li class="referenceLabel"><a href="#BIB23" class="label intra_ref">Balzarini et al., 1998b</a></li><li class="author">J. Balzarini, H. Pelemans, G. Riess, M. Roesner, I. Winkler, E. De Clercq, J.-P. Kleim</li><li class="title"><p>Retention of marked sensitivity to (<em>S</em>)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline-2(1<em>H</em>)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine)</p></li><li class="source"><p>Biochem. Pharmacol., 55 (1998), pp. 617–625</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref23" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref23'] = new Array();
        </script></li><li id="BIB24" data-t="r"><ul class="reference" id="bibsbref24"><li class="referenceLabel"><a href="#BIB24" class="label intra_ref">Barth et al., 1996</a></li><li class="author">B. Barth, M. Dierich, G. Heinisch, V. Jenny, B. Matuszczak, K. Mereiter, R. Planer, I. Schöpf, H. Stoiber, T. Traugott, P. von Aufschnaiter</li><li class="title"><p>Pyridazino[3,4-<em>b</em>][1,5]benzoxazepin-5(6<em>H</em>)-ones: synthesis and biological evaluation</p></li><li class="source"><p>Antiviral Chem. Chemother., 7 (1996), pp. 300–312</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref24" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref24'] = new Array();
        </script></li><li id="BIB25" data-t="r"><ul class="reference" id="bibsbref25"><li class="referenceLabel"><a href="#BIB25" class="label intra_ref">Bellarosa et al., 1996</a></li><li class="author">D. Bellarosa, G. Antonelli, F. Bambacioni, D. Giannotti, G. Viti, R. Nannicini, A. Giachetti, F. Dianzani, M. Witvrouw, R. Pauwels, J. Desmyter, E. De Clercq</li><li class="title"><p>New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase</p></li><li class="source"><p>Antiviral Res., 30 (1996), pp. 109–124</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref25" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref25'] = new Array();
        </script></li><li id="BIB26" data-t="r"><ul class="reference" id="bibsbref26"><li class="referenceLabel"><a href="#BIB26" class="label intra_ref">Boyer et al., 1994</a></li><li class="author">P.L. Boyer, J. Ding, E. Arnold, S.H. Hughes</li><li class="title"><p>Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase</p></li><li class="source"><p>Antimicrob. Agents Chemother., 38 (1994), pp. 1909–1914</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref26" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref26'] = new Array();
        </script></li><li id="BIB27" data-t="r"><ul class="reference" id="bibsbref27"><li class="referenceLabel"><a href="#BIB27" class="label intra_ref">Boyer et al., 1998</a></li><li class="author">P.L. Boyer, H.-Q. Gao, S.H. Hughes</li><li class="title"><p>A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer</p></li><li class="source"><p>Antimicrob. Agents Chemother., 42 (1998), pp. 447–452</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref27" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref27'] = new Array();
        </script></li><li id="BIB28" data-t="r"><ul class="reference" id="bibsbref28"><li class="referenceLabel"><a href="#BIB28" class="label intra_ref">Brennan et al., 1995</a></li><li class="author">T.M. Brennan, D.L. Taylor, C.G. Bridges, J.P. Leyda, A.S. Tyms</li><li class="title"><p>The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds</p></li><li class="source"><p>Antiviral Res., 26 (1995), pp. 173–187</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref28" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref28'] = new Array();
        </script></li><li id="BIB29" data-t="r"><ul class="reference" id="bibsbref29"><li class="referenceLabel"><a href="#BIB29" class="label intra_ref">Buckheit et al., 1993</a></li><li class="author">R.W. Buckheit Jr., M.G. Hollingshead, J. Germany-Decker, E.L. White, J.B. McMahon, L.B. Allen, L.J. Ross, W.D. Decker, L. Westbrook, W.M. Shannon, O. Weislow, J.P. Bader, M.R. Boyd</li><li class="title"><p>Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor</p></li><li class="source"><p>Antiviral Res., 21 (1993), pp. 247–265</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref29" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref29'] = new Array();
        </script></li><li id="BIB30" data-t="r"><ul class="reference" id="bibsbref30"><li class="referenceLabel"><a href="#BIB30" class="label intra_ref">Buckheit et al., 1994a</a></li><li class="author">R.W. Buckheit Jr., V. Fliakas-Boltz, W.D. Decker, J.L. Roberson, C.A. Pyle, E.L. White, B.J. Bowdon, J.B. McMahon, M.R. Boyd, J.P. Bader, D.G. Nickell, H. Barth, T.K. Antonucci</li><li class="title"><p>Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors</p></li><li class="source"><p>Antiviral Res., 25 (1994), pp. 43–56</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref30" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref30'] = new Array();
        </script></li><li id="BIB31" data-t="r"><ul class="reference" id="bibsbref31"><li class="referenceLabel"><a href="#BIB31" class="label intra_ref">Buckheit et al., 1994b</a></li><li class="author">R.W. Buckheit Jr., E.L. White, J. Germany-Decker, L.B. Allen, L.J. Ross, W.M. Shannon, P.A.J. Janssen, M.A. Chirigos</li><li class="title"><p>Cell-based and biochemical analysis of the anti-HIV activity of combinations of 3′-azido-3′-deoxythymidine and analogues of TIBO</p></li><li class="source"><p>Antiviral Chem. Chemother., 5 (1994), pp. 35–42</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref31" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref31'] = new Array();
        </script></li><li id="BIB32" data-t="r"><ul class="reference" id="bibsbref32"><li class="referenceLabel"><a href="#BIB32" class="label intra_ref">Buckheit et al., 1995</a></li><li class="author">R.W. Buckheit Jr., V. Fliakas-Boltz, S. Yeagy-Bargo, O. Weislow, D.L. Mayers, P.L. Boyer, S.H. Hughes, B.-C. Pan, S.-H. Chu, J.P. Bader</li><li class="title"><p>Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase</p></li><li class="source"><p>Virology, 210 (1995), pp. 186–193</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref32" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref32'] = new Array();
        </script></li><li id="BIB33" data-t="r"><ul class="reference" id="bibsbref33"><li class="referenceLabel"><a href="#BIB33" class="label intra_ref">Buckheit et al., 1997</a></li><li class="author">R.W. Buckheit Jr., M.J. Snow, V. Fliakas-Boltz, T.L. Kinjerski, J.D. Russell, L.A. Pallansch, W.G. Brouwer, S.S. Yang</li><li class="title"><p>Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates</p></li><li class="source"><p>Antimicrob. Agents Chemother., 41 (1997), pp. 831–837</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref33" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref33'] = new Array();
        </script></li><li id="BIB34" data-t="r"><ul class="reference" id="bibsbref34"><li class="referenceLabel"><a href="#BIB34" class="label intra_ref">Byrnes et al., 1994</a></li><li class="author">V.W. Byrnes, E.A. Emini, W.A. Schleif, J.H. Condra, C.L. Schneider, W.J. Long, J.A. Wolfgang, D.J. Graham, L. Gotlib, A.J. Schlabach, B.S. Wolanski, O.M. Blahy, J.C. Quintero, A. Rhodes, E. Roth, D.L. Titus, V.V. Sardana</li><li class="title"><p>Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors</p></li><li class="source"><p>Antimicrob. Agents Chemother., 38 (1994), pp. 1404–1407</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref34" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref34'] = new Array();
        </script></li><li id="BIB35" data-t="r"><ul class="reference" id="bibsbref35"><li class="referenceLabel"><a href="#BIB35" class="label intra_ref">CAESAR Coordinating Committee, 1997</a></li><li class="author">CAESAR Coordinating Committee</li><li class="title"><p>Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial</p></li><li class="source"><p>Lancet, 349 (1997), pp. 1413–1421</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref35" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref35'] = new Array();
        </script></li><li id="BIB36" data-t="r"><ul class="reference" id="bibsbref36"><li class="referenceLabel"><a href="#BIB36" class="label intra_ref">Campiani et al., 1996</a></li><li class="author">G. Campiani, V. Nacci, I. Fiorini, M.P. De Filippis, A. Garofalo, G. Greco, E. Novellino, S. Altamura, L. Di Renzo</li><li class="title"><p>Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity</p></li><li class="source"><p>J. Med. Chem., 39 (1996), pp. 2672–2680</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref36" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref36'] = new Array();
        </script></li><li id="BIB37" data-t="r"><ul class="reference" id="bibsbref37"><li class="referenceLabel"><a href="#BIB37" class="label intra_ref">Cao et al., 1995</a></li><li class="author">Y. Cao, L. Qin, L. Zhang, J. Safrit, D.D. Ho</li><li class="title"><p>Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection</p></li><li class="source"><p>New Engl. J. Med., 332 (1995), pp. 201–208</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref37" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref37'] = new Array();
        </script></li><li id="BIB38" data-t="r"><ul class="reference" id="bibsbref38"><li class="referenceLabel"><a href="#BIB38" class="label intra_ref">Carr et al., 1996</a></li><li class="author">A. Carr, S. Vella, M.D. de Jong, F. Sorice, A. Imrie, C.A. Boucher, D.A. Cooper</li><li class="title"><p>A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients</p></li><li class="source"><p>AIDS, 10 (1996), pp. 635–641</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref38" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref38'] = new Array();
        </script></li><li id="BIB39" data-t="r"><ul class="reference" id="bibsbref39"><li class="referenceLabel"><a href="#BIB39" class="label intra_ref">Chimirri et al., 1997</a></li><li class="author">A. Chimirri, S. Grasso, C. Molica, A.-M. Monforte, P. Monforte, M. Zappalà, G. Bruno, F. Nicolò, M. Witvrouw, H. Jonckheere, J. Balzarini, E. De Clercq</li><li class="title"><p>Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2′,6′-difluorophenyl)-1<em>H</em>,3<em>H</em>-thiazolo[3,4-<em>a</em>]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor</p></li><li class="source"><p>Antiviral Chem. Chemother., 8 (1997), pp. 363–370</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref39" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref39'] = new Array();
        </script></li><li id="BIB40" data-t="r"><ul class="reference" id="bibsbref40"><li class="referenceLabel"><a href="#BIB40" class="label intra_ref">Chong et al., 1994</a></li><li class="author">K.-T. Chong, P.J. Pagano, R.R. Hinshaw</li><li class="title"><p>Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro</p></li><li class="source"><p>Antimicrob. Agents Chemother., 38 (1994), pp. 288–293</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref40" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref40'] = new Array();
        </script></li><li id="BIB41" data-t="r"><ul class="reference" id="bibsbref41"><li class="referenceLabel"><a href="#BIB41" class="label intra_ref">Craib et al., 1997</a></li><li class="author">K.J.P. Craib, S.A. Strathdee, R.S. Hogg, B. Leung, J.S.G. Montaner, M.V. O'Shaughnessy, M.T. Schechter</li><li class="title"><p>Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection</p></li><li class="source"><p>J. Infect. Dis., 176 (1997), pp. 798–800</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref41" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref41'] = new Array();
        </script></li><li id="BIB42" data-t="r"><ul class="reference" id="bibsbref42"><li class="referenceLabel"><a href="#BIB42" class="label intra_ref">D'Aquila et al., 1996</a></li><li class="author">R.T. D'Aquila, M.D. Hughes, M.D. Johnson, V.A. Johnson, M.S. Fischl, J.-P. Sommadossi, S.-H. Liou, J. Timpone, M. Myers, M. Myers, N. Basgoz, M. Niu, M.S. Hirsch, National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators</li><li class="title"><p>Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial</p></li><li class="source"><p>Ann. Intern. Med., 124 (1996), pp. 1019–1030</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref42" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref42'] = new Array();
        </script></li><li id="BIB43" data-t="r"><ul class="reference" id="bibsbref43"><li class="referenceLabel"><a href="#BIB43" class="label intra_ref">Davey et al., 1993</a></li><li class="author">R.T. Davey Jr., R.L. Dewar, G.F. Reed, M.B. Vasudevachari, M.A. Polis, J.A. Kovacs, J. Falloon, R.E. Walker, H. Masur, S.E. Haneiwich, D.G. O'Neill, M.R. Decker, J.A. Metcalf, M.A. Deloria, O.L. Laskin, N. Salzman, H.C. Lane</li><li class="title"><p>Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 90 (1993), pp. 5608–5612</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref43" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref43'] = new Array();
        </script></li><li id="BIB44" data-t="r"><ul class="reference" id="bibsbref44"><li class="referenceLabel"><a href="#BIB44" class="label intra_ref">Davey et al., 1996</a></li><li class="author">R.T. Davey Jr., D.G. Chaitt, G.F. Reed, W.W. Freimuth, B.R. Herpin, J.A. Metcalf, P.S. Eastman, J. Falloon, J.A. Kovacs, M.A. Polis, R.E. Walker, H. Masur, J. Boyle, S. Coleman, S.R. Cox, L. Wathen, C.L. Daenzer, H.C. Lane</li><li class="title"><p>Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients</p></li><li class="source"><p>Antimicrob. Agents Chemother., 40 (1996), pp. 1657–1664</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref44" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref44'] = new Array();
        </script></li><li id="BIB45" data-t="r"><ul class="reference" id="bibsbref45"><li class="referenceLabel"><a href="#BIB45" class="label intra_ref">Debyser et al., 1991</a></li><li class="author">Z. Debyser, R. Pauwels, K. Andries, J. Desmyter, M. Kukla, P.A.J. Janssen, E. De Clercq</li><li class="title"><p>An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-<em>jk</em>][1,4]benzodiazepin-2(1<em>H</em>)-one and -thione derivatives</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 88 (1991), pp. 1451–1455</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref45" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref45'] = new Array();
        </script></li><li id="BIB46" data-t="r"><ul class="reference" id="bibsbref46"><li class="referenceLabel"><a href="#BIB46" class="label intra_ref">Debyser et al., 1992</a></li><li class="author">Z. Debyser, R. Pauwels, M. Baba, J. Desmyter, E. De Clercq</li><li class="title"><p>Common features in the interaction of tetrahydroimidazo[4,5,1-<em>jk</em>][1,4]benzodiazepin-2(1<em>H</em>)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase</p></li><li class="source"><p>Mol. Pharmacol., 41 (1992), pp. 963–968</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref46" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref46'] = new Array();
        </script></li><li id="BIB47" data-t="r"><ul class="reference" id="bibsbref47"><li class="referenceLabel"><a href="#BIB47" class="label intra_ref">De Clercq, 1995</a></li><li class="author">E. De Clercq</li><li class="title"><p>Antiviral therapy for human immunodeficiency virus infections</p></li><li class="source"><p>Clin. Microbiol. Rev., 8 (1995), pp. 200–239</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref47" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref47'] = new Array();
        </script></li><li id="BIB48" data-t="r"><ul class="reference" id="bibsbref48"><li class="referenceLabel"><a href="#BIB48" class="label intra_ref">De Clercq, 1996a</a></li><li class="author">E. De Clercq</li><li class="title"><p>Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development</p></li><li class="source"><p>Med. Res. Rev., 16 (1996), pp. 125–157</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref48" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref48'] = new Array();
        </script></li><li id="BIB49" data-t="r"><ul class="reference" id="bibsbref49"><li class="referenceLabel"><a href="#BIB49" class="label intra_ref">De Clercq, 1996b</a></li><li class="author">E. De Clercq</li><li class="title"><p>What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections?</p></li><li class="source"><p>Rev. Med. Virol., 6 (1996), pp. 97–117</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref49" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref49'] = new Array();
        </script></li><li id="BIB50" data-t="r"><ul class="reference" id="bibsbref50"><li class="referenceLabel"><a href="#BIB50" class="label intra_ref">De Clercq, 1997</a></li><li class="author">E. De Clercq</li><li class="title"><p>In search of a selective antiviral chemotherapy</p></li><li class="source"><p>Clin. Microbiol. Rev., 10 (1997), pp. 674–693</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref50" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref50'] = new Array();
        </script></li><li id="BIB51" data-t="r"><ul class="reference" id="bibsbref51"><li class="referenceLabel"><a href="#BIB51" class="label intra_ref">De Jong et al., 1997</a></li><li class="author">M.D. De Jong, S. Vella, A. Carr, C.A.B. Boucher, A. Imrie, M. French, J. Hoy, S. Sorice, S. Pauluzzi, F. Chiodo, G.J. Weverling, M.E. van der Ende, Ph.J. Frissen, H.M. Weigel, R.H. Kauffmann, J.M.A. Lange, R. Yoon, M. Moroni, E. Hoenderdos, G. Leitz, D.A. Cooper, D. Hall, P. Reiss</li><li class="title"><p>High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication</p></li><li class="source"><p>J. Infect. Dis., 175 (1997), pp. 966–970</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref51" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref51'] = new Array();
        </script></li><li id="BIB52" data-t="r"><ul class="reference" id="bibsbref52"><li class="referenceLabel"><a href="#BIB52" class="label intra_ref">De Lucca and Otto, 1992</a></li><li class="author">G.V. De Lucca, M.J. Otto</li><li class="title"><p>Synthesis and anti-HIV activity of pyrrolo-[1,2-<em>d</em>]-(1,4)-benzodiazepin-6-ones</p></li><li class="source"><p>Bioorg. Med. Chem. Lett., 2 (1992), pp. 1639–1644</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref52" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref52'] = new Array();
        </script></li><li id="BIB53" data-t="r"><ul class="reference" id="bibsbref53"><li class="referenceLabel"><a href="#BIB53" class="label intra_ref">De Wit et al., 1992</a></li><li class="author">S. De Wit, P. Hermans, B. Sommereijns, E. O'Doherty, R. Westenborghs, V. Van De Velde, G.F.M.J. Cauwenbergh, N. Clumeck</li><li class="title"><p>Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion</p></li><li class="source"><p>Antimicrob. Agents Chemother., 36 (1992), pp. 2661–2663</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref53" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref53'] = new Array();
        </script></li><li id="BIB54" data-t="r"><ul class="reference" id="bibsbref54"><li class="referenceLabel"><a href="#BIB54" class="label intra_ref">Ding et al., 1995a</a></li><li class="author">J. Ding, K. Das, C. Tantillo, W. Zhang, A.D. Clark Jr., S. Jesen, X. Lu, Y. Hsiou, A. Jacobo-Molina, K. Andries, R. Pauwels, H. Moereels, L. Koymans, P.A.J. Janssen, R.H. Smith Jr., M. Kroeger Koepke, C.J. Michejda, S.H. Hughes, E. Arnold</li><li class="title"><p>Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor <em>α</em>-APA R 95845 at 2.8 Å resolution</p></li><li class="source"><p>Structure, 3 (1995), pp. 365–379</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref54" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref54'] = new Array();
        </script></li><li id="BIB55" data-t="r"><ul class="reference" id="bibsbref55"><li class="referenceLabel"><a href="#BIB55" class="label intra_ref">Ding et al., 1995b</a></li><li class="author">J. Ding, K. Das, H. Moereels, L. Koymans, K. Andries, P.A.J. Janssen, S.H. Hughes, E. Arnold</li><li class="title"><p>Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors</p></li><li class="source"><p>Struct. Biol., 2 (1995), pp. 407–415</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref55" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref55'] = new Array();
        </script></li><li id="BIB56" data-t="r"><ul class="reference" id="bibsbref56"><li class="referenceLabel"><a href="#BIB56" class="label intra_ref">Di Santo et al., 1998</a></li><li class="author">R. Di Santo, R. Costi, M. Artico, S. Massa, M.E. Marongiu, A.G. Loi, A. De Montis, P. La Colla</li><li class="title"><p>1,2,5-Benzothiadiazepine and pyrrolo[2,1-<em>d</em>][1,2,5]benzothiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity</p></li><li class="source"><p>Antiviral Chem. Chemother., 9 (1998), pp. 127–137</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref56" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref56'] = new Array();
        </script></li><li id="BIB57" data-t="r"><ul class="reference" id="bibsbref57"><li class="referenceLabel"><a href="#BIB57" class="label intra_ref">Dollé et al., 1995</a></li><li class="author">V. Dollé, C.H. Nguyen, A.M. Aubertin, A. Kirn, M.L. Andreola, G. Jamieson, L. Tarrago-Litvak, E. Bisagni</li><li class="title"><p>A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors</p></li><li class="source"><p>J. Med. Chem., 38 (1995), pp. 4679–4686</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref57" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref57'] = new Array();
        </script></li><li id="BIB58" data-t="r"><ul class="reference" id="bibsbref58"><li class="referenceLabel"><a href="#BIB58" class="label intra_ref">Dueweke et al., 1992</a></li><li class="author">T.J. Dueweke, F.J. Kézdy, G.A. Waszak, M.R. Deibel Jr., W.G. Tarpley</li><li class="title"><p>The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase</p></li><li class="source"><p>J. Biol. Chem., 267 (1992), pp. 27–30</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref58" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref58'] = new Array();
        </script></li><li id="BIB59" data-t="r"><ul class="reference" id="bibsbref59"><li class="referenceLabel"><a href="#BIB59" class="label intra_ref">Dueweke et al., 1993a</a></li><li class="author">T.J. Dueweke, S.M. Poppe, D.L. Romero, S.M. Swaney, A.G. So, K.M. Downey, I.W. Althaus, F. Reusser, M. Busso, L. Resnick, D.L. Mayers, J. Lane, P.A. Aristoff, R.C. Thomas, W.G. Tarpley</li><li class="title"><p>U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication</p></li><li class="source"><p>Antimicrob. Agents Chemother., 37 (1993), pp. 1127–1131</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref59" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref59'] = new Array();
        </script></li><li id="BIB60" data-t="r"><ul class="reference" id="bibsbref60"><li class="referenceLabel"><a href="#BIB60" class="label intra_ref">Dueweke et al., 1993b</a></li><li class="author">T.J. Dueweke, T. Pushkarskaya, S.M. Poppe, S.M. Swaney, J.Q. Zhao, I.S.Y. Chen, M. Stevenson, W.G. Tarpley</li><li class="title"><p>A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 90 (1993), pp. 4713–4717</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref60" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref60'] = new Array();
        </script></li><li id="BIB61" data-t="r"><ul class="reference" id="bibsbref61"><li class="referenceLabel"><a href="#BIB61" class="label intra_ref">Esnouf, 1997</a></li><li class="author">R.M. Esnouf</li><li class="title"><p>An extensively modified version of MolScript that includes greatly enhanced coloring capabilities</p></li><li class="source"><p>J. Mol. Graphics, 15 (1997), pp. 132–134</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref61" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref61'] = new Array();
        </script></li><li id="BIB62" data-t="r"><ul class="reference" id="bibsbref62"><li class="referenceLabel"><a href="#BIB62" class="label intra_ref">Esnouf et al., 1995</a></li><li class="author">R. Esnouf, J. Ren, C. Ross, Y. Jones, D. Stammers, D. Stuart</li><li class="title"><p>Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors</p></li><li class="source"><p>Struct. Biol., 2 (1995), pp. 303–308</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref62" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref62'] = new Array();
        </script></li><li id="BIB63" data-t="r"><ul class="reference" id="bibsbref63"><li class="referenceLabel"><a href="#BIB63" class="label intra_ref">Esnouf et al., 1997a</a></li><li class="author">R.M. Esnouf, J. Ren, A.L. Hopkins, C.K. Ross, E.Y. Jones, D.K. Stammers, D.I. Stuart</li><li class="title"><p>Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 94 (1997), pp. 3984–3989</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref63" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref63'] = new Array();
        </script></li><li id="BIB64" data-t="r"><ul class="reference" id="bibsbref64"><li class="referenceLabel"><a href="#BIB64" class="label intra_ref">Esnouf et al., 1997b</a></li><li class="author">R.M. Esnouf, D.I. Stuart, E. De Clercq, E. Schwartz, J. Balzarini</li><li class="title"><p>Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives</p></li><li class="source"><p>Biochem. Biophys. Res. Commun., 234 (1997), pp. 458–464</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref64" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref64'] = new Array();
        </script></li><li id="BIB65" data-t="r"><ul class="reference" id="bibsbref65"><li class="referenceLabel"><a href="#BIB65" class="label intra_ref">Finzi et al., 1997</a></li><li class="author">D. Finzi, M. Hermankova, T. Pierson, L.M. Carruth, C. Buck, R.E. Chaisson, T.C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D.D. Ho, D.D. Richman, R.F. Siliciano</li><li class="title"><p>Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy</p></li><li class="source"><p>Science, 279 (1997), pp. 1295–1300</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref65" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref65'] = new Array();
        </script></li><li id="BIB66" data-t="r"><ul class="reference" id="bibsbref66"><li class="referenceLabel"><a href="#BIB66" class="label intra_ref">Goldman et al., 1991</a></li><li class="author">M.E. Goldman, J.H. Nunberg, J.A. O'Brien, J.C. Quintero, W.A. Schleif, K.F. Freund, S.L. Gaul, W.S. Saari, J.S. Wai, J.M. Hoffman, P.S. Anderson, D.J. Hupe, E.A. Emini, A.M. Stern</li><li class="title"><p>Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 88 (1991), pp. 6863–6867</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref66" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref66'] = new Array();
        </script></li><li id="BIB67" data-t="r"><ul class="reference" id="bibsbref67"><li class="referenceLabel"><a href="#BIB67" class="label intra_ref">Goldman et al., 1992</a></li><li class="author">M.E. Goldman, J.A. O'Brien, T.L. Ruffing, J.H. Nunberg, W.A. Schleif, J.C. Quintero, P.K.S. Siegl, J.M. Hoffman, A.M. Smith, E.A. Emini</li><li class="title"><p>L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro</p></li><li class="source"><p>Antimicrob. Agents Chemother., 36 (1992), pp. 1019–1023</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref67" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref67'] = new Array();
        </script></li><li id="BIB68" data-t="r"><ul class="reference" id="bibsbref68"><li class="referenceLabel"><a href="#BIB68" class="label intra_ref">Grob et al., 1997</a></li><li class="author">P.M. Grob, Y. Cao, E. Muchmore, D.D. Ho, S. Norris, J.W. Pav, C.-K. Shih, J. Adams</li><li class="title"><p>Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase</p></li><li class="source"><p>Nat. Med., 3 (1997), pp. 665–670</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref68" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref68'] = new Array();
        </script></li><li id="BIB69" data-t="r"><ul class="reference" id="bibsbref69"><li class="referenceLabel"><a href="#BIB69" class="label intra_ref">Havlir and Richman, 1996</a></li><li class="author">D.V. Havlir, D.D. Richman</li><li class="title"><p>Viral dynamics of HIV: implications for drug development and therapeutic strategies</p></li><li class="source"><p>Ann. Intern. Med., 124 (1996), pp. 984–994</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref69" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref69'] = new Array();
        </script></li><li id="BIB70" data-t="r"><ul class="reference" id="bibsbref70"><li class="referenceLabel"><a href="#BIB70" class="label intra_ref">Havlir et al., 1995a</a></li><li class="author">D. Havlir, S.H. Cheeseman, M. McLaughlin, R. Murphy, A. Erice, S.A. Spector, T.C. Greenough, J.L. Sullivan, D. Hall, M. Myers, M. Lamson, D.D. Richman</li><li class="title"><p>High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection</p></li><li class="source"><p>J. Infect. Dis., 171 (1995), pp. 537–545</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref70" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref70'] = new Array();
        </script></li><li id="BIB71" data-t="r"><ul class="reference" id="bibsbref71"><li class="referenceLabel"><a href="#BIB71" class="label intra_ref">Havlir et al., 1995b</a></li><li class="author">D. Havlir, M.M. McLaughlin, D.D. Richman</li><li class="title"><p>A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of &gt;500/mm<sup>3</sup>: AIDS clinical trials group protocol 208</p></li><li class="source"><p>J. Infect. Dis., 172 (1995), pp. 1379–1383</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref71" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref71'] = new Array();
        </script></li><li id="BIB72" data-t="r"><ul class="reference" id="bibsbref72"><li class="referenceLabel"><a href="#BIB72" class="label intra_ref">Ho et al., 1995</a></li><li class="author">D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, M. Markowitz</li><li class="title"><p>Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection</p></li><li class="source"><p>Nature, 373 (1995), pp. 123–126</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref72" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref72'] = new Array();
        </script></li><li id="BIB73" data-t="r"><ul class="reference" id="bibsbref73"><li class="referenceLabel"><a href="#BIB73" class="label intra_ref">Ijichi et al., 1995</a></li><li class="author">K. Ijichi, M. Fujiwara, Y. Hanasaki, H. Watanabe, K. Katsuura, H. Takayama, S. Shirakawa, S.-I. Sakai, S. Shigeta, K. Konno, T. Yokota, M. Baba</li><li class="title"><p>Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 <em>N</em>,<em>N</em>-dialkylcarbamate derivatives</p></li><li class="source"><p>Antimicrob. Agents Chemother., 39 (1995), pp. 2337–2340</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref73" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref73'] = new Array();
        </script></li><li id="BIB74" data-t="r"><ul class="reference" id="bibsbref74"><li class="referenceLabel"><a href="#BIB74" class="label intra_ref">Ijichi et al., 1996</a></li><li class="author">K. Ijichi, M. Fujiwara, H. Nagano, Y. Matsumoto, Y. Hanasaki, T. Ide, K. Katsuura, H. Takayama, S. Shirakawa, N. Aimi, S. Shigeta, K. Konno, M. Matsushima, T. Yokota, M. Baba</li><li class="title"><p>Anti-HIV-1 activity of thiadiazole derivatives: a structure–activity relationship, reverse transcriptase inhibition, and lipophilicity</p></li><li class="source"><p>Antiviral Res., 31 (1996), pp. 87–94</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref74" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref74'] = new Array();
        </script></li><li id="BIB75" data-t="r"><ul class="reference" id="bibsbref75"><li class="referenceLabel"><a href="#BIB75" class="label intra_ref">Ito et al., 1991</a></li><li class="author">M. Ito, M. Baba, S. Shigeta, E. De Clercq, R.T. Walker, H. Tanaka, T. Miyasaka</li><li class="title"><p>Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferon</p></li><li class="source"><p>Antiviral Res., 15 (1991), pp. 323–330</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref75" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref75'] = new Array();
        </script></li><li id="BIB76" data-t="r"><ul class="reference" id="bibsbref76"><li class="referenceLabel"><a href="#BIB76" class="label intra_ref">Jonckheere et al., 1994</a></li><li class="author">H. Jonckheere, J.-M. Taymans, J. Balzarini, S. Velázquez, M.-J. Camarasa, J. Desmyter, E. De Clercq, J. Anné</li><li class="title"><p>Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-<em>O</em>-(tert-butyldimethylsilyl)-3′-spiro-5′′-(4′′-amino-1′′,2′′-oxathiole-2′′,2′′-dioxide)] (TSAO) derivatives is determined by the mutation Glu<sup>138</sup>→Lys on the p51 subunit</p></li><li class="source"><p>J. Biol. Chem., 269 (1994), pp. 25255–25258</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref76" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref76'] = new Array();
        </script></li><li id="BIB77" data-t="r"><ul class="reference" id="bibsbref77"><li class="referenceLabel"><a href="#BIB77" class="label intra_ref">Jourdan et al., 1997</a></li><li class="author">F. Jourdan, J. Renault, C. Fossey, R. Bureau, D. Ladurée, M. Robba, A.M. Aubertin, A. Kirn</li><li class="title"><p>Design, synthesis and antiviral activity of new pyridinone derivatives</p></li><li class="source"><p>Antiviral Chem. Chemother., 8 (1997), pp. 161–172</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref77" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref77'] = new Array();
        </script></li><li id="BIB78" data-t="r"><ul class="reference" id="bibsbref78"><li class="referenceLabel"><a href="#BIB78" class="label intra_ref">Kashman et al., 1992</a></li><li class="author">Y. Kashman, K.R. Gustafson, R.W. Fuller, J.H. Cardellina II, J.B. McMahon, M.J. Currens, R.W. Buckheit Jr., S.H. Hughes, G.M. Cragg, M.R. Boyd</li><li class="title"><p>The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, <em>Calophyllum lanigerum</em></p></li><li class="source"><p>J. Med. Chem., 35 (1992), pp. 2735–2743</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref78" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref78'] = new Array();
        </script></li><li id="BIB79" data-t="r"><ul class="reference" id="bibsbref79"><li class="referenceLabel"><a href="#BIB79" class="label intra_ref">Kelly et al., 1997</a></li><li class="author">T.A. Kelly, D.W. McNeil, J.M. Rose, E. David, C.-K. Shih, P.M. Grob</li><li class="title"><p>Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones</p></li><li class="source"><p>J. Med. Chem., 40 (1997), pp. 2430–2433</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref79" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref79'] = new Array();
        </script></li><li id="BIB80" data-t="r"><ul class="reference" id="bibsbref80"><li class="referenceLabel"><a href="#BIB80" class="label intra_ref">Kim et al., 1997</a></li><li class="author">D.-K. Kim, J. Gam, Y.-W. Kim, J. Lim, H.-T. Kim, K.H. Kim</li><li class="title"><p>Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils</p></li><li class="source"><p>J. Med. Chem., 40 (1997), pp. 2363–2373</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref80" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref80'] = new Array();
        </script></li><li id="BIB81" data-t="r"><ul class="reference" id="bibsbref81"><li class="referenceLabel"><a href="#BIB81" class="label intra_ref">Kleim et al., 1993</a></li><li class="author">J.-P. Kleim, R. Bender, U.-M. Billhardt, C. Meichsner, G. Riess, M. Rösner, I. Winkler, A. Paessens</li><li class="title"><p>Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication</p></li><li class="source"><p>Antimicrob. Agents Chemother., 37 (1993), pp. 1659–1664</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref81" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref81'] = new Array();
        </script></li><li id="BIB82" data-t="r"><ul class="reference" id="bibsbref82"><li class="referenceLabel"><a href="#BIB82" class="label intra_ref">Kleim et al., 1994</a></li><li class="author">J.-P. Kleim, R. Bender, R. Kirsch, C. Meichsner, A. Paessens, G. Riess</li><li class="title"><p>Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase</p></li><li class="source"><p>Virology, 200 (1994), pp. 696–701</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref82" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref82'] = new Array();
        </script></li><li id="BIB83" data-t="r"><ul class="reference" id="bibsbref83"><li class="referenceLabel"><a href="#BIB83" class="label intra_ref">Kleim et al., 1995</a></li><li class="author">J.-P. Kleim, R. Bender, R. Kirsch, C. Meichsner, A. Paessens, M. Rösner, H. Rübsamen-Waigmann, R. Kaiser, M. Wichers, K.E. Schneweis, I. Winkler, G. Riess</li><li class="title"><p>Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication</p></li><li class="source"><p>Antimicrob. Agents Chemother., 39 (1995), pp. 2253–2257</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref83" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref83'] = new Array();
        </script></li><li id="BIB84" data-t="r"><ul class="reference" id="bibsbref84"><li class="referenceLabel"><a href="#BIB84" class="label intra_ref">Kleim et al., 1996</a></li><li class="author">J.-P. Kleim, M. Rösner, I. Winkler, A. Paessens, R. Kirsch, Y. Hsiou, E. Arnold, G. Riess</li><li class="title"><p>Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 93 (1996), pp. 34–38</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref84" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref84'] = new Array();
        </script></li><li id="BIB85" data-t="r"><ul class="reference" id="bibsbref85"><li class="referenceLabel"><a href="#BIB85" class="label intra_ref">Kleim et al., 1997</a></li><li class="author">J.-P. Kleim, I. Winkler, M. Rösner, R. Kirsch, H. Rübsamen-Waigmann, A. Paessens, G. Riess</li><li class="title"><p>In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitory HBY 097</p></li><li class="source"><p>Virology, 231 (1997), pp. 112–118</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref85" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref85'] = new Array();
        </script></li><li id="BIB86" data-t="r"><ul class="reference" id="bibsbref86"><li class="referenceLabel"><a href="#BIB86" class="label intra_ref">Koup et al., 1991</a></li><li class="author">R.A. Koup, V.J. Merluzzi, K.D. Hargrave, J. Adams, K. Grozinger, R.J. Eckner, J.L. Sullivan</li><li class="title"><p>Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587</p></li><li class="source"><p>J. Infect. Dis., 163 (1991), pp. 966–970</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref86" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref86'] = new Array();
        </script></li><li id="BIB87" data-t="r"><ul class="reference" id="bibsbref87"><li class="referenceLabel"><a href="#BIB87" class="label intra_ref">Kroeger Smith et al., 1995</a></li><li class="author">M.B. Kroeger Smith, C.A. Rouzer, L.A. Taneyhill, N.A. Smith, S.H. Hughes, P.L. Boyer, P.A.J. Janssen, H. Moereels, L. Koymans, E. Arnold, J. Ding, K. Das, W. Zhang, C.J. Michejda, R.H. Smith Jr.</li><li class="title"><p>Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity</p></li><li class="source"><p>Protein Sci., 4 (1995), pp. 2203–2222</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref87" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref87'] = new Array();
        </script></li><li id="BIB88" data-t="r"><ul class="reference" id="bibsbref88"><li class="referenceLabel"><a href="#BIB88" class="label intra_ref">Larder, 1992</a></li><li class="author">B.A. Larder</li><li class="title"><p>3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors</p></li><li class="source"><p>Antimicrob. Agents Chemother., 36 (1992), pp. 2664–2669</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref88" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref88'] = new Array();
        </script></li><li id="BIB89" data-t="r"><ul class="reference" id="bibsbref89"><li class="referenceLabel"><a href="#BIB89" class="label intra_ref">Livermore et al., 1993</a></li><li class="author">D.G.H. Livermore, R.C. Bethell, N. Cammack, A.P. Hancock, M.M. Hann, D.V.S. Green, R.B. Lamont, S.A. Noble, D.C. Orr, J.J. Payne, M.V.J. Ramsay, A.H. Shingler, C. Smith, R. Storer, C. Williamson, T. Willson</li><li class="title"><p>Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-<em>b</em>]pyridazines</p></li><li class="source"><p>J. Med. Chem., 36 (1993), pp. 3784–3794</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref89" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref89'] = new Array();
        </script></li><li id="BIB90" data-t="r"><ul class="reference" id="bibsbref90"><li class="referenceLabel"><a href="#BIB90" class="label intra_ref">Luzuriaga et al., 1997</a></li><li class="author">K. Luzuriaga, Y. Bryson, P. Krogstad, J. Robinson, B. Stechenberg, M. Lamson, S. Cort, J.L. Sullivan</li><li class="title"><p>Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection</p></li><li class="source"><p>New Engl. J. Med., 336 (1997), pp. 1343–1349</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref90" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref90'] = new Array();
        </script></li><li id="BIB91" data-t="r"><ul class="reference" id="bibsbref91"><li class="referenceLabel"><a href="#BIB91" class="label intra_ref">Maass et al., 1993</a></li><li class="author">G. Maass, U. Immendoerfer, B. Koenig, U. Leser, B. Mueller, R. Goody, E. Pfaff</li><li class="title"><p>Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase</p></li><li class="source"><p>Antimicrob. Agents Chemother., 37 (1993), pp. 2612–2617</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref91" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref91'] = new Array();
        </script></li><li id="BIB92" data-t="r"><ul class="reference" id="bibsbref92"><li class="referenceLabel"><a href="#BIB92" class="label intra_ref">Marschner et al., 1998</a></li><li class="author">I.C. Marschner, A.C. Collier, R.W. Coombs, R.T. D'Aquila, V. DeGruttola, M.A. Fischl, S.M. Hammer, M.D. Hughes, V.A. Johnson, D.A. Katzenstein, D.D. Richman, L.M. Smeaton, S.A. Spector, M.S. Saag</li><li class="title"><p>Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy</p></li><li class="source"><p>J. Infect. Dis., 177 (1998), pp. 40–47</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref92" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref92'] = new Array();
        </script></li><li id="BIB93" data-t="r"><ul class="reference" id="bibsbref93"><li class="referenceLabel"><a href="#BIB93" class="label intra_ref">Massa et al., 1995</a></li><li class="author">S. Massa, A. Mai, M. Artico, G. Sbardella, E. Tramontano, A.G. Loi, P. Scano, P. La Colla</li><li class="title"><p>Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1</p></li><li class="source"><p>Antiviral Chem. Chemother., 6 (1995), pp. 1–8</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref93" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref93'] = new Array();
        </script></li><li id="BIB94" data-t="r"><ul class="reference" id="bibsbref94"><li class="referenceLabel"><a href="#BIB94" class="label intra_ref">Mayers et al., 1997</a></li><li class="source">Mayers, D., Riddler, S., Bach, M., Stein, D.F., Havlir, M.D., Kahn, J., Ruiz, N., Labriola, D.F. and the DMP 266 Clinical Development Team, 1997. Durable clinical anti-HIV-1 activity and tolerability for DMP 266 in combination with indinavir (IDV) at 24 weeks. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, 30 September 1997, abstract I-175.</li><li data-sr="N" class="external refPlaceHolder" id="bibsbref94" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref94'] = new Array();
        </script></li><li id="BIB95" data-t="r"><ul class="reference" id="bibsbref95"><li class="referenceLabel"><a href="#BIB95" class="label intra_ref">Mellors et al., 1992</a></li><li class="author">J.W. Mellors, G.E. Dutschman, G.-J. Im, E. Tramontano, S.R. Winkler, Y.-C. Cheng</li><li class="title"><p>In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase</p></li><li class="source"><p>Mol. Pharmacol., 41 (1992), pp. 446–451</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref95" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref95'] = new Array();
        </script></li><li id="BIB96" data-t="r"><ul class="reference" id="bibsbref96"><li class="referenceLabel"><a href="#BIB96" class="label intra_ref">Mellors et al., 1993</a></li><li class="author">J.W. Mellors, G.-J. Im, E. Tramontano, S.R. Winkler, D.J. Medina, G.E. Dutschman, H.Z. Bazmi, G. Piras, C.J. Gonzalez, Y.-C. Cheng</li><li class="title"><p>A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5<em>S</em>)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-<em>jk</em>][1,4]benzodiazepin-2(1<em>H</em>)-thione (TIBO R82150)</p></li><li class="source"><p>Mol. Pharmacol., 43 (1993), pp. 11–16</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref96" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref96'] = new Array();
        </script></li><li id="BIB97" data-t="r"><ul class="reference" id="bibsbref97"><li class="referenceLabel"><a href="#BIB97" class="label intra_ref">Mellors et al., 1996</a></li><li class="author">J.W. Mellors, C.R. Rinaldo Jr., P. Gupta, R.M. White, J.A. Todd, L.A. Kingsley</li><li class="title"><p>Prognosis in HIV-1 infection predicted by the quantity of virus in plasma</p></li><li class="source"><p>Science, 272 (1996), pp. 1167–1170</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref97" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref97'] = new Array();
        </script></li><li id="BIB98" data-t="r"><ul class="reference" id="bibsbref98"><li class="referenceLabel"><a href="#BIB98" class="label intra_ref">Merluzzi et al., 1990</a></li><li class="author">V.J. Merluzzi, K.D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J.C. Wu, C.-K. Shih, K. Eckner, S. Hattox, J. Adams, A.S. Rosenthal, R. Faanes, R.J. Eckner, R.A. Koup, J.L. Sullivan</li><li class="title"><p>Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor</p></li><li class="source"><p>Science, 250 (1990), pp. 1411–1413</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref98" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref98'] = new Array();
        </script></li><li id="BIB99" data-t="r"><ul class="reference" id="bibsbref99"><li class="referenceLabel"><a href="#BIB99" class="label intra_ref">Mertens et al., 1993</a></li><li class="author">A. Mertens, H. Zilch, B. Konig, W. Schafer, T. Poll, W. Kampe, H. Seidel, U. Leser, H. Leinert</li><li class="title"><p>Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-<em>a</em>]isoindol-5(9<em>H</em>)-ones and related compounds with anti-HIV-1 activity</p></li><li class="source"><p>J. Med. Chem., 36 (1993), pp. 2526–2535</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref99" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref99'] = new Array();
        </script></li><li id="BIB100" data-t="r"><ul class="reference" id="bibsbref100"><li class="referenceLabel"><a href="#BIB100" class="label intra_ref">Miyasaka et al., 1989</a></li><li class="author">T. Miyasaka, H. Tanaka, M. Baba, H. Hayakawa, R.T. Walker, J. Balzarini, E. De Clercq</li><li class="title"><p>A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine</p></li><li class="source"><p>J. Med. Chem., 32 (1989), pp. 2507–2509</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref100" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref100'] = new Array();
        </script></li><li id="BIB101" data-t="r"><ul class="reference" id="bibsbref101"><li class="referenceLabel"><a href="#BIB101" class="label intra_ref">Moxham et al., 1997</a></li><li class="author">C.P. Moxham, K. Borroto-Esoda, D. Noel, P.A. Furman, G.M. Szczech, D.W. Barry</li><li class="title"><p>Preliminary efficacy, pharmacokinetics and safety of repeated multiple doses of MKC-442 in HIV-infected volunteers. Abstracts of the Tenth International Conference on Antiviral Research, Atlanta, GA, 6–11 April 1997</p></li><li class="source"><p>Antiviral Res., 34 (2) (1997), p. A44</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref101" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref101'] = new Array();
        </script></li><li id="BIB102" data-t="r"><ul class="reference" id="bibsbref102"><li class="referenceLabel"><a href="#BIB102" class="label intra_ref">Nunberg et al., 1991</a></li><li class="author">J.H. Nunberg, W.A. Schleif, E.J. Boots, J.A. O'Brien, J.C. Quintero, J.M. Hoffman, E.A. Emini, M.E. Goldman</li><li class="title"><p>Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors</p></li><li class="source"><p>J. Virol., 65 (1991), pp. 4887–4892</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref102" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref102'] = new Array();
        </script></li><li id="BIB103" data-t="r"><ul class="reference" id="bibsbref103"><li class="referenceLabel"><a href="#BIB103" class="label intra_ref">O'Brien et al., 1996</a></li><li class="author">W.A. O'Brien, P.M. Hartigan, D. Martin, J. Esinhart, A. Hill, S. Benoit, M. Rubin, M.S. Simberhoff, J.D. Hamilton, Veterans Affairs Cooperative Study Group on AIDS</li><li class="title"><p>Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS</p></li><li class="source"><p>New Engl. J. Med., 334 (1996), pp. 426–431</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref103" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref103'] = new Array();
        </script></li><li id="BIB104" data-t="r"><ul class="reference" id="bibsbref104"><li class="referenceLabel"><a href="#BIB104" class="label intra_ref">Okamoto et al., 1996</a></li><li class="author">M. Okamoto, M. Makino, K. Yamada, K. Nakade, S. Yuasa, M. Baba</li><li class="title"><p>Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells</p></li><li class="source"><p>Antiviral Res., 31 (1996), pp. 69–77</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref104" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref104'] = new Array();
        </script></li><li id="BIB105" data-t="r"><ul class="reference" id="bibsbref105"><li class="referenceLabel"><a href="#BIB105" class="label intra_ref">Pagano and Chong, 1995</a></li><li class="author">P.J. Pagano, K.-T. Chong</li><li class="title"><p>In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-<em>α</em></p></li><li class="source"><p>J. Infect. Dis., 171 (1995), pp. 61–71</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref105" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref105'] = new Array();
        </script></li><li id="BIB106" data-t="r"><ul class="reference" id="bibsbref106"><li class="referenceLabel"><a href="#BIB106" class="label intra_ref">Pantaleo et al., 1995</a></li><li class="author">G. Pantaleo, S. Menzo, M. Vaccarezza, C. Graziosi, O.J. Cohen, J.F. Demarest, D. Montefiori, J.M. Orenstein, C. Fox, L.K. Schrager, J.B. Margolick, S. Buchbinder, J.V. Giorgi, A.S. Fauci</li><li class="title"><p>Studies in subjects with long-term nonprogressive human immunodeficiency virus infection</p></li><li class="source"><p>New Engl. J. Med., 332 (1995), pp. 209–216</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref106" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref106'] = new Array();
        </script></li><li id="BIB107" data-t="r"><ul class="reference" id="bibsbref107"><li class="referenceLabel"><a href="#BIB107" class="label intra_ref">Pauwels et al., 1990</a></li><li class="author">R. Pauwels, K. Andries, J. Desmyter, D. Schols, M.J. Kukla, H.J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M.A.C. Janssen, E. De Clercq, P.A.J. Janssen</li><li class="title"><p>Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives</p></li><li class="source"><p>Nature, 343 (1990), pp. 470–474</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref107" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref107'] = new Array();
        </script></li><li id="BIB108" data-t="r"><ul class="reference" id="bibsbref108"><li class="referenceLabel"><a href="#BIB108" class="label intra_ref">Pauwels et al., 1993</a></li><li class="author">R. Pauwels, K. Andries, Z. Debyser, P. Van Daele, D. Schols, P. Stoffels, K. De Vreese, R. Woestenborghs, A.-M. Vandamme, C.G.M. Janssen, J. Anné, G. Cauwenbergh, J. Desmyter, J. Heykants, M.A.C. Janssen, E. De Clercq, P.A.J. Janssen</li><li class="title"><p>Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of <em>α</em>-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 90 (1993), pp. 1711–1715</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref108" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref108'] = new Array();
        </script></li><li id="BIB109" data-t="r"><ul class="reference" id="bibsbref109"><li class="referenceLabel"><a href="#BIB109" class="label intra_ref">Pauwels et al., 1994</a></li><li class="author">R. Pauwels, K. Andries, Z. Debyser, M.-J. Kukla, D. Schols, H.J. Breslin, R. Woestenborghs, J. Desmyter, M.A.C. Janssen, E. De Clercq, P.A.J. Janssen</li><li class="title"><p>New tetrahydroimidazo[4,5,1-<em>jk</em>][1,4]-benzodiazepin-2(1<em>H</em>)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs</p></li><li class="source"><p>Antimicrob. Agents Chemother., 38 (1994), pp. 2863–2870</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref109" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref109'] = new Array();
        </script></li><li id="BIB110" data-t="r"><ul class="reference" id="bibsbref110"><li class="referenceLabel"><a href="#BIB110" class="label intra_ref">Pelemans et al., 1997</a></li><li class="author">H. Pelemans, R. Esnouf, A. Dunkler, M.A. Parniak, A.-M. Vandamme, A. Karlsson, E. De Clercq, J.-P. Kleim, J. Balzarini</li><li class="title"><p>Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1</p></li><li class="source"><p>J. Virol., 71 (1997), pp. 8195–8203</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref110" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref110'] = new Array();
        </script></li><li id="BIB111" data-t="r"><ul class="reference" id="bibsbref111"><li class="referenceLabel"><a href="#BIB111" class="label intra_ref">Perelson et al., 1996</a></li><li class="author">A.S. Perelson, A.U. Neumann, M. Markowitz, J.M. Leonard, D.D. Ho</li><li class="title"><p>HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time</p></li><li class="source"><p>Science, 271 (1996), pp. 1582–1586</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref111" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref111'] = new Array();
        </script></li><li id="BIB112" data-t="r"><ul class="reference" id="bibsbref112"><li class="referenceLabel"><a href="#BIB112" class="label intra_ref">Pialoux et al., 1991</a></li><li class="author">G. Pialoux, M. Youle, B. Dupont, B. Gazzard, G.F.M.J. Cauwenbergh, P.A.M. Stoffels, S. Davies, J. De Saint Martin, P.A.J. Janssen</li><li class="title"><p>Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex</p></li><li class="source"><p>Lancet, 338 (1991), pp. 140–143</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref112" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref112'] = new Array();
        </script></li><li id="BIB113" data-t="r"><ul class="reference" id="bibsbref113"><li class="referenceLabel"><a href="#BIB113" class="label intra_ref">Ren et al., 1995a</a></li><li class="author">J. Ren, R. Esnouf, E. Garman, D. Somers, C. Ross, I. Kirby, J. Keeling, G. Darby, Y. Jones, D. Stuart, D. Stammers</li><li class="title"><p>High resolution structures of HIV-1 RT from four RT-inhibitor complexes</p></li><li class="source"><p>Struct. Biol., 2 (1995), pp. 293–302</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref113" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref113'] = new Array();
        </script></li><li id="BIB114" data-t="r"><ul class="reference" id="bibsbref114"><li class="referenceLabel"><a href="#BIB114" class="label intra_ref">Ren et al., 1995b</a></li><li class="author">J. Ren, R. Esnouf, A. Hopkins, C. Ross, Y. Jones, D. Stammers, D. Stuart</li><li class="title"><p>The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design</p></li><li class="source"><p>Structure, 3 (1995), pp. 915–926</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref114" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref114'] = new Array();
        </script></li><li id="BIB115" data-t="r"><ul class="reference" id="bibsbref115"><li class="referenceLabel"><a href="#BIB115" class="label intra_ref">Richman et al., 1991a</a></li><li class="author">D. Richman, C.-K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, J. Griffin</li><li class="title"><p>Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 88 (1991), pp. 11241–11245</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref115" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref115'] = new Array();
        </script></li><li id="BIB116" data-t="r"><ul class="reference" id="bibsbref116"><li class="referenceLabel"><a href="#BIB116" class="label intra_ref">Richman et al., 1991b</a></li><li class="author">D. Richman, A.S. Rosenthal, M. Skoog, R.J. Eckner, T.-C. Chou, J.P. Sabo, V.J. Merluzzi</li><li class="title"><p>BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine</p></li><li class="source"><p>Antimicrob. Agents Chemother., 35 (1991), pp. 305–308</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref116" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref116'] = new Array();
        </script></li><li id="BIB117" data-t="r"><ul class="reference" id="bibsbref117"><li class="referenceLabel"><a href="#BIB117" class="label intra_ref">Richman et al., 1994</a></li><li class="author">D.D. Richman, D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S.A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, J. Griffin</li><li class="title"><p>Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy</p></li><li class="source"><p>J. Virol., 68 (1994), pp. 1660–1666</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref117" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref117'] = new Array();
        </script></li><li id="BIB118" data-t="r"><ul class="reference" id="bibsbref118"><li class="referenceLabel"><a href="#BIB118" class="label intra_ref">Romero et al., 1991</a></li><li class="author">D.L. Romero, M. Busso, C.-K. Tan, F. Reusser, J.R. Palmer, S.M. Poppe, P.A. Aristoff, K.M. Downey, A.G. So, L. Resnick, W.G. Tarpley</li><li class="title"><p>Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication</p></li><li class="source"><p>Proc. Natl. Acad. Sci. USA, 88 (1991), pp. 8806–8810</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref118" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref118'] = new Array();
        </script></li><li id="BIB119" data-t="r"><ul class="reference" id="bibsbref119"><li class="referenceLabel"><a href="#BIB119" class="label intra_ref">Romero et al., 1993</a></li><li class="author">D.L. Romero, R.A. Morge, M.J. Genin, C. Biles, M. Busso, L. Resnick, I.W. Althaus, F. Reusser, R.C. Thomas, W.G. Tarpley</li><li class="title"><p>Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure–activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1<em>H</em>-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino]pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate</p></li><li class="source"><p>J. Med. Chem., 36 (1993), pp. 1505–1508</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref119" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref119'] = new Array();
        </script></li><li id="BIB120" data-t="r"><ul class="reference" id="bibsbref120"><li class="referenceLabel"><a href="#BIB120" class="label intra_ref">Rübsamen-Waigmann et al., 1997</a></li><li class="author">H. Rübsamen-Waigmann, E. Huguenel, A. Paessens, J.-P. Kleim, M.A. Wainberg, A. Shah</li><li class="title"><p>Second-generation non-nucleoside reverse transcriptase inhibitor HBY 097 and HIV-1 viral load</p></li><li class="source"><p>Lancet, 349 (1997), p. 1517</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref120" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref120'] = new Array();
        </script></li><li id="BIB121" data-t="r"><ul class="reference" id="bibsbref121"><li class="referenceLabel"><a href="#BIB121" class="label intra_ref">Saag et al., 1993</a></li><li class="author">M.S. Saag, E.A. Emini, O.L. Laskin, J. Douglas, W.I. Lapidus, W.A. Schleif, R.J. Whitley, C. Hildebrand, V.W. Byrnes, J.C. Kappes, K.W. Anderson, F.E. Massari, G.M. Shaw, L-697,661 Working Group</li><li class="title"><p>A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase</p></li><li class="source"><p>New Engl. J. Med., 329 (1993), pp. 1065–1072</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref121" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref121'] = new Array();
        </script></li><li id="BIB122" data-t="r"><ul class="reference" id="bibsbref122"><li class="referenceLabel"><a href="#BIB122" class="label intra_ref">Saag et al., 1996</a></li><li class="author">M.S. Saag, M. Holodniy, D.R. Kuritzkes, W.A. O'Brien, R. Coombs, M.E. Poscher, D.M. Jacobsen, G.M. Shaw, D.D. Richman, P.A. Volberding</li><li class="title"><p>HIV viral load markers in clinical practice</p></li><li class="source"><p>Nat. Med., 2 (1996), pp. 625–629</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref122" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref122'] = new Array();
        </script></li><li id="BIB123" data-t="r"><ul class="reference" id="bibsbref123"><li class="referenceLabel"><a href="#BIB123" class="label intra_ref">Sahai, 1996</a></li><li class="author">J. Sahai</li><li class="title"><p>Risks and synergies from drug interactions</p></li><li class="source"><p>AIDS, 10 (Suppl. 1) (1996), pp. S21–S25</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref123" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref123'] = new Array();
        </script></li><li id="BIB124" data-t="r"><ul class="reference" id="bibsbref124"><li class="referenceLabel"><a href="#BIB124" class="label intra_ref">Schinazi et al., 1997</a></li><li class="author">R.F. Schinazi, B.A. Larder, J.W. Mellors</li><li class="title"><p>Mutations in retroviral genes associated with drug resistance</p></li><li class="source"><p>Int. Antiviral News, 5 (1997), pp. 129–142</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref124" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref124'] = new Array();
        </script></li><li id="BIB125" data-t="r"><ul class="reference" id="bibsbref125"><li class="referenceLabel"><a href="#BIB125" class="label intra_ref">Schooley et al., 1996</a></li><li class="author">R.T. Schooley, T.B. Campbell, D.R. Kuritzkes, T. Blaschke, D.S. Stein, M.E. Rosandich, J. Phair, J.C. Pottage, F. Messari, A. Collier, J. Kahn, ACTG 184 Protocol Team</li><li class="title"><p>Phase 1 study of combination therapy with L-697,661 and zidovudine</p></li><li class="source"><p>J. Acquired Immune Defic. Syndr. Hum. Retrovirol., 12 (1996), pp. 363–370</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref125" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref125'] = new Array();
        </script></li><li id="BIB126" data-t="r"><ul class="reference" id="bibsbref126"><li class="referenceLabel"><a href="#BIB126" class="label intra_ref">Seki et al., 1995</a></li><li class="author">M. Seki, Y. Sadakata, S. Yuasa, M. Baba</li><li class="title"><p>Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442</p></li><li class="source"><p>Antiviral Chem. Chemother., 6 (1995), pp. 73–79</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref126" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref126'] = new Array();
        </script></li><li id="BIB127" data-t="r"><ul class="reference" id="bibsbref127"><li class="referenceLabel"><a href="#BIB127" class="label intra_ref">Silvestri et al., 1998</a></li><li class="author">R. Silvestri, M. Artico, B. Bruno, S. Massa, E. Novellino, G. Greco, M.E. Marongiu, A. Pani, A. De Montis, P. La Colla</li><li class="title"><p>Synthesis and biological evaluation of 5<em>H</em>-indolo [3,2-<em>b</em>][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126</p></li><li class="source"><p>Antiviral Chem. Chemother., 9 (1998), pp. 139–148</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref127" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref127'] = new Array();
        </script></li><li id="BIB128" data-t="r"><ul class="reference" id="bibsbref128"><li class="referenceLabel"><a href="#BIB128" class="label intra_ref">Skowron et al., 1998</a></li><li class="source">Skowron, G., Leoung, G., Dusek, A., Anderson, R., Grosso, R., Jacobs, M., Lamson, M., Kerr, B., Beebe, S., 1998. dNN study: stavudine (d4T), nelfinavir (NFV), and nevirapine (NVP): preliminary safety, activity, and pharmacokinetic (PK) interactions. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1–5 February 1998, abstract 350.</li><li data-sr="N" class="external refPlaceHolder" id="bibsbref128" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref128'] = new Array();
        </script></li><li id="BIB129" data-t="r"><ul class="reference" id="bibsbref129"><li class="referenceLabel"><a href="#BIB129" class="label intra_ref">Spence et al., 1995</a></li><li class="author">R.A. Spence, W.M. Kati, K.S. Anderson, K.A. Johnson</li><li class="title"><p>Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors</p></li><li class="source"><p>Science, 267 (1995), pp. 988–993</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref129" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref129'] = new Array();
        </script></li><li id="BIB130" data-t="r"><ul class="reference" id="bibsbref130"><li class="referenceLabel"><a href="#BIB130" class="label intra_ref">Staszewski et al., 1995</a></li><li class="author">S. Staszewski, F.E. Massari, A. Kober, R. Gohler, S. Durr, K.W. Anderson, C.L. Schneider, J.A. Waterbury, K.K. Bakshi, V.I. Taylor, C.S. Hildebrand, C. Kreisl, B. Hoffstedt, W.A. Schleif, H. von Briesen, H. Rübsamen-Waigmann, G.B. Calandra, J.L. Ryan, W. Stille, E.A. Emini, V.W. Byrnes</li><li class="title"><p>Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high level resistance to L-697,661, a non-nucleoside reverse transcriptase inhibitor</p></li><li class="source"><p>J. Infect. Dis., 171 (1995), pp. 159–165</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref130" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref130'] = new Array();
        </script></li><li id="BIB131" data-t="r"><ul class="reference" id="bibsbref131"><li class="referenceLabel"><a href="#BIB131" class="label intra_ref">Staszewski et al., 1996a</a></li><li class="author">S. Staszewski, V. Miller, A. Kober, R. Colebunders, B. Vandercam, J. Delescluse, N. Clumeck, F. Van Wanzeele, M. De Brabander, J. De Creé, M. Moeremans, K. Andries, C. Boucher, P. Stoffels, P.A.J. Janssen, Members of the Loviride Collaborative Study Group</li><li class="title"><p>Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients</p></li><li class="source"><p>Antiviral Ther., 1 (1996), pp. 42–50</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref131" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref131'] = new Array();
        </script></li><li id="BIB132" data-t="r"><ul class="reference" id="bibsbref132"><li class="referenceLabel"><a href="#BIB132" class="label intra_ref">Staszewski et al., 1996b</a></li><li class="author">S. Staszewski, V. Miller, S. Rehmet, T. Stark, J. De Creé, M. De Brabander, M. Peeters, K. Andries, M. Moeremans, M. De Raeymaeker, G. Pearce, R. Van Den Broeck, W. Verbiest, P. Stoffels</li><li class="title"><p>Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients</p></li><li class="source"><p>AIDS, 10 (1996), pp. F1–F7</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref132" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref132'] = new Array();
        </script></li><li id="BIB133" data-t="r"><ul class="reference" id="bibsbref133"><li class="referenceLabel"><a href="#BIB133" class="label intra_ref">Tantillo et al., 1994</a></li><li class="author">C. Tantillo, J. Ding, A. Jacobo-Molina, R.G. Nanni, P.L. Boyer, S.H. Hughes, R. Pauwels, K. Andries, P.A.J. Janssen, E. Arnold</li><li class="title"><p>Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase</p></li><li class="source"><p>J. Mol. Biol., 243 (1994), pp. 369–387</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref133" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref133'] = new Array();
        </script></li><li id="BIB134" data-t="r"><ul class="reference" id="bibsbref134"><li class="referenceLabel"><a href="#BIB134" class="label intra_ref">Terrett et al., 1992</a></li><li class="author">N.K. Terrett, D. Bojanic, J.R. Merson, P.T. Stephenson</li><li class="title"><p>Imidazo[2′,3′:6,5]dipyrido[3,2-<em>b</em>:2′,3′-<em>e</em>]-1,4-diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine</p></li><li class="source"><p>Bioorg. Med. Chem. Lett., 2 (1992), pp. 1745–1750</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref134" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref134'] = new Array();
        </script></li><li id="BIB135" data-t="r"><ul class="reference" id="bibsbref135"><li class="referenceLabel"><a href="#BIB135" class="label intra_ref">Tucker et al., 1994</a></li><li class="author">T.J. Tucker, T.A. Lyle, C.M. Wiscount, S.F. Britcher, S.D. Young, W.M. Sanders, W.C. Lumma, M.E. Goldman, J.A. O'Brien, R.G. Ball, C.F. Homnick, W.A. Schleif, E.A. Emini, J.R. Huff, P.S. Anderson</li><li class="title"><p>Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1<em>H</em>)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors</p></li><li class="source"><p>J. Med. Chem., 37 (1994), pp. 2437–2444</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref135" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref135'] = new Array();
        </script></li><li id="BIB136" data-t="r"><ul class="reference" id="bibsbref136"><li class="referenceLabel"><a href="#BIB136" class="label intra_ref">Vasudevachari et al., 1992</a></li><li class="author">M.B. Vasudevachari, C. Battista, H.C. Lane, M.C. Psallidopoulos, B. Zhao, J. Cook, J.R. Palmer, D.L. Romero, W.G. Tarpley, N.P. Salzman</li><li class="title"><p>Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors</p></li><li class="source"><p>Virology, 190 (1992), pp. 269–277</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref136" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref136'] = new Array();
        </script></li><li id="BIB137" data-t="r"><ul class="reference" id="bibsbref137"><li class="referenceLabel"><a href="#BIB137" class="label intra_ref">Wainberg et al., 1996</a></li><li class="author">M.A. Wainberg, W.C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M.A. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, V.R. Prasad</li><li class="title"><p>Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase</p></li><li class="source"><p>Science, 271 (1996), pp. 1282–1285</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref137" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref137'] = new Array();
        </script></li><li id="BIB138" data-t="r"><ul class="reference" id="bibsbref138"><li class="referenceLabel"><a href="#BIB138" class="label intra_ref">Wei et al., 1995</a></li><li class="author">X. Wei, S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, J.D. Lifson, S. Bonhoeffer, M.A. Nowak, B.H. Hahn, M.S. Saag, G.M. Shaw</li><li class="title"><p>Viral dynamics in human immunodeficiency virus type 1 infection</p></li><li class="source"><p>Nature, 373 (1995), pp. 117–122</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref138" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref138'] = new Array();
        </script></li><li id="BIB139" data-t="r"><ul class="reference" id="bibsbref139"><li class="referenceLabel"><a href="#BIB139" class="label intra_ref">Williams et al., 1993</a></li><li class="author">T.M. Williams, T.M. Ciccarone, S.C. MacTough, C.S. Rooney, S.K. Balani, J.H. Condra, E.A. Emini, M.E. Goldman, W.J. Greenlee, L.R. Kauffman, J.A. O'Brien, V.V. Sardana, W.A. Schleif, A.D. Theoharides, P.S. Anderson</li><li class="title"><p>5-Chloro-3-(phenylsulfonyl)indole-2-caboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase</p></li><li class="source"><p>J. Med. Chem., 36 (1993), pp. 1291–1294</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref139" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref139'] = new Array();
        </script></li><li id="BIB140" data-t="r"><ul class="reference" id="bibsbref140"><li class="referenceLabel"><a href="#BIB140" class="label intra_ref">Winslow et al., 1996</a></li><li class="author">D.L. Winslow, S. Garber, C. Reid, H. Scarnati, D. Baker, M.M. Rayner, E.D. Anton</li><li class="title"><p>Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266</p></li><li class="source"><p>AIDS, 10 (1996), pp. 1205–1209</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref140" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref140'] = new Array();
        </script></li><li id="BIB141" data-t="r"><ul class="reference" id="bibsbref141"><li class="referenceLabel"><a href="#BIB141" class="label intra_ref">Witvrouw et al., 1998</a></li><li class="author">M. Witvrouw, M.E. Arranz, C. Pannecouque, R. Declercq, H. Jonckheere, J.-C. Schmit, A.-M. Vandamme, J.A. Diaz, S.T. Ingate, J. Desmyter, R. Esnouf, L. Van Meervelt, S. Vega, J. Balzarini, E. De Clercq</li><li class="title"><p>1,1,3-Trioxo-2<em>H</em>,4<em>H</em>-thieno[3,4-<em>e</em>][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors (NNRTIs) with anti-HIV-1 activity</p></li><li class="source"><p>Antimicrob. Agents Chemother., 42 (1998), pp. 618–623</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref141" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref141'] = new Array();
        </script></li><li id="BIB142" data-t="r"><ul class="reference" id="bibsbref142"><li class="referenceLabel"><a href="#BIB142" class="label intra_ref">Wong et al., 1997</a></li><li class="author">J.K. Wong, M. Hezareh, H.F. Günthard, D.V. Havlir, C.C. Ignacio, C.A. Spina, D.D. Richman</li><li class="title"><p>Recovery of replication-competent HIV despite prolonged suppression of plasma viremia</p></li><li class="source"><p>Science, 278 (1997), pp. 1291–1295</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref142" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref142'] = new Array();
        </script></li><li id="BIB143" data-t="r"><ul class="reference" id="bibsbref143"><li class="referenceLabel"><a href="#BIB143" class="label intra_ref">Young et al., 1995</a></li><li class="author">S.D. Young, S.F. Britcher, L.O. Tran, L.S. Payne, W.C. Lumma, T.A. Lyle, J.R. Huff, P.S. Anderson, D.B. Olsen, S.S. Carroll, D.J. Pettibone, J.A. O'Brien, R.G. Ball, S.K. Balani, J.H. Lin, I.-W. Chen, W.A. Schleif, V.V. Sardana, W.J. Long, V.W. Byrnes, E.A. Emini</li><li class="title"><p>L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase</p></li><li class="source"><p>Antimicrob. Agents Chemother., 39 (1995), pp. 2602–2605</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref143" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref143'] = new Array();
        </script></li><li id="BIB144" data-t="r"><ul class="reference" id="bibsbref144"><li class="referenceLabel"><a href="#BIB144" class="label intra_ref">Yuasa et al., 1993</a></li><li class="author">S. Yuasa, Y. Sadakata, H. Takashima, K. Sekiya, N. Inouye, M. Ubasawa, M. Baba</li><li class="title"><p>Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442</p></li><li class="source"><p>Mol. Pharmacol., 44 (1993), pp. 895–900</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref144" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref144'] = new Array();
        </script></li><li id="BIB145" data-t="r"><ul class="reference" id="bibsbref145"><li class="referenceLabel"><a href="#BIB145" class="label intra_ref">Zembower et al., 1997</a></li><li class="author">D.E. Zembower, S. Liao, M.T. Flavin, Z.-Q. Xu, T.L. Stup, R.W. Buckheit Jr., A. Khilevich, A.A. Mar, A.K. Sheinkman</li><li class="title"><p>Structural analogues of the calanolide anti-HIV agents. Modification of the <em>trans</em>-10,11-dimethyldihydropyran-12-ol ring (ring C)</p></li><li class="source"><p>J. Med. Chem., 40 (1997), pp. 1005–1017</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref145" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref145'] = new Array();
        </script></li><li id="BIB146" data-t="r"><ul class="reference" id="bibsbref146"><li class="referenceLabel"><a href="#BIB146" class="label intra_ref">Zhang et al., 1995</a></li><li class="author">H. Zhang, L. Vrang, K. Backbro, P. Lind, C. Sahlberg, T. Unge, B. Öberg</li><li class="title"><p>Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127</p></li><li class="source"><p>Antiviral Res., 28 (1995), pp. 331–342</p></li><li data-sr="N" class="external refPlaceHolder" id="bibsbref146" data-refres="N"><img class="refimgLoader" alt="" src="loading_icon.gif"></li></ul><script language="Javascript" type="text/javascript">

             myMap['bibsbref146'] = new Array();
        </script></li></ol><div class="artFooterContent"><dl class="footnote" id="FN1" data-t="n"><dt class="label"><a href="#bFN1" class="intra_ref">1</a></dt><dd><p>Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.</p></dd></dl><!--footerNotes--></div><!--VALIDHTML--><p class="copyright">Copyright © 1998 Elsevier Science B.V. All rights reserved.</p><!--VALIDHTML-->
<script>prs.rt('data_end');</script>
       
        
    <div style="height: 0px;" id="pStretcher"></div></div>
 </div>
 <div style="top: 26px; overflow: hidden; left: 961px; width: 300px;" id="rightPane" class="column js" aria-label="Related content" role="complementary">
   <div style="display: none;" class="toggleSideBar">
      <a tabindex="0">
         <div class="close" title="Open to view article outline"></div>
      </a>
    </div>
    <iframe class="dummyiFrame" border="0" style="position: absolute; background: none repeat ; 0% transparent; border: 0px none; top: 0px; left: 0px; width: 100%; height: 100%; z-index: -1;" src="S0166354298000254_3.html" frameborder="0"></iframe>
    <div style="margin-left: 0px; width: 298px;" role="tablist" id="rightInner" class="rightInner js ui-accordion ui-widget ui-helper-reset">
       <h2 tabindex="-1" aria-selected="false" aria-controls="ui-accordion-rightInner-panel-0" id="ui-accordion-rightInner-header-0" role="tab" class="accordionHead first-tab bibliographic ui-accordion-header ui-helper-reset ui-state-default ui-corner-all">
    <span class="showHideIcon"></span>
    Bibliographic information
</h2>
<div aria-hidden="true" aria-expanded="false" role="tabpanel" aria-labelledby="ui-accordion-rightInner-header-0" id="ui-accordion-rightInner-panel-0" style="display: none; height: 676px; overflow: auto;" class="accordionContent ui-accordion-content ui-helper-reset ui-widget-content ui-corner-bottom">
    <div style="width: 265px;" class="innerPadding js_bibliographic_content">

    </div>
</div>


  <h2 tabindex="0" aria-selected="true" aria-controls="ui-accordion-rightInner-panel-1" id="ui-accordion-rightInner-header-1" role="tab" class="accordionHead relatedArticles ui-accordion-header ui-helper-reset ui-state-default ui-accordion-header-active ui-state-active ui-corner-top">
    <span class="showHideIcon"></span>
    Citing and related articles
  </h2>
  <div aria-hidden="false" aria-expanded="true" role="tabpanel" aria-labelledby="ui-accordion-rightInner-header-1" id="ui-accordion-rightInner-panel-1" style="display: block; height: 676px; background-color: rgb(236, 242, 246); overflow-x: hidden; overflow-y: auto;" class="accordionContent ui-accordion-content ui-helper-reset ui-widget-content ui-corner-bottom ui-accordion-content-active">
    <div style="width: 265px;" class="innerPadding js_citation_content">
      
        
     

     
     
        <div class="articleList">
             <h3>Related articles</h3>
             <ol id="relArtList"><li class="note"><p>No articles found.</p></li></ol>
        </div>
     

     
         
             <ol class="citedByLink"><div class="boxLink"><a href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science?_ob=RedirectURL&amp;_method=outwardLink&amp;_partnerName=656&amp;_eid=1-s2.0-S0166354298000254&amp;_pii=S0166354298000254&amp;_origin=article&amp;_zone=art_page&amp;_targetURL=http%3A%2F%2Fwww.scopus.com%2Finward%2Fcitedby.url%3Feid%3D2-s2.0-0032437454%26partnerID%3D10%26rel%3DR3.0.0%26md5%3D2efbe66d1b134dfa9026bae320e22f16&amp;_acct=C000007922&amp;_version=1&amp;_userid=103680&amp;md5=9f894bdc86fbdbe5dea0ad0a829ae418" rel="nofollow" class="olSpawnWindow" target="outwardLink"><span class="scopus_logo_txt">Cited by in Scopus (279)</span></a></div></ol>
         
     

     
         
             <div class="articleList">
                 <h3>Related reference work articles</h3>
                 <ol id="relRefList"><li class="note"><p>No articles found.</p></li></ol>
             </div>
         
      

    <div class="rightAdPlaceHolder"><div id="articleRightAdSm"><iframe class="usmonndchupfwwcnugwg" border="0" cellspacing="0" src="S0166354298000254_4.html" frameborder="0" scrolling="no"></iframe></div></div></div>
  </div>



  <h2 tabindex="-1" aria-selected="false" aria-controls="ui-accordion-rightInner-panel-2" id="ui-accordion-rightInner-header-2" role="tab" class="accordionHead applications ui-accordion-header ui-helper-reset ui-state-default ui-corner-all">
    <span class="showHideIcon"></span>
    Applications and tools
  </h2>
  <div aria-hidden="true" aria-expanded="false" role="tabpanel" aria-labelledby="ui-accordion-rightInner-header-2" id="ui-accordion-rightInner-panel-2" style="height: 676px; overflow: auto; visibility: hidden; top: -1000px; position: absolute; left: -1000px;" class="accordionContent ui-helper-reset ui-widget-content ui-corner-bottom">
    <div style="width: 285px;" class="innerPaddingApp js_application_content">

      
        <div id="SD_AT1P" class="boxLink sgfNoTitleBar sgfNoGadgetBorder"></div>
      

      
        <div id="SD_FTA1" class="boxLink sgfHorToolbar sgfShowMyApps sgfShowMoreLessApps"></div>
      

    </div>
  </div>


<h2 tabindex="-1" aria-selected="false" aria-controls="ui-accordion-rightInner-panel-3" id="ui-accordion-rightInner-header-3" role="tab" class="accordionHead last-tab workspace ui-accordion-header ui-helper-reset ui-state-default ui-corner-all">
    <span class="showHideIcon"></span>
    Workspace
</h2>
<div aria-hidden="true" aria-expanded="false" role="tabpanel" aria-labelledby="ui-accordion-rightInner-header-3" id="ui-accordion-rightInner-panel-3" style="display: none; height: 676px; overflow: auto;" class="accordionContent ui-accordion-content ui-helper-reset ui-widget-content ui-corner-bottom">
    <div style="" class="innerPadding js_workspace_content">
        <div style="width: 260px;" class="scrollArea">
           <li class="note"><p>No content has been selected.</p></li>
           <div id="workSpaceView"></div>
        </div>
    </div>
    <div class="hidescrollbar"></div>
</div>

    </div>
 </div>
</div>
<div style="clear: both;"></div>
<div style="width: 1262px; left: 0px; height: 0px; display: none;" class="js" id="footer-area" aria-label="product support" role="contentinfo">
  <div id="sdFoot">
    <div id="footer">	
  <div class="bottomArticle"></div>
  <div class="padding">
    <div id="linkArea">
      <div class="padding">
        <div style="float: left; width: 0px; height: 1px;"></div>
        <div id="banner-bottom">
          <a href="http://www.elsevier.com.libgate.library.nuigalway.ie/" target="_top"><img src="wordmark_elsevier.png" alt="Elsevier homepage (opens in a new window)" title="Elsevier homepage (opens in a new window)"></a>
        </div>
        <ul class="col5">
<li><a target="_top" href="http://www.info.sciverse.com/sciencedirect?utm_source=sciencedirect&amp;utm_medium=link&amp;utm_campaign=aboutsd">About ScienceDirect</a></li>
</ul>
<ul class="col5">
<li><a target="_top" href="http://www.elsevier.com.libgate.library.nuigalway.ie/?utm_source=sciencedirect&amp;utm_medium=link&amp;utm_campaign=aboutelsevier">About Elsevier</a></li>
</ul>
<ul class="col5">
<li> <a target="_top" href="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/contactus">Contact and support</a></li>
</ul>
<ul class="col5">
<li><a target="_top" href="http://www.elsevierscitech.com/forms/sd/form.html?utm_source=sciencedirect&amp;utm_medium=link&amp;utm_campaign=advert">Information for advertisers</a></li>
</ul>
<ul class="col5">
<li><a target="_top" href="http://www.elsevier.com.libgate.library.nuigalway.ie/locate/termsandconditions?utm_source=sciencedirect&amp;utm_medium=link&amp;utm_campaign=terms">Terms and conditions</a></li>
</ul>
<ul class="col5">
<li><a target="_top" href="http://www.elsevier.com.libgate.library.nuigalway.ie/privacypolicy?utm_source=sciencedirect&amp;utm_medium=link&amp;utm_campaign=privacy">Privacy policy</a></li>
</ul>
        <div class="clear"></div>
        <!-- CSAS will be providing the links-->
      </div>
      <div class="padding" style="padding-top: 8px; padding-bottom: 4px; font-size: 11px;">

        Copyright © 2013 <a href="http://www.elsevier.com.libgate.library.nuigalway.ie/" target="_top">Elsevier B.V.</a> All rights reserved.  SciVerse® is a registered trademark of Elsevier Properties S.A., used under license. ScienceDirect® is a registered trademark of Elsevier B.V.
      </div>
      <div class="padding" style="padding-bottom: 4px; padding-top: 0px; font-size: 11px;">

              Cookies are used by this site. To decline or learn more, visit our <a href="http://www.info.sciverse.com/sciencedirect/cookies" target="_top">Cookies</a> page
        </div> 
    </div>
  </div>
</div> <!--footer-->

  </div><!--sdFooter-->
</div><!--footer-area-->


<form name="citationInfo" id="citationInfo" method="POST" action="http://www.sciencedirect.com.libgate.library.nuigalway.ie/science/article/pii/S0166354298000254?np=y">
    <input name="art_citation" value="" type="hidden">
</form>
<div id="pdfModalWindow" class="pdfModalWindow" style="display: none;" onclick="pdfCite.closePopup();"></div>


<!-- PDFKING/PDFCITE -->
<div id="suggestedPdfList" style="display: none;">

</div>


<script src="sdX_131R4.js"></script>
<script src="sd_131R4.js"></script>
<script>

var sciverse="empty";
var SDM=new Object;
SDM.tm=new Object;
SDM.tm.ahm='h'
SDM.tm.chm='h'


SDM.pm=new Object;
SDM.pm.contentType = 'JL';
SDM.doi = '10.1016/S0166-3542(98)00025-4';
SDM.pm.issn_or_isbn = "01663542";
SDM.pm.mod_ISBN = "";
  SDM.isMRWMODArticle = false ; 
 
SDM.pm.mod_cid="";
SDM.pm.mod_srcTitle="";
SDM.pm.pii = 'S0166354298000254';
SDM.pm.cid = '271065';
SDM.pm.eid = '1-s2.0-S0166354298000254';
SDM.pm.pdfEid = '1-s2.0-S0166354298000254-main.pdf';
SDM.pm.pdfSize = '3561653';
SDM.pm.coverDate = '1998-Jun-01';
SDM.pm.itemWeight = 'FULL-TEXT';
SDM.pm.indexType = '';





SDM.pf = new Object;
SDM.pf.dc = new Object;
SDM.pf.dc.retry = 10;
SDM.pf.dc.retryDelay = 300;
SDM.pf.dc.retryFactor = 1.0;

SDM.pf.er = new Object;

SDM.pf.er.epub = new Object;
SDM.pf.er.epub.name = 'ePub';
SDM.pf.er.epub.retry = 5;
SDM.pf.er.epub.retryDelay = 2000;
SDM.pf.er.epub.retryFactor = 1.0;
SDM.pf.er.epub.msgDelay = 1500;
SDM.pf.er.epub.msgType = 'rect';
SDM.pf.er.epub.msgImg = 'epubAnim.gif';
SDM.pf.er.epub.url='http://www.sciencedirect.com/science/ereader/epub/S0166354298000254/1369326418/01663542/1-s2.0-S0166354298000254/serial/?md5=735e71e2521d692d37774ffdb4a98819';


SDM.pf.er.mobi = new Object;
SDM.pf.er.mobi.name = 'Mobipocket';
SDM.pf.er.mobi.retry = 5;
SDM.pf.er.mobi.retryDelay = 2000;
SDM.pf.er.mobi.retryFactor = 1.0;
SDM.pf.er.mobi.msgDelay = 1500;
SDM.pf.er.mobi.msgType = 'rect';
SDM.pf.er.mobi.msgImg = 'mobiAnim.gif';
SDM.pf.er.mobi.url='http://www.sciencedirect.com/science/ereader/mobi/S0166354298000254/1369326418/01663542/1-s2.0-S0166354298000254/serial/?md5=735e71e2521d692d37774ffdb4a98819';






SDM.pm.toc=new Object;
SDM.pm.toc.retry = 20;
SDM.pm.toc.retryDelay = 1000;
SDM.pm.toc.retryFactor = 1.09;
 SDM.tocJson = '{"PII":"S0166354298000254","EID":"1-s2.0-S0166354298000254","TIMESTAMP":"2010-11-02T22:25:35.051292-04:00","TOC":[{"dummy": "dummy"}, {"sT":"Abstract", "sID":"section_abstract", "cT":[ {"sT":"", "sID":"absSec_1" } ] }, {"sT":"Keywords", "sID":"kwd_1"}, {"sT":"1. Introduction", "sID":"section_lbl1", "faID":[ {"dummy": "dummy"} ] },{"sT":"2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)", "sID":"section_lbl2", "faID":[ {"dummy": "dummy"}, {"fID":"FIG1", "fT":"fig","fL":"Fig. 1", "fI":"gr1.sml","fIh":"93"}, {"fID":"FIG2", "fT":"fig","fL":"Fig. 2", "fI":"gr2.sml","fIh":"94"}, {"fID":"FIG3", "fT":"fig","fL":"Fig. 3", "fI":"gr3.sml","fIh":"93"}, {"fID":"FIG4", "fT":"fig","fL":"Fig. 4", "fI":"gr4.sml","fIh":"94"}, {"fID":"FIG5", "fT":"fig","fL":"Fig. 5", "fI":"gr5.sml","fIh":"93"},{"fID":"TBL1", "fT":"tbl","fL":"Table 1"} ] },{"sT":"3. Interaction of NNRTIs with their pocket site at the HIV-1 RT", "sID":"section_lbl3", "faID":[ {"dummy": "dummy"}, {"fID":"FIG6", "fT":"fig","fL":"Fig. 6", "fI":"gr6v7.sml","fIh":"92"}, {"fID":"FIG7", "fT":"fig","fL":"Fig. 7", "fI":"gr6v7.sml","fIh":"92"}, {"fID":"FIG8", "fT":"fig","fL":"Fig. 8", "fI":"gr8v9.sml","fIh":"93"}, {"fID":"FIG9", "fT":"fig","fL":"Fig. 9", "fI":"gr8v9.sml","fIh":"93"} ] },{"sT":"4. HIV-1 resistance to NNRTIs", "sID":"section_lbl4", "faID":[ {"dummy": "dummy"}, {"fID":"FIG10", "fT":"fig","fL":"Fig. 10", "fI":"gr10.sml","fIh":"76"},{"fID":"TBL2", "fT":"tbl","fL":"Table 2"} ] },{"sT":"5. Optimization of NNRTI treatment regimens", "sID":"section_lbl5", "faID":[ {"dummy": "dummy"}, {"fID":"FIG11", "fT":"fig","fL":"Fig. 11", "fI":"gr11.sml","fIh":"94"}, {"fID":"FIG12", "fT":"fig","fL":"Fig. 12", "fI":"gr12v13.sml","fIh":"94"}, {"fID":"FIG13", "fT":"fig","fL":"Fig. 13", "fI":"gr12v13.sml","fIh":"94"} ] },{"sT":"6. In vivo efficacy of NNRTIs", "sID":"section_lbl6", "faID":[ {"dummy": "dummy"}, {"fID":"FIG14", "fT":"fig","fL":"Fig. 14", "fI":"gr14.sml","fIh":"94"}, {"fID":"FIG15", "fT":"fig","fL":"Fig. 15", "fI":"gr15.sml","fIh":"92"}, {"fID":"FIG16", "fT":"fig","fL":"Fig. 16", "fI":"gr16.sml","fIh":"93"}, {"fID":"FIG17", "fT":"fig","fL":"Fig. 17", "fI":"gr17.sml","fIh":"94"}, {"fID":"FIG18", "fT":"fig","fL":"Fig. 18", "fI":"gr18.sml","fIh":"92"}, {"fID":"FIG19", "fT":"fig","fL":"Fig. 19", "fI":"gr19.sml","fIh":"94"}, {"fID":"FIG20", "fT":"fig","fL":"Fig. 20", "fI":"gr20.sml","fIh":"93"} ] },{"sT":"7. Conclusion", "sID":"section_lbl7", "faID":[ {"dummy": "dummy"},{"fID":"TBL3", "fT":"tbl","fL":"Table 3"} ] }, {"sT":"Acknowledgements", "sID":"ack001"} , {"sT":"References", "sID":"bibl001"} , {"sT":"", "sID":"","faID":[ {"dummy": "dummy"} ] }]}';
 SDM.tocCacheAvail=true; 


SDM.ep=new Object;
SDM.ep.imgBase = "http://cdn.els-cdn.com/sd";
SDM.ep.urlPrefix = "http://www.sciencedirect.com/science";
SDM.ep.refLinkURL = "http://www.sciencedirect.com/science/relLink/ajaxReq?_eid=1-s2.0-S0166354298000254";
SDM.ep.updatedCitedBy = "http://www.sciencedirect.com/science/referenceResolution/ajaxRefResol?_updateCitedBy=";
SDM.ep.refResolvePath = "http://www.sciencedirect.com/science/referenceResolution/ajaxRefResol?_eid=1-s2.0-S0166354298000254&_refCnt=146&_docType=converted-article";
SDM.breadCrumbPathURL = "http://www.sciencedirect.com/science/module/breadCrumbPaths/isbn//pii/S0166354298000254";

SDM.ldrAvail = true;
SDM.ep.crossMarkURL = "http://www.sciencedirect.com/science/crossMark";
SDM.ep.crossMarkLib = "http://crossmark.crossref.org/javascripts/crossmark.min.js";
SDM.ep.userActionURL = "http://www.sciencedirect.com/science/UserActions"
SDM.ep.svShindigLib="http://sciverse-shindig.elsevier.com/gadgets/js/shindig-container:pubsub-2.js?c=1";
SDM.ep.svSciverseLib="http://www.sciencedirect.com/gadgetservices/gadgets/v3_1/js/SciverseShindigService,GadgetToolBar,jquery-outside,jquery.ba-bbq.min,SciverseShindigContainer,ScienceDirectShindigServices.js";
SDM.ep.downloadCsvURL = "http://services.elsevier.com/SDWebExport/export/table/csv";
SDM.ep.downloadActionURL = "http://www.sciencedirect.com/science/downloadActions/keyEvent/S0166354298000254/01663542";
SDM.ep.gigyaLib="//cdn.gigya.com/JS/socialize.js?apiKey=3__Bt7bHrGM8mjKPwBuOVjWyMi678aF6-PewcnoHJJ6UR1fS5t9NG9RBbKHjE0oA6J";

SDM.urlPrefix = "http://www.sciencedirect.com/science";
SDM.refLinkURL = "http://www.sciencedirect.com/science/relLink/ajaxReq?_eid=1-s2.0-S0166354298000254";

SDM.imageUrlPrefix = "http://ars.els-cdn.com/content/image/";
SDM.staticImageUrlPrefix = "http://cdn.els-cdn.com/sd";

SDM.prodColor="sci_dir";if(SDM.prodColor=="sci_dir")SDM.prodColor="";

SDM.pageTransKey = "05/23/2013 12:26:58 EDT#2849_004#56760#140.203.12.206";
SDM.pageType = "article_full";

  SDM.webUserId = "103680";
  SDM.contentType = "JL";
  SDM.issn_or_isbn = "01663542";
  SDM.sds = "52ab44608e6c591b461efb6e0f90580cb473d7f5e91f8089f15a4c8896b540a9d34978ae01fc1a93323c59a5e498f167";
  SDM.tid = "96fd4d1a-c3c5-11e2-bf03-00000aacb361";
  SDM.ud = "103680|<SAInfo><SAId>17</SAId><SAName>IRELAND University Consortium</SAName><SANum>S000000017</SANum></SAInfo>|C000007922|14110|IPRANGE";
  SDM.pru = "http://pa.elsevier.com";
  SDM.crossMarkURL = "http://www.sciencedirect.com/science/crossMark";
  SDM.crossMarkLib = "http://crossmark.crossref.org/javascripts/crossmark.min.js";
 SDM.isCrossMark=false; 
  SDM.keOriginContentFamily = "serial"
  SDM.userActionURL = "http://www.sciencedirect.com/science/UserActions"
  SDM.sciverseUrlPfx="http://www.sciencedirect.com";
  SDM.sciverseJsonObject='';
  SDM.sciverseGadgetDetailsID = "8778428e-f997-4912-a234-e21c2f50fc9a";
SDM.fullSize = true;
SDM.outlineGraphics = true;
SDM.outlineTab = "";
SDM.outlineImgFence = true;
SDM.entitled = true;
SDM.urlTOCLink="http://www.sciencedirect.com/science/article/pii/S0166354298000254";
SDM.urlTOCLinkQueryStr="?_rdoc=1&_fmt=full&_origin=&md5=22543fb95e34d36391c44b9d9cd72533";

SDM.displayGadgets=true;
SDM.euidCookieObject='7758d5ca52e9aa7bcc2327738fce1e57f3d8bd8eccacdbe4103b9a2eee7eecd6b58cd62090cb76e4';
SDM.adArticleLeftURL="/science/advertisement/left/num/532358/mainCat/general/cat/general/acct/caf12c083b5a42c1c4723593daa096bf/isn/01663542/doi/10.1016_S0166-3542(98)00025-4/page/article";
SDM.adArticleOptionsURL="/science/advertisement/options/num/532358/mainCat/general/cat/general/acct/caf12c083b5a42c1c4723593daa096bf/isn/01663542/doi/10.1016_S0166-3542(98)00025-4/page/article";
SDM.adArticleRightSmURL="/science/advertisement/rightsm/num/532358/mainCat/general/cat/general/acct/caf12c083b5a42c1c4723593daa096bf/isn/01663542/doi/10.1016_S0166-3542(98)00025-4/page/article";
SDM.adArticleRightLgURL="/science/advertisement/rightlg/num/532358/mainCat/general/cat/general/acct/caf12c083b5a42c1c4723593daa096bf/isn/01663542/doi/10.1016_S0166-3542(98)00025-4/page/article";
SDM.adReqOutline=true;
SDM.adReqOptions=false;
SDM.relatedRefAvail=true;
SDM.mlktAvail = true;
SDM.citedByScAvail = false;
SDM.crawlerAvail = false;
SDM.outwardLinks = '<div class="olLeftMiddle"><div class="boxLink"><a href="/science?_ob=RedirectURL&_method=outwardLink&_partnerName=19979&_eid=1-s2.0-S0166354298000254&_pii=S0166354298000254&_origin=article&_zone=rightPane&_targetURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0166354298000254%3Fshowall%3Dtrue&_acct=C000007922&_version=1&_userid=103680&md5=a52063708b33ec1561bf2c962a040bd4"  rel="nofollow" class="olSpawnWindow" target="outwardLink"><img src="http://www.sciencedirect.com.libgate.library.nuigalway.ie/scidirimg/gw_rtn_ihub.gif" alt="Get Full Text Elsewhere" title="Get Full Text Elsewhere" border="0"></a></div></div><div class="tableFmDivider">&nbsp;</div><div class="olLeftMiddle"><div class="boxLink"><a href="/science?_ob=RedirectURL&_method=outwardLink&_partnerName=254&_eid=1-s2.0-S0166354298000254&_pii=S0166354298000254&_origin=article&_zone=rightPane&_targetURL=http%3A%2F%2Fsfxhosted.exlibrisgroup.com%2Fgalway%3Fctx_ver%3DZ39.88-2004%26ctx_enc%3Dinfo%3Aofi%2Fenc%3AUTF-8%26url_ver%3DZ39.88-2004%26rfr_id%3Dinfo%3Asid%2FElsevier%3ASD%26svc_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Asch_svc%26rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal%26rft.aulast%3DDECLERCQ%26rft.auinit%3DE%26rft.date%3D1998%26rft.issn%3D01663542%26rft.volume%3D38%26rft.issue%3D3%26rft.spage%3D153%26rft.epage%3D179%26rft.title%3DAntiviral%2520Research%26rft.atitle%3DThe%2520role%2520of%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520(NNRTIs)%2520in%2520the%2520therapy%2520of%2520HIV-1%2520infection%26rft_id%3Dinfo%3Adoi%2F10.1016%2FS0166-3542(98)00025-4&_acct=C000007922&_version=1&_userid=103680&md5=627215af31263d46e657b4b0b011893e"  rel="nofollow" class="olSpawnWindow" target="outwardLink"><img src="http://sfxhosted.exlibrisgroup.com.libgate.library.nuigalway.ie/galway/sfx.gif" alt="More related information in NUI, Galway" title="More related information in NUI, Galway" border="0"></a></div></div><div class="tableFmDivider">&nbsp;</div><div class="olLeftMiddle"><div class="boxLink"><a href="/science?_ob=RedirectURL&_method=outwardLink&_partnerName=5978&_eid=1-s2.0-S0166354298000254&_pii=S0166354298000254&_origin=article&_zone=rightPane&_targetURL=http%3A%2F%2Flinkinghub.pangaea.de%2Felsevier%2FredirectToSupplement%2F10.1016%2FS0166-3542(98)00025-4&_acct=C000007922&_version=1&_userid=103680&md5=7508661e4a8594420f6270cc952f7e46"  rel="nofollow" class="olSpawnWindow" target="outwardLink"><img src="http://linkinghub.pangaea.de/elsevier/supplementBanner/10.1016/S0166-3542(98)00025-4" alt="PANGAEA Supplementary Data" title="PANGAEA Supplementary Data" border="0"></a></div></div><div class="olLeftMiddle"><div class="boxLink SC_record"><a href="/science?_ob=RedirectURL&_method=outwardLink&_partnerName=655&_eid=1-s2.0-S0166354298000254&_pii=S0166354298000254&_origin=article&_zone=rightPane&_targetURL=http%3A%2F%2Fwww.scopus.com%2Finward%2Frecord.url%3Feid%3D2-s2.0-0032437454%26partnerID%3D10%26rel%3DR3.0.0%26md5%3D2efbe66d1b134dfa9026bae320e22f16&_acct=C000007922&_version=1&_userid=103680&md5=4a115ab39ec3343cbebe2857503ceeb7"  rel="nofollow" class="olSpawnWindow" target="outwardLink">View Record in Scopus</a></div></div>';
   SDM.doi = '10.1016/S0166-3542(98)00025-4'; 
 SDM.isSpecialIssue=false; 
 SDM.hubEid = '1-s2.0-S0166354200X00411'; 


 SDM.relatedCitingPanelAvail = true; 
 SDM.applicationsPanelAvail=true; 
 SDM.rerunJson =''; 
 SDM.rerunAvail=true; 
 SDM.helpUrlDomain = "#";
 SDM.permAndReprint='<div class="boxLink"><a href="/science?_ob=RedirectURL&_method=outwardLink&_partnerName=936&_eid=1-s2.0-S0166354298000254&_pii=S0166354298000254&_origin=article&_zone=art_page&_targetURL=https%3A%2F%2Fs100.copyright.com%2FAppDispatchServlet%3FpublisherName%3DELS%26contentID%3DS0166354298000254%26orderBeanReset%3Dtrue&_acct=C000007922&_version=1&_userid=103680&md5=7f795f55e4dec892159e436c7e305c94"  rel="nofollow" class="olSpawnWindow" target="outwardLink">Permissions & Reprints</a></div>'; 
 SDM.ppvMsg=''; 

SDM.ignoreForceAbst=false;
 
SDM.blk_all_social_logins='Y';

var googleAds = '';

SDM.svapi = SVApi;

</script>


<script>


initializeArticlePage();
</script>



<script>$(document).ready( ArticlePage.showLeftAd() );</script>








<script>

  prs.rt('body_end');
  
</script>


<ul style="z-index: 62; display: none;" tabindex="0" id="ui-id-1" class="ui-autocomplete ui-menu ui-widget ui-widget-content ui-corner-all"></ul><img style="display: none;" src="pageReport"></body>
</html>
